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Studies on in vitro human T cell reactivity to antigens of Mycobacterium tuberculosis 
Studies on Mycobacterium tuberculosis (MTB) antigens are important to improve 
immunodiagnostics and vaccine efficacy. A novel genome based strategy for antigen 
discovery is to relate what is highly expressed by bacilli in vivo or in vitro, to what is 
recognized by human T cells as antigens.  
As hypoxia is a relevant stimulus that MTB encounters in vivo, whole genome based 
transcriptional profiles of M. tuberculosis subject to prolonged hypoxia (described as the 
Enduring hypoxic response [EHR]) were analyzed, to guide the discovery of novel 
potential antigens, by a combined bioinformatic and empirical approach and to determine 
evidence of infection stage specific recognition.  
29 candidate genes were selected by bioinformatic prediction and evaluated empirically 
using IFN-γ and IL-2 ELISpot, and Acr-1, CFP-10, ESAT-6 as reference antigens. 26 of 
29 proteins induced an IFN-γ response in PBMC of persons with active or latent 
tuberculosis. IL-2 responses were of lower magnitude than that of IFN-γ and the antigenic 
repertoire far more focused.  
Ten proteins induced a dominant IFN-γ response in ≥ 50% of the donors. Five novel 
immunodominant proteins: Rv1957, Rv1954c, Rv1955, Rv2022c and Rv1471, showed 
responses similar to CFP-10 and ESAT-6 in both magnitude and frequency. With the 
exception of Rv1471, these novel genes are shared only within MTB complex. With the 
exception of modest IFN-  response to the peptide pools of Rv0849-2, Rv2659c-2, 
Rv2693c-1 and very low levels for Rv2021c, there was no strong evidence of infection 











RD2 encoded, Rv1986 was found to be a major target of central memory CD4+ T cells, 
inducing IL-2 response, several times greater than ESAT-6 or CFP-10, and that this 
response is directed narrowly to two epitope regions. This immunodominant target is 
absent in most commonly used BCG vaccine strains. 
In addition, T cell determinants of species specific Rv2654c and dosR regulated Rv1733c 
were mapped. T cell epitope mapping of Rv2654c revealed, that the dominant epitope 
recognized in this population (p51-65) is different from what is previously described.  
These findings revealed that a number of genes induced by hypoxia are in fact potent T-
cell targets and therefore offers general support to the important role of hypoxia in the 
natural course of tuberculosis infection. Only moderate evidence of infection stage specific 
recognition of antigens was observed. The approach described for antigen discovery could 
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"Studies on in vitro human T cell reactivity to antigens of  
Mycobacterium tuberculosis" 
 
 Chapter 1 is an Introduction. 
 Chapter 2 is the materials and methods.  
 Chapter 3 describes the comparison of various techniques and evaluation of 
performance of synthetic peptides and recombinant proteins with the discovery that 
there is poor correlation between techniques and that the peptides are degraded, 
while the recombinant proteins are cleaved in long-term whole blood cultures.  
 Chapter 4 describes antigenic mapping infection stage specific antigens: species 
specific RD-11 encoded Rv2654c (TB7.7) and dosR encoded Rv1733, with the 
discovery that the commercially used p38-55 peptide of Rv2654c is not immuno-
dominant in this population. 
 Chapter 5 describes informatics and empirical analysis of novel hypoxia inducible 
targets of human T cell response in subjects with active and latent TB with the 
discovery of immuno-dominant antigens and that these antigens do not induce a 
differential recognition between the 2 clinical groups.  
 Chapter 6 describes the analysis of hypoxia-inducible species-specific 
determinants of the human T cell response with the discovery that RD-2 encoded 
Rv1986, which is deleted from the commonly used BCG strains, constitutes a 
major target of memory T cells. 





















Chapter 1: Introduction 
The chapters of this thesis describe the in vitro reactivity of human T cell response to novel 
T cell antigenic targets of Mycobacterium tuberculosis (MTB) using bioinformatic 
prediction algorithm and empirical testing. The antigens tested are either hypoxia induced: 
under in vitro culture conditions (relating to the physiology of the bacilli in vivo) or are 
encoded by various regions of difference. Therefore, this introductory chapter reviews a 
brief history of tuberculosis, its pathology, T cell antigen discovery in Mycobacterium 
tuberculosis and the techniques used in antigen discovery. 
Historical background  
Tuberculosis caused by Mycobacterium tuberculosis has claimed its victims throughout 
much of known human history and it is considered the greatest present bacterial cause of 
death.  Evidence of tuberculosis, in the pre-historic era, dates back to 8000 BC.  Johann 
Lukas Schönlein of Würzburg, listed scrofula, tubercles and phthisis as separate diseases 
under the heading of „haematoses‟ and in 1834, he coined the term „tuberculosis‟ to 
describe affliction with tubercles (Herzog, 1998). 
However, understanding the pathogenesis of tuberculosis began only in the 19th century 
with the identification of tubercle bacilli as the etiological agent by Robert Koch (in 1882). 
Within few years after the discovery of the bacilli, Koch also produced a glycerin extract 
of dead tubercle bacilli, which he initially named „lymph‟ and later „tuberculin‟ and 
promoted it as an effective remedy. Clemens von Pirquet, developed the tuberculin skin 
test (TST) in 1907 using Koch‟s tuberculin. He introduced the term “latent tuberculosis”-
describing children who did not manifest any symptoms of tuberculosis but had a positive 
skin response to tuberculin. In 1908, Charles Mantoux introduced the use of cannulated 











Seibert further developed purified protein derivative (PPD), in the form, which is currently 
in use (Daniel, 2006; Herzog, 1998). 
A major breakthrough in the history of tuberculosis was the successful attenuation of M. 
bovis for use as a vaccine, by Albert Calmette and his associate Camille Guérin, from 
where the name Bacille Calmette-Guérin  (BCG) derives and was successfully developed 
in 1921. Over the years this vaccine was accepted and remains in use all over the world 
today (Daniel, 2006). 
Another equally important contribution to the diagnosis of TB is the revolutionary advance 
in the field of physics in the year 1895: the discovery of X-rays by Wilhelm Conrad von 
Röntgen. With the aid of the rapidly evolving radiological techniques, the development, 
course and severity of tuberculosis could now be accurately monitored and studied. 
Rapidly progressing discoveries in tuberculosis saw another milestone with the 
development of antibiotic Streptomycin in the 1940s for the treatment of tuberculosis. 
Following this several other agents were successfully developed: p-aminosalicylic acid 
(1949), isoniazid (1952), pyrazinamide (1954), cycloserine (1955), ethambutol (1962) and 
rifampin (rifampicin; 1963). 
Current Global burden of tuberculosis 
Even after such rapid progress in discoveries ranging from diagnostics to treatment and 
prevention in the field of tuberculosis, the latest global burden of tuberculosis estimates 
that almost one third of the world‟s population is infected with tuberculosis, with 8.9-9.9 
million incident cases, 9.6-13.0 million prevalent cases, 1.1-1.7 million deaths amongst 
HIV-1 uninfected and an additional 0.45-0.62 million deaths in HIV-1 infected persons 












Figure 1 Estimated incidence of Global tuberculosis (As of 2008) (WHO, 2010) 
Control of Tuberculosis 
Control strategies against tuberculosis still remain largely dependent on the partially 
effective BCG vaccine and the early diagnosis and treatment of active tuberculosis. 
Isoniazid preventive therapy and antiretroviral therapy for HIV-1 infected people are 
further measures.  The enormous reservoir of latent tuberculosis also adds potential threat 
to the control strategy, increasing the lifetime chances of developing active form of 
tuberculosis, especially in the HIV-1 infected persons. In addition, administration of a live 
vaccine to HIV-1 co-infected children carries the potential risk of developing disseminated 
BCG disease (Hesseling et al., 2007; Hesseling et al., 2003). In addition, the HIV-1 
pandemic has made the diagnosis and treatment of tuberculosis difficult, due to atypical 











Diagnosis of Tuberculosis 
The diagnosis of tuberculosis plays a key role in the control of tuberculosis. In general, 
diagnosis largely relies on clues from the clinical presentation and symptoms of the illness 
such as cough, night sweats, weight loss, fever and radiological changes.  
Laboratory diagnosis is based on either (i) detecting the bacilli or (ii) detecting an immune 
response to the bacilli. 
(i) Detecting the bacilli 
Presence of MTB bacilli in the stained (Ziehl Neelsen) sputum smear, viewed under light 
microscopy is the most commonly used technique. The sputum smear is highly specific for 
the diagnosis of pulmonary tuberculosis, cost effective and does not need specialized 
laboratory, but it is labour intensive and insensitive. The use of fluorescent dye and 
fluorescent microscopy increases the sensitivity of the sputum smear detection (Mitchison, 
1972; Steingart et al., 2006). However, these facilities are not always available in resource-
limited settings. Sputum microscopy however, is not sensitive for detection of MTB in 
extrapulmonary and paucibacillary tuberculosis. In HIV-1 infected persons and in children, 
the sputum smear is often negative.  
Culture of sputum, is the current gold standard in the laboratory diagnosis of tuberculosis. 
The major draw back however is the time delay, as it can take up to 3-4 weeks to grow in 
solid media, and 1-10 days in the liquid media (Lagrange and Herrmann, 2008; Lalvani, 
2007; Lalvani and Pareek, 2009a; Lange and Mori, 2010; Lange et al., 2009). 
While microscopy and culture are still the major backbone for laboratory diagnosis of 
tuberculosis (TB), new methods including molecular diagnostic tests have evolved over the 
last two decades (Palomino, 2005). The majority of molecular tests have been focused on: 











tuberculosis, by amplification techniques such as polymerase chain reaction (PCR); and 
(ii) detection of mutations in the genes which are associated with resistance to anti-
tuberculosis drugs by sequencing or nucleic acid hybridization. These are extensively 
reviewed (Balasingham et al., 2009; Lange and Mori, 2010). 
(ii) Detection of immune response 
Humoral immune response 
For several decades, B cell targets of MTB were considered with the primary purpose of 
developing serodiagnostic assays. Evidence in the literature suggests that circulating 
antibodies to mycobacterial antigens have been described as early as 1965 (Daniel et al., 
1979) which employed  the use of sterile culture filtrates of mycobacterial culture, which 
lacked specificity (Daniel and Debanne, 1987; Grange, 1984). Progress, in terms of 
specificity and sensitivity, were achieved with the aid of monoclonal antibodies directed 
against immunodominant species-specific antigen determinants (Hewitt et al., 1982). 
Further use of specific whole antigen molecules like 38-kDa 19- kDa and 14-kDa 
molecules increased the sensitivity of diagnosis in both smear positive and smear negative 
tuberculosis (Bothamley et al., 1992; Jackett et al., 1988).  
Recently, Steingart and colleagues conducted a systematic review and meta-analysis on the 
performance of serodiagnosis and found 254 studies evaluating 51 distinct single antigens 
and 30 multiple- antigen combinations for diagnosing pulmonary tuberculosis. The authors 
conclude that (i) none of the antigens achieve sufficient sensitivity to replace sputum 
microscopy, (ii) no single antigen provides a sensitivity that is sufficient for a single 
antigen to be used to device a serodiagnostic test for TB and (iii) that it is unlikely that a 
single antigen based serodiagnostic test could be devised; however, (iv) combination of 












Cellular immune response 
The TST (Tuberculin skin test: intradermal injection of a standard dose (2 Tuberculin 
units) of PPD) detects a delayed type hypersensitivity (DTH) reaction against MTB 
infection. It is based on the cellular reaction to PPD after 48-72 hours after intradermal 
injection and defined by a local skin induration and is still considered and used as an 
effective tool for the diagnosis of tuberculosis, for over a century. The major drawbacks 
include, operational disadvantages requiring two patient visits, and variability in measuring 
induration (Huebner et al., 1993). In addition, the response is not MTB specific, as it 
contains a crude mixture of proteins, which are shared widely by other mycobacteria, 
including BCG, and therefore cannot readily distinguish between BCG vaccination, MTB 
infection or exposure to other environmental mycobacteria. The sensitivity however, is 
highly dependent on the host immune status, and dramatically decreases with acquired 
immunodeficiency like HIV-1 infection, in children, treatment of corticosteroids (Menzies 
et al., 2007). In addition, on an average 10-20% of persons with active tuberculosis do not 
react, and the reaction is variable (Huebner et al., 1993). 
Advances in the genomic research of MTB lead to the landmark discovery of the genomic 
region of difference (RD1) which is absent in non virulent M. bovis vaccine strains (BCG) 
(discussed in detail later), led to the development of in vitro T cell based immunodiagnosis 
measuring Interferon- gamma  (IFN-γ) release in response to the RD1-encoded antigens 
ESAT-6 and CFP-10. The assays show promising results for diagnosis of latent 
tuberculosis with operational advantage requiring only one patient visit, higher sensitivity 
compared to the TST, and unaffected by prior BCG vaccination (Pai et al., 2009) and 
considered the major advance in the last decade (Lalvani and Pareek, 2009a; Lange and 
Mori, 2010; Pai et al., 2008). These assays are also less affected by the immune status of 
the person tested (Rangaka et al., 2007b). However, these assays do not differentiate 











Treatment of tuberculosis 
Antibiotic regimes used as anti-TB treatment, have been shown to be associated with cure 
rates of up to 95%, and require at least six months treatment. The necessity for long-term 
treatment has contributed to poor treatment adherence, which may be confounded by other 
factors such as re-treatment, poor medical supervision, irregular supply of drugs and 
inappropriate drug dosage, which eventually lead to the development of drug resistance. 
Alternative approaches like DOTS were introduced to handle the treatment services (Weis 
et al., 1994).  
It is estimated that 0.5 million cases of multidrug resistant TB (MDR-TB) (defined as TB 
that are resistant to at least isoniazid and rifampicin) occurs each year. In addition, 58 
countries have reported at least one case of extensively drug resistant tuberculosis XDR-
TB (defined as MDR-TB plus resistance to a fluoroquinolone and at least one second-line 
injectable agent: amikacin, kanamycin and/or capreomycin) as of March 2010 and 5.4% of 
MDR-TB cases are XDR-TB (WHO, 2010). 
Mycobacterium tuberculosis infection  
Infection with MTB follows a pattern of events that are established through observation in 
humans and in animal models. Tuberculosis is spread by airborne droplet nuclei, which 
contain Mycobacterium tuberculosis. It remains viable for minutes to hours, after 
expectoration by people with pulmonary or laryngeal tuberculosis during coughing, 
sneezing, or talking. The infectious droplet nuclei are inhaled and lodge in the alveoli. In 
the alveolar sacs, M. tuberculosis is engulfed by alveolar macrophages, key cells of the 
innate immune system that act as a front-line barrier against infection. The bacilli can resist 
the bactericidal mechanisms induced by the macrophages (i.e., phagolysosome formation), 
and multiply inside the phagosome (thus avoiding the macrophage apoptosis), in a 











leads to a local inflammatory response that results in recruitment of mononuclear cells 
from the neighboring blood vessels, providing fresh host cells for the expanding bacterial 
population. These cells constitute the granuloma, the hallmark of tuberculosis disease 
pathology. With the development of acquired immune response and the arrival of 
lymphocytes, the granuloma acquires a more organized, stratified structure (Russell et al., 
2010).  
The development of immune response (DTH) about 4-6 weeks after the primary infection 
is indicated by a positive TST reaction. The balance between the host immunity and the 
bacillary multiplication determines the outcome of the tuberculosis. 
An encounter with MTB is classically regarded to give rise to three outcomes:  (i) a 
minority of the population (5%) rapidly develop primary active TB disease – with clinical 
symptoms;  (ii) majority of the infected persons show no disease symptoms but develop an 
effective acquired immune response and referred to have latent tuberculosis infection; (iii) 
a proportion of those latently infected persons might reactivate and develop the disease and 
known as post primary active disease. 
Active TB 
5–10% of infected individuals (mainly infants) will develop rapidly progressive clinical 
disease and referred to as primary active TB. Primary TB usually occurs within 1–2 years 
after the initial infection. This results from local bacillary multiplication and spread in the 
lung or spread in the blood, through out the body, with seeding of bacilli in various tissues 
and organs. 
Post-primary, or secondary, TB can occur many years after infection owing to loss of 
immune control or the reactivation of latent bacilli. The immune response of the patient 
results in a pathological lesion that is characterized by localized, often extensive tissue 











includes extensive lung destruction with cavitation, positive sputum smear, and upper lobe 
involvement. Patients with these lesions are the main transmitters of infection.  
Latent TB infection 
Majority of MTB infected persons will not develop any clinical symptoms, and are 
referred as to have “latent” TB infection. Latent TB is defined on solely on the evidence of 
sensitization by mycobacterial proteins: a positive result in either TST or an in vitro 
interferon gamma (IFN- ) release assay (Pai et al., 2008). However, TST and IFN-  release 
assays do not distinguish latent TB from active disease. In contrast to the risk of MTB 
infection, which is largely determined by an exogenous factor, the risk of TB following 
MTB infection is largely endogenous, determined by the individual‟s immune status. A 
significant improvement in the understanding of the MTB latency is necessary to be able to 
answer question on the control of TB.  
The bacilli are then thought to enter a state of latency based resistant bacillary forms 
capable of surviving under stressful conditions generated by the host (Cardona, 2007). The 
actual physical location of bacilli during latent infection remains a topic of considerable 
debate over a decade and whether latency is synonymous to chronic persistent infection 
with viable MTB in all instances is not known. The knowledge of physical nature of MTB 
during latency is important to determine treatment, post exposure vaccine and diagnosis. 
The two common viewpoints, (although not mutually exclusive), that exists on latent TB 
are: (1) MTB persists mostly in a “lazy” state within granulomatous lesions, periodically 
recrudescent, a dynamic immunological interplay between MTB and the host, and a 
continuous recruitment of cells into the granuloma. Reactivation occurs when this dynamic 
cellular exchange becomes dysregulated; (2) dormant MTB reside within alveolar 











resuscitation promoting factors within MTB and the escape of newly dividing 
microorganisms into alveoli and bronchi (Ehlers, 2009). 
Spectrum of tuberculosis infection 
As a complication of purely clinical definition of active and latent tuberculosis, TB is 
commonly thought of as having a simple binary distribution. Although latent TB is 
generally related to bacterial containment in some inactive form, the current definition of 
latent TB includes a diverse range of individuals from those who have completely cleared 
the infection to those who are incubating actively replicating bacteria in the absence of 
clinical symptoms (Young et al., 2009), as also evident from animal models (Lin et al., 
2009b).  
Figure 2 Tuberculosis infection as a spectrum (Young et al., 2009) 
Likewise, a range of diverse pathological presentation characterizes active TB in humans 
and nonhuman primates, ranging from sterile tissue to caseous hypoxic lesion containing 











bacteria. Therefore it is proposed that the MTB infection may be better viewed as a 
continuous spectrum extending from sterilizing immunity, to subclinical active disease, to 
fulminant active disease corresponding to partially overlapping regions of biological 
heterogenicity (Barry et al., 2009; Young et al., 2009). 
Current Vaccine: BCG  
Bacille Calmette-Guérin (BCG) was one of the first live-attenuated vaccines to be used in 
humans. It remains the most commonly used and only available vaccine for tuberculosis 
worldwide, with over 120 million doses administered each year. BCG immunization is 
considered effective in children, providing 80% protection against severe and disseminated 
tuberculosis, such as tuberculous meningitis and miliary disease (Trunz et al., 2006; 
Walker et al., 2006). BCG immunization also reduces the risk of tuberculosis in adults, by 
an average of 50% as shown in a recent meta-analysis, however various reports suggests 
wide range of efficacy in different populations (Brewer, 2000; Colditz et al., 1994).  
Comparative genomics studies investigated the genetic diversity of BCG vaccine strains. 
In addition to the regions of difference, discovered in avirulent BCG in relation to M. 
tuberculosis and virulent M. bovis (Mahairas et al., 1996), genetic divergence with various 
BCG vaccine strains were also found. These can be characterized by the presence or 
absence of RD2, RD14, RD15 and RD16 (Behr and Small, 1997; Behr et al., 1999; Brosch 
et al., 2002; Gordon et al., 2001; Mahairas et al., 1996). BCG vaccines were thus divided 
in to early strains, represented by BCG Japan, BCG Birkhaug, BCG Sweden, and BCG 
Russia; and late strains including BCG Pasteur, BCG Danish, BCG Glaxo and BCG 
Prague (shown in Figure 3) (Brosch et al., 2007). Potential influence of these genetic 
differences, through antigenic variation, on the protective immunity and efficacy of BCG 
immunization with various vaccine strains has generated considerable concerns 











Behr and Small, first suggested that attenuation of BCG vaccine strains induced 
progressive loss of its efficacy and therefore it fails to mimic the natural infection of 
tuberculosis (Behr and Small, 1997).  The genetic diversity of different BCG vaccine 
strains has also been shown to have variable effect on immunogenicity (Aguirre-Blanco et 
al., 2007; Behr, 2002; Hussey et al., 2002; Mostowy and Behr, 2002; Narayanan, 2006; 
Vijayalakshmi et al., 1995; Wu et al., 2007). Most of the meta analysis of BCG vaccine 
efficacy, however used data set obtained from the use of late BCG strains (Colditz et al., 
1994).  
In South Africa, Davids et al., showed that BCG Japan induced higher frequencies of IFN-
γ producing CD4 and CD8 T cells, greater secretion of IFN-γ, TNF and IL-2 and greater T 
cell proliferation, than BCG Danish (Davids et al., 2006). This led to the speculation that 
early BCG vaccines strains might confer better protection against tuberculosis (Brosch et 
al., 2007). 
Recently, immune response to various BCG vaccine strains used world wide in both 
animal models and in humans has been reviewed. In animal models, BCG-Pasteur, BCG-
Denmark and BCG-Glaxo were found to associate more with better protection in mice and 
BCG-Danish more effective in guinea pigs. In humans, only small number of studies 
compared the immunological response between the use of different strains, however the 
results were either contradicting or inconclusive, and insufficient data available, amidst a 
good evidence to support the perception that the induced immune response and protection 
afforded against TB differs between BCG vaccine strains. The authors concluded that there 
is an urgent need for well designed, adequately powered studies to compare the immune 
response induced by different, genetically distinct BCG vaccine strains in humans, to 













Figure 3 Phylogeny of BCG vaccine strains (Brosch et al., 2007) 
 
With potential draw backs in all control measures, there is an urgent need for new 
immunodominant antigenic candidates to be developed as new vaccine and / or diagnostic 
tests: which could be potentially (i) useful as a post exposure prophylaxis in the latently 
infected persons, (ii) differentiate active and latent tuberculosis, (iii) used as diagnostic 
marker to identify those at high risk of developing active tuberculosis, and (iv) used to 
monitor treatment response. 
Correlates of protection 
In humans, correlates of protection against TB are not completely known. Studies 











the CD4+ and CD8+ T cell subsets (Lazarevic et al., 2005), are essential components of an 
effective immune response, but very little is known about the specific phenotypes of these 
cells and about the M. tuberculosis antigen targets (Delogu and Fadda, 2009). Moreover, it 
is thought that the humoral response against M. tuberculosis may not be relevant for 
protection (Kaufmann, 2001). 
The majority of T cells at the disease site in humans are CD4+ T cells, as their primary role 
is to produce cytokines that assist and orchestrate other immune cells in the environment. 
TB-specific CD4+ T cells produce primarily type 1 cytokines, or Th1 cytokines, which 
include interferon-gamma (IFN-γ), IL-2 and tumour necrosis factor (TNF) (Hanekom et 
al., 2007).  
In murine models, roles of CD4 T cells, IFN-γ and tumor necrosis factor (TNF) in 
controlling acute and latent MTB have been demonstrated (Botha and Ryffel, 2003; Flynn 
et al., 1993; Flynn et al., 1995; Mogues et al., 2001). In humans studies on those infected 
with HIV-1 provides evidence that increase in CD4+ T cell numbers with antiretroviral 
therapy correlate with the decrease in susceptibility to develop active tuberculosis, 
suggesting that these T cells play an important role in the protection against TB (Maartens 
and Wilkinson, 2007). The protective role of IFN-γ was best demonstrated by the fact that 
people with defective type 1 cytokine pathway poorly control non pathogenic 
mycobacteria (Newport et al., 1996). Administration of anti-TNF monoclonal antibody 
infliximab treatment was shown to reactivate TB in some patients (Keane et al., 2001).   
Although IFN-γ is essential to human defense against mycobacteria, it is increasingly 
recognized that assay of PBMC secretion of IFN-γ is a poor correlate of protection in field 
studies of tuberculosis (Hanekom et al., 2007). Greater attention to markers such as IL-2, 
which might better reflect immunological memory, is now being paid. The emerging 











infection. In a study assessing the capacity for IFN-  and IL-2 secretion by MTB specific T 
cells in HIV uninfected persons with active tuberculosis indicated a co-dominance of IFN-
 single positive and IFN- / IL-2 double positive T cell, followed by a shift to a 
dominance of IFN-  / IL-2 double positive and IL-2 single positive T cells after treatment 
(Millington et al., 2007). In HIV-1 infected persons, disease progression and increase in 
viral load is found to correlate with the loss of IL-2 secretory function by CD4 T cells. 
This novel finding implicates that IL-2 or IL-2 / IFN-  as correlate of protection (Day et 
al., 2008). 
Antigen discovery in tuberculosis 
Most humans have the inherent potential to control tuberculosis either partially or 
completely, following an exposure or infection. Evidence suggests that in those infected 
with Mycobacterium tuberculosis, 90% control the pathogen and prevent development of 
disease via the immune response. Therefore as suggested by Behr and Small (Behr and 
Small, 1997), a vaccine that could elicit an immune response similar to the natural human 
infection with MTB should be effective, and thereby contain bacterial multiplication, 
dissemination, limit tissue damage, and block the development of the disease. Identifying 
antigenic candidates capable of inducing TB specific cellular immune responses are thus 
crucial for vaccine development. 
Both T and B cell are thought to play roles in conjunction with each other in the immune 
regulation. The discovery of immunodominant antigens in M. tuberculosis has hitherto 
largely been based on dominance in antibody responses that are not the basis of protection 
against tuberculosis.  
Antigen discovery in tuberculosis is one of the most promising areas of current research 
priorities. Advances in the technologies such as genomics, proteomics and informatics 











al., 2005; Lin and Ottenhoff, 2008a; Vordermeier et al., 2009; Zvi et al., 2008). Empirical 
evaluation is still considered ultimately the most reliable methodology for such 
discoveries. However, technologies complementing and reducing the length and breath of 
experimental evaluation are widely desired.  
T cell recognition 
T cells are lymphocytes that recognize antigens, via their T cell receptors (TcR), in the 
form of processed peptide fragments presented with MHC molecules. The T cell subset 
responsible for regulating the immune response to M. tuberculosis is considered to be the 
CD4 T cells. CD4 T cell binds with MHC II molecules (described below) on the antigen 
presenting cells.  T cells expressing CD4 molecules recognize exogeneous antigens. The 
complex formed by the MHC II-peptide-TcR triggers an immune response and the release 
of various cytokines via type 1 consisting mainly of proinflamatory cytokines (IFN- , TNF 
and IL-2) or type 2 regulatory / inflammatory cytokine (IL-4, IL-10, IL5, IL6, IL13) (van 
Crevel et al., 2002).  
T cell recognition is a fundamental mechanism of the adaptive immune system by which 
the host identifies and responds to foreign antigens. Identifying T cell epitopes are 
important in understanding the disease pathogenesis and is crucial for the development of 
vaccine candidates. It has been theorized that effective vaccines can be developed using 
the minimum essential subsets of T cell epitopes (Lafuente and Reche, 2009).  
Components of T cell recognition  
Major histocompatibility complex (MHC) proteins, also known as human leukocyte 
antigens (HLA), play a vital role in the adaptive immunity mediated by the T cells 
(Dimitrov et al., 2010). MHC molecules are glycoprotein which bind short peptides, 
derived from host and/or pathogen proteins and presents them to T cells. There are two 











bind to peptides that are processed from endogenously synthesized antigen and are 
recognized by CD8 T cells. In contrast MHC class II molecules are expressed on most 
professional antigen presenting cells (APC), and they bind to peptides that are processed 
from extracellular antigens, and are recognized by the CD4 T cells. MHC (HLA) gene 
expression is codominant, and an individual typically can express 6 different MHC class I 
molecules and 12 or more MHC class II molecules. In the entire population, there are over 
a hundred of different MHC alleles rendering the HLA locus the most polymorphic gene 
system known (Terasaki et al., 2007). 
In the MHC class II molecules, the peptide-binding grove is open, allowing the N- and C 
terminal ends of the peptide to extend beyond the binding grove. Therefore the MHC II-
bound peptides vary widely in length (9-22 residue), although only a core of 9 residues 
(peptide binding core) fits in to the MHC class II binding groove. The MHC class II 
binding grove has pockets that are outlined by polymorphic residues in which peptide side 
chains are nestled. Therefore, positions 1 and 9 of the peptide-binding core of MHCII-
bound peptides are anchor positions (Wang et al., 2001). A major contribution however is 
due to a set of conserved hydrogen bonds that form between the amino acid components of 
the peptide core and the MHCII molecule (Lafuente and Reche, 2009). In addition, the 
peptide binding core flanking residues (PFR) also contribute to the overall binding and the 
resulting T cell response (O'Brien et al., 2008; Wilkinson et al., 1997a) 
The most important factor that contributes to the immune response to a protein is that the 
antigen-presenting cells (APC) must process and present T cell epitopes, which in turn 
triggers a T cell response. T cells recognize linear epitopes, which are derived from 
proteins that are processed by the APC. During the process, large numbers of peptide 
fragments are formed. However, only 2 % of all the fragments might have the right amino 
acid side chain that would allow them to bind to the MHC binding grove and be presented 











strength of T cell epitope binding to MHC molecule. Only peptides with the higher binding 
affinity to the MHC molecules are more likely to be recognized by the T cell receptor 
(Weber et al., 2009). 
T cell Epitope prediction  
The ability of MHC class II molecules to bind peptides has been traditionally assayed in 
vitro, using purified glycoprotein. Competition assays between the labeled ligand-peptide 
and the competitor peptides, using enzymatic detection system, were the most reliable and 
commonly used methods of comparing peptide-affinities. Assays utilize the direct binding 
of labeled peptides to live antigen presenting cells have the advantage that the binding 
occurs in a native environment (Buus, 1999). The peptide binding motifs have been studied 
by comparing peptide analogues with multiple single amino acid substitution or C – or N-
terminal truncation. 
Identification of T cell epitopes requires the synthesis of overlapping peptides that span the 
entire length of the protein, followed by experimental assay for each peptide, such as 
proliferation assays by thimidine incorporation (Jurcevic et al., 1996), measurement of 
IFN-γ and IL-2 secretion by ELISA or ELISpot (Pathan et al., 2001), Intracellular cytokine 
staining (Lalvani et al., 1998) or Tetramers (Altman et al., 1996), allowing the 
identification of a small number of  T cell epitopes. Although these methods allow accurate 
determination of the breadth of T cell responses in vitro, the systematic T cell epitope 
mapping of larger proteins is costly; cumbersome and restricts the ability to assay multiple 
protein candidates.  
Computer aided epitope prediction  
Alternative computational approaches have been developed for the prediction of T cell 











identification. These bioinformatic tools promise rapid movement from genome sequence 
to antigen discovery and vaccine design (Tsurui and Takahashi, 2007).  
There are multiple methods and models available for predicting MHC-peptide binding, 
which differ in the techniques and algorithms that are applied. In general, Peptide binding 
algorithms can be classified into 2 larger groups: (i) those that are generated from 
sequences of peptide binders (sequence based models or peptide-data driven models) and 
(ii) those that do not require any peptide binding data and are based solely on the sequence 
and structure of MHC molecules.  
The sequence based models in turn can be classified in to two types. (a) Those based on 
qualitative data that describe the ability of peptides to bind to MHC molecules (binders and 
non-binders); referred as binding pattern recognition models. These models predict, with 
some certainty, whether a test peptide binds to a given MHC molecule. (b) Those trained 
on quantitative data consisting of peptides whose binding affinity for MHC molecules has 
been determined; referred as quantitative binding affinity models. These models target the 
prediction of actual binding affinity for the peptides to MHC. The MHC binding peptide 
prediction algorithms are described in Figure 3 and the methods are reviewed in (Lafuente 
and Reche, 2009).  











Evaluation of MHC class II peptide algorithms 
MHC prediction algorithms are comprehensively and critically reviewed and suggest, the 
potentially advantages and drawbacks of each prediction algorithm, and significant 
progress has been reported with regard to in silico predictive accuracy and the range of 
MHC molecules that it can be targeted for peptide binding predictions. Peptide-data driven 
models were thought to overwhelmingly outperform modeling based methods (Lafuente 
and Reche, 2009; Nielsen et al., 2010; Stern and Calvo-Calle, 2009; Tsurui and Takahashi, 
2007). Several studies were carried out using experimental evaluation and compared the 
performance of these prediction algorithms with in vitro screening methods. Although 
these studies show some splendid examples of the utility of these methodologies, they also 
describe high levels of discrepancy in the prediction efficiency especially in the MHCII 
prediction system. Therefore, it has been widely suggested that until an efficient stand-
alone algorithm becomes available, these techniques need to be used with caution 
(Gowthaman and Agrewala, 2008; Gowthaman and Agrewala, 2009; Lin et al., 2008). 
 
Utility of in silico methods in the context of Mycobacterium tuberculosis antigen 
discovery 
With the advent of the whole genome sequence of MTB and the description of various 
genomic regions of interest, MHC-peptide binding prediction algorithms are widely used 
in the antigen discovery in human and bovine tuberculosis, in addition to other infectious 
diseases (Mustafa, 2009a; Mustafa, 2009b; Vordermeier et al., 2009; Wang et al., 2009a). 
Computational methodologies were used in the selection of 189 vaccine candidates from 
whole genome (3989 ORF) analysis of MTB (Zvi et al., 2008), and to identify novel 











Chapter 5 in this thesis describes the use of in silico methodology to predict MHCII- 
binding peptides using the ProPred algorithm. ProPred (Singh and Raghava, 2001) 
(http://www.imtech.res.in/raghava/propred/index.html) web interface allows to predict 
MHC Class-II binding regions in an antigen sequence, using virtual quantitative matrices 
as described by Sturniolo et al., (Sturniolo et al., 1999) and assists in locating promiscuous 
binding regions. Quantitative matrices are the most widely used models in predicting 
MHC-peptide binding. This has been developed by the use of peptide libraries to obtain a 
quantitative representation of the interaction of all natural amino acid residues with 
structurally identified binding pockets of HLA-DR molecule (pocket binding profile).  
ProPred allows prediction of all 51 HLA alleles, performs analysis for each HLA-DR 
allele independently and predicts the binding strength. Besides the server also has the 
option to plot the threshold profile (threshold versus binding peptides), which can assist the 
users in selecting an appropriate threshold for locating promiscuous binders. In addition to 
analyzing the best scoring peptide, the server computes the binding strength of all peptides 
in the selected subsequence and presents a calculated binding score.  
ProPred has been critically evaluated for its performance with empirical testing in 
comparison with other in silico prediction algorithms. RANPKPEP, SVMHC and ProPred 
were found to perform better than other programs for prediction of peptides binding to 
HLA-class II molecules (Gowthaman and Agrewala, 2008), while NETMHCIIPAN, 
ProPred, IEDB and MULTIPRED were found to be best predictors in vaccine research 
(Lin et al., 2008). 
 
Empirical techniques used in antigen discovery 
Assay of the T cell response to antigens of Mycobacterium tuberculosis is critical markers 











antigens will be critical to decide which should move on to further studies, and the ability 
to compare results would be an important aspect. However, these potential comparisons 
are confounded by variation in individual laboratory approaches that use different readout 
methodologies to define the immunogenicity of such candidates. These include: 
1. Nature of cells to be stimulated: whole blood or PBMC  
2. Nature of candidate antigen: overlapping synthetic peptides or recombinant 
proteins 
3. Time of culture: short term (< 24 hours), intermediate (2-3 days) or prolonged (>5 
days) 
4. Methods of read out: ELISA or ELISpot or FACS.  
These read out methodologies that are most widely in use; and the factors that influence 
the results of immunogenicity evaluation of candidate antigens are reviewed below. 
 
Use of Whole blood or PBMC 
 
Time to Incubation of whole blood and isolation of PBMC  
Time to incubation of whole blood and the isolation of PBMC are considered critical for 
the T cell-specific evaluation of antigens. The maximum time delay from the time of 
collection to the setting up of assay is 4 hours in our laboratory. However, delay in the 
incubation > 2 hours were reported to reduce T cell IFN-γ production in short term cultures 
(Hanekom et al., 2004). However, It has been shown that prolonged incubation time assays 













(Agger et al., 2003; Black et al., 2009; Black 
et al., 2002; Cockle et al., 2002; Ewer et al., 
2006; Hanekom et al., 2008; Sidders et al., 
2008; Weir et al., 1994) 
PBMC 
(Bertholet et al., 2008; Brock et al., 2004; Hanekom et al., 
2008; Jurcevic et al., 1996; Leyten et al., 2006; Wilkinson 
et al., 1998a; Wilkinson et al., 1998b) 
Advantages 
 Smaller blood volumes required 
 Assessment of a all types of 
peripheral blood leukocytes  
 The measured T cell response will 
reflect cellular and soluble 
components that affect antigen 
presentation and T cell activation 
 Requires relatively few resources 
 Assessment may often be 
completed in 2 phases: (i) 
immediate incubation with antigen, 
(ii) cryopreservation of plasma, 
fixed white cells (after red cell 
lysis) or RNA for later analysis. 
Advantages 
 Cleaner system for the study of novel antigen 
responses.  
 PBMC-based assays are incubated on a per-
cell basis and the results are corrected to 
number of cells used; resulting in increased 
sensitivity in T cell depletion, such as in HIV-
1 infection. 
 Allow for a description of T cell responses 
without the influence of other whole blood 
components. 
 Cryopreserved PBMC also enables batched 
analysis, which is of particular importance for 
reducing variability in antigen screening and 
also in longitudinal vaccination studies 
 Cryopreserved PBMC are available at a later 
date for application of scientific advances and 
re evaluation of novel finding. 
Disadvantages 
 Exact cell numbers are not known, 
T cell depletion therefore results in 
poor sensitivity 
 Measurement of response reflects 
not only T cells, but other 
peripheral blood components 
 Need for immediate processing of 
collected blood limits versatility in 
what may be measured 
Disadvantages 
 PBMC isolation results in considerable cellular 
loss and therefore require larger blood 
volumes 
 Culture of PBMC requires additional nutrients 
in the forms of foetal calf or unrelated human 
serum; however, serum-free media may also 
be used 
 In short term assays, the cellular activation as a 
result of PBMC isolation may result in higher 
backgrounds, compared with similar 
incubation of whole blood. 
 Optimal procedures such as liquid nitrogen storage 












Comparison of whole blood and PBMC based culture systems 
The comparability for the use of whole blood and PBMC based culture systems has been 
tested in tuberculosis and in other conditions. In a study comparing tuberculosis specific 
(ESAT-6 and CFP-10) IFN-γ response in overnight in house ELISpot using PBMC and 72 
hours whole blood culture, showed good correlation (r=0.689, p≤0.0001) and an agreement 
of 81% (k=0.59) (Scholvinck et al., 2004). However, when either in-house ELISpot 
(Adetifa et al., 2007) or commercial T.SPOT (PBMC) (Lee et al., 2006) was compared 
with the commercial QFT-GIT (whole blood), the PBMC based ELISpot / T.SPOT were 
found to have higher sensitivity than whole blood based QFT-GIT for detecting TB disease 
(Adetifa et al., 2007) and MTB infection (Lee et al., 2006) while the QFT-GIT was 
suggestive of higher specificity for detecting MTB infection (Lee et al., 2006). 
 
Effect of cryopreservation on T cells 
The frequencies and type 1 / type 2 cytokine signatures of recall antigen specific CD4+ and 
CD8+ T cell were shown to be unaffected after cryopreservation as examined by ELISpot 
(Kreher et al., 2003). The use of media additives and the temperature of the wash medium 
for thawing (37°C) were found to be important factors for maximizing the retention of 













Nature of stimulating antigen  
Recombinant proteins 
(Chen et al., 2009; Leyten et al., 2006; Lin 
et al., 2009a; Schuck et al., 2009; 
Wilkinson et al., 1997b) 
Synthetic overlapping peptides 
(Aagaard et al., 2004; Ewer et al., 2006; Jurcevic et 
al., 1996; Millington et al., 2007; Wilkinson et al., 
1997b) 
 Offers the advantage of 
studying T cell response as a 
whole protein. 
 To study functional, structural 
studies of the Protein, protein-
protein interaction and enzyme 
kinetic. 
 The production of recombinant 
proteins, the purification 
required for use in T cell 
assays is laborious and costly. 
 The advantage to use mixture of 
overlapping peptides include synthesise 
and purification in larger quantities, low 
cost as compared to the recombinant 
proteins.  
 Allow evaluation of dominant epitope 
regions within the proteins.  
 Allows design and selection of 
promiscuous HLA presentable regions 
of the protein and thereby reducing the 
cost of impracticability of larger 
number of proteins (Jurcevic et al., 
1996). 
Duration of incubation  
The fundamental difference in the assays used for the evaluation of antigen candidates in 
various laboratories is the duration of culture. The assays may have: 
Short incubation: assays measure the cytokine production by the short lived effector cells 
that are particularly well detected by ELISpot and Flow Cytometry.  
 6-12 hours (Whole blood/PBMC-FACS): For flow cytometry analysis, whole blood 
or PBMC are typically incubated with specific antigens for 6 to 12 hours. 
Brefeldin-A or Monensin is added for the last few hours (5 hrs) of incubation to 
capture cytokines intracellularly. The cells may be cryopreserved before further 
analysis. The advantage of this assay is that multiple parameters may be measured 











2008; Tena-Coki et al., 2010). The cost and resources required particularly for 
multiparameter analysis remains a major drawback. 
 16-24 hours (Whole blood / PBMC): Most widely used incubation time for 
ELISpot assays, and also for ELISA and FACS. 
Intermediate term incubation: 
 48-72 hours: Intermediate time assays measure both effector and memory T cell 
response. These are widely used to culture PBMC or whole blood and to measure 
the cytokine secretion in the supernatent (Scholvinck et al., 2004), but also been 
used for ELISpot based assays to identify response to antigens (Bertholet et al., 
2008). 
Prolonged incubation: 
 >5 days (whole blood, PBMC culture / Lymphocyte stimulation test and 
proliferation assay): assays measure the response of central memory T cells that are 
required to differentiate before producing enough cytokine response. Whole blood 
(diluted) or PBMC is cultured with specific antigens and incubated for 5-7 days, 
supernatents harvested and secreted cytokines are measured by ELISA or multiple 
cytokine measurement technologies (Black et al., 2002; Hanekom et al., 2008; Weir 
et al., 1994). 
The advantages of these assays include relative ease, and the low volume of 
samples necessary allowing a degree of automation and processing of large sample 
numbers 
 Cultured ELISpot assay: where PBMC is cultured with antigenic stimuli (+/- IL-2) 











Cultured ELISpot were shown to reveal more durable memory T cell response 
(Todryk et al., 2009) 
 Proliferation of PBMC is conventionally used with thymidine incorporation, by 
BrdU incorporation or by other non-isotopic stains (Roche). PBMC proliferation 
and soluble cytokine production has been extensively described for mycobacterial 
antigen studies (Jurcevic et al., 1996; Wilkinson et al., 1998a) and in novel vaccine 
trial (Beveridge et al., 2007). However, Thymidine incorporation, while sensitive, 
provides a single outcome, which cannot be combined with other markers, and 
leads to the generation of radioactive waste, with consequent disposal costs and 
hazards.  
Correlation of assays with various incubation time points 
Major discrepancy was reported between the results of two short-incubation assays  
(ELISA, ELISpot, FACS) and prolonged incubation time assay (6 day lymphocyte 
stimulation test or cultured FACS) using the same antigen stimulation. These differences 
have been attributed mainly to the variation in time duration of incubation (Leyten et al., 
2007; Schuck et al., 2009). Discordant results was also reported between overnight PBMC 
based ELISpot and 72 hour whole blood assay (Scholvinck et al., 2004). However these 
differences were suggested to be a result of the measurement of various components of the 
T cell response. 
Read out methods 
The most widely used read out methods in antigen evaluation are (i) ELISpot, (ii) ELISA 
and (iii) FACS.  
ELISpot (Enzyme-linked immunosorbent spot) uses nitrocellulose membranes and anti 
cytokine monoclonal antibodies for detection of T cell response. It is a commonly used 











stimulation with an antigen or peptide. It measures the number of spot forming cells (SFC) 
[cytokine producing cells] at a specific concentration of effector cells. Cytokine secreting 
T cells are detected as coloured spots via staining with an enzyme linked anti-cytokine 
monoclonal antibody.  The spots can be enumerated with the naked eye, however the 
development of ELISpot readers have automated the enumeration of spot forming cells and 
facilitated the ongoing development of standardized protocols. The assay was shown to 
have high sensitivity for detecting fewer antigen specific T cells per million PBMC. This 
techniques has been widely used in antigen evaluation and screening (Lalvani et al., 2001b; 
Bertholet et al., 2008; Chen et al., 2009). 
ELISA (Enzyme-linked immunosorbent assay) measures the quantity of cytokine secreted 
in to the culture supernatants (PBMC or whole blood) in response to the antigen 
stimulation. This is measured as the intensity of optical density produced by the enzyme 
liked substrate solution, read at an optimal wavelength. ELISAs for a cytokine (such as 
IFN- ) is most widely used assay, to measure the response to antigen in medium to long 
term culture assays (Leyten et al., 2006; Wilkinson et al., 2005a). 
Fluorescence-assisted cell sorting (FACS): Flow cytometry and intracellular cytokine 
staining enables the simultaneous measurement of multiple cell surface antigens and 
cytokine producing capacity at a single cell level.   It also enables the measurement of the 
proportion of specific subtypes within a population of cells and the absolute number of 
cells in a volume of whole blood. Flow cytometry in conjunction with fluorescent 
conjugated monoclonal antibodies (mAbs) are used to characterize distinct cell types and 
activation states. The use of anti-cytokine antibodies in a staining technique that allows the 
intracellular detection of cytokines and cell surface molecules, without the separation of 
cells, has greatly enhanced the use of flow cytometry to determine immunophenotype in 











Strategies in Antigen discovery 
There have been many strategies for identification of mycobacterial immunodominant 
antigens using post genomic methods including, proteomic identification, T cell epitope 
prediction, genomic comparison to identify pathogen specific open reading frames, and 
biology driven (expression under certain conditions). For the purpose of this thesis, further 
descriptions are restricted only to the later two.  
Genomic location: Role in T cell antigen discovery 
The major landmark in the T cell based antigen discovery of Mycobacterium tuberculosis 
was the description of distinct genomic regions of difference. Mahairas et al., (Mahairas et 
al., 1996) described 3 genomic regions of difference (designated RD1 to RD3) found to be 
deleted in avirulent BCG, when studied by subtractive genomic hybridization to identify 
genetic differences with virulent M. bovis and M. tuberculosis and avirulent BCG. Of 
them, it was found that RD1 has been conserved in all virulent laboratory and clinical 
isolates of M. bovis and M. tuberculosis. The reintroduction of RD1 into BCG was found 
to initiate expression of at least 10 proteins and was found to resulted in a protein 
expression profile almost identical to that of virulent M. bovis and M. tuberculosis as 
determined by two-dimensional gel electrophoresis (Mahairas et al., 1996). Another 
significant finding was also that RD2-encoded segment was found to be deleted only from 
sub strains derived from the original BCG Pasteur strain after 1925.  In addition they also 
identified that an ORF (ORF1C) in the RD1 encoded region contained previously 
described novel, immunogenic antigen esat-6 (Andersen et al., 1995; Boesen et al., 1995; 
Sorensen et al., 1995) and ORF2G in the RD2-encoded region contained Mpt-64 (Li et al., 
1993) a secreted protein absent in BCG and reported to be absent from some BCG  vaccine 











Since the completion of the whole genome annotation of Mycobacterium tuberculosis 
(Cole et al., 1998) several different approaches have been employed to compare the 
genomes of the members of MTB complex, extending from various DNA array 
technologies (Behr et al., 1999; Gordon et al., 1999a; Gordon et al., 1999b) to highly 
sensitive whole genome comparison (Brosch et al., 2007; Gordon et al., 2001) which 
detected the full range of polymorphisms and gene rearrangements. Many of these studies 
compared the virulent and avirulent strains in the hope of understanding the difference 
linked to changes in pathogenesis.  
Several genes encoded by the regions of difference, attracted researchers as they encoded 
potential virulence factors similar to those characterized for other microbial pathogens.  
Pym et al., further experimentally demonstrated that reintroduction of RD-encoded genes 
in to BCG does result in a significant increase in virulence (Pym et al., 2002) and Lewis 
KN et al., demonstrated that deletion of RD1 from MTB resembles attenuated BCG (Lewis 
et al., 2003). 
Two RD1-encoded, co regulated secreted proteins ESAT-6 and CFP-10 (Berthet et al., 
1998) have attracted considerable immunological interest as a result of potent antigenicity 
for T and B cells. Mice and Guinea pigs vaccinated with the recombinant strain of BCG 
complemented with ESAT-6 and CFP-10 were found to be better protected against 
challenge with M. tuberculosis, showing less severe pathology and reduced dissemination 












Figure 5 Deletions in the M. bovis genome in relation to MTB (Gordon et al., 2001) 
ESAT-6 and CFP-10 have been extensively investigated as T cell targets for 
immunodiagnosis of active tuberculosis (Arend et al., 2000a; Lalvani et al., 2001b; 
Mustafa et al., 2000; Ravn et al., 1999; Vincenti et al., 2003). Both antigens were found to 
be frequently recognized in vivo and in vitro based on the induction of delayed-type 
hypersensitivity responses and the ability to induce interferon-gamma production by 
lymphocytes, respectively. The combination of ESAT-6 and CFP10 was found to be highly 
sensitive and specific for both in vivo and in vitro diagnosis (van Pinxteren et al., 2000). 
Studies were also carried out to differentiate MTB infection with that of Mycobacterium 
avium complex (Lein et al., 1999) and to differentiate between BCG vaccinated with the 
hope to replace the non-specific PPD based Skin test.  
A few other RD encoded proteins (other than RD1) were evaluated to find potential 











In bovines, 13 ORFs from RD1, RD2 and RD14 regions of MTB genome was evaluated 
using overlapping peptide pools spanning the ORF were studied in M. bovis infected, BCG 
vaccinated and control cattle‟s and 8 immunodominant antigens (Rv1983, Rv1986, 
Rv3873, Rv3878, Rv3879c, Rv1970c, and Rv1769) were identified that could either 
differentiate BCG vaccinated and M. bovis infected or improve the specificity than PPD 
(Cockle et al., 2002).  
RD2 and RD11 encoded proteins such as MPT-64, CFP-21, nrdf1, PPE57, PPE59, 
Rv1978, were found to increases the sensitivity and specificity in detecting active TB 
when PPE57 or nrdf1 was used in addition to ESAT-6 or CFP-10 in IFN-  based ELISpot 
(Chen et al., 2009). CFP21-MPT64 fusion protein was found to improve the diagnosis of 
latent TB with increased sensitivity and specificity than TST (Fu et al., 2009).  
RD11 encoded Rv2654c was found to specific for the diagnosis of active TB (Aagaard et 
al., 2004) and one dominant peptide (p4) has been included in the commercialized IGRA 
QFT-IT to improve the specificity (Brock et al., 2004; Parkash et al., 2009).  
Al-Attiyah and Mustaffa, evaluated cellular immune response induced by 11 RD-encoded 
antigens (RD1, RD4, RD5, RD6, RD7, RD9, RD10, RD11, RD12, RD13 and RD15) using 
synthetic overlapping peptides covering the entire region. The authors conclude that RD1 
encoded antigens induced the best overall Th1 response in both active and latent 
tuberculosis; and that RD-encoded could be divided into two group, that preferentially 
induces the secretion of either IFN-  (RD1, RD5, RD7, RD9 and RD10) or IL-10 (RD12, 
RD13 and RD15) suggesting a possible role in protection and pathogenesis of tuberculosis 
(Al-Attiyah and Mustafa, 2008). 
Whilst genomic region based candidates offered MTB specific antigenic candidates and 
the potential of development into vaccine candidates, they however did not have the ability 











MTB biology driven antigen discovery 
An alternative genome based strategy of antigen discovery is to relate what is highly 
expressed by the bacilli in vivo or in vitro and there by available as an antigen, and relate it 
to what is recognized in vivo.  
It is believed that the bacilli themselves adapt to the stress condition upon the encounter 
under the adverse conditions created by the host immune response (latent TB). The ability 
to resume growth when conditions become favorable within the granuloma is however 
retained. These persistent bacteria are thought to have encounter depletion of nutrients, 
shifts in pH, production of growth limiting products, and depletion of oxygen and led to 
the various models of latency (Zhang, 2004), where in vitro bacterial cultures are subject to 
various stress conditions like hypoxia (Wayne and Sohaskey, 2001), nutritional starvation 
(Betts et al., 2002), acidic pH (Roxas and Li, 2009), nitric oxide, and high temperature 
(Stewart et al., 2002). MTB subject to these culture conditions (stress) were shown to 
induce distinct set of gene expression profiles (Betts et al., 2002; Roxas and Li, 2009; 
Rustad et al., 2008; Stewart et al., 2002; Zucker et al., 2001), different from normal 
optimum growth conditions. A detailed analysis of MTB genes that are switched on 
predominantly during latent stage infection was considered a research priority to lead to 
the identification of new antigenic targets for anti-TB strategies (Lin and Ottenhoff, 2008a; 
Lin and Ottenhoff, 2008b). As MTB is believed to encounter these stress condition in vivo, 
the genes that are highly induced under stress condition may also be highly expressed in 
vivo, and therefore these genes are considered to be available as potential antigens for T 
cell immune response and more likely antigenic. This approach has been shown to aid 
antigen discovery in bovines (Sidders et al., 2008). 
Hypoxia 
From a variety of human, animal and in vitro studies, it is apparent that the oxygen tension 











observations have led to description of models of latency and reactivation that suggest a 
prominent role for Oxygen status (Boshoff and Barry, 2005; Gomez and McKinney, 2004; 
Rao et al., 2008; Via et al., 2008). These in vitro culture models represent proxies of 
conditions that tubercle bacilli are thought to encounter in vivo during persistence in 
immune competent host.  
Initial hypoxic response and DosR (Dormancy Survival Regulon) 
The advent of MTB genome sequence made it possible to characterize the whole 
transcriptomic response of MTB in response to defined in vitro conditions using 
microarrays. Sherman et al., first described the initial hypoxic response of MTB where the 
transcriptional profile of H37Rv was evaluated, with samples taken from aerated log phase 
cultures and cultures exposed to 2 hours of 0.2% O2, which consisted of about 48 genes. 
Many of these genes were found to play a role in the adaptation of hypoxic stress. These 
genes were controlled by a two-component transcriptional regulator system DosR/DosS 
(Sherman et al., 2001) 
This was supported by the observation that the genes of DosR regulon, which are 
expressed as a part of adaptation to the initial hypoxic response of MTB, are upregulated in 
vitro in IFN-γ activated MTB infected murine macrophages (Schnappinger et al., 2003; Shi 
et al., 2003; Timm et al., 2003), and have increased level of RNA in human lung tissue in 
patients with active TB (Timm et al., 2003). 
DosR is widely considered essential for the TB latency and therefore, led to many studies 
looking at the immunogenicity of these candidate genes, and were found to encode a 
number of MTB antigens with the potential to induce a strong T cell IFN-γ responses 
(Black et al., 2009; Demissie et al., 2006; Leyten et al., 2006; Roupie et al., 2007; 
Wilkinson et al., 1998a). Acr-1 is one of the well described dosR regulated antigen, shown 











In animal models, mice persistently infected with MTB were shown to induce an immune 
response against Rv1733c, Rv2031c, and Rv2626c (Roupie et al., 2007) Another study 
evaluated 51 dosR antigens in 3 African populations and found Rv1733c, Rv0081, 
Rv1735c, and Rv1737c to induce high positive response in MTB infected persons (Black 
et al., 2009).  
DosR encoded immunodominant antigens were termed as “latency antigens” (Demissie et 
al., 2006; Leyten et al., 2006; Schuck et al., 2009), as some of these antigens were 
preferentially recognized, by a higher IFN-γ response, by those with latent infection, when 
compared to those with active tuberculosis.   
Evidence of infection stage specific antigens are reported in some assay condition: Acr-1 
(Demissie et al., 2006; Geluk et al., 2007; Wilkinson et al., 1998b); Rv1733c, Rv2029c, 
Rv2627c and Rv2628 (Leyten et al., 2006); Rv0569, Rv1733c, Rv1734, Rv2003, 
Rv2005c, Rv2006 (Schuck et al., 2009),  were shown to induce strong IFN-  response in 
those with latent tuberculosis and Rv2628 was found to be associated with cured 
tuberculosis and remote infection (Goletti et al., 2009). 
Further studies to characterize DosR, also revealed the regulon appears expressed in 
conditions marked by significant bacterial replication, suggesting that the role of dosR may 
not be specific to latency and that other factors may also be involved. This led to further 
characterization of the hypoxic response in more depth revealing that the initial hypoxia 
response regulated by dosR contributes modestly to survival under hypoxic conditions in 
vitro and it is dispensable for virulence in mice (Rustad et al., 2008). These observations 














Enduring Hypoxic Response  (EHR) of MTB 
The transcriptional profile of Mycobacterium tuberculosis H37Rv was evaluated through 
an extended time course, with samples taken from aerated log phase cultures and cultures 
exposed to four, eight, twelve, 24, 96, and 168 hours of hypoxia. Each hypoxic time point 
was analyzed with at least three biological replicates using high density oligonucleotide 
microarrays (Rustad et al., 2008). 
This lead to the observation that the ~50 genes of the DosR regulon are maximally induced 
early in the time course, but gradually declined such that by 24 hours, about half the 
regulon was not significantly induced. 
However, a second transcriptional response, much larger than the DosR regulon that was 
induced for much longer period, is now recognized. The number of induced genes 
increased until 96 hours into the experiment. The growth of these gene sets was largely 
found to be additive- each subsequent set contained most of the genes induced at the 
preceding time point. By four days of hypoxia, the number of induced genes seemed to 
stabilize. The enduring hypoxic response (EHR), was thus defined as the set of MTB genes 
not induced initially, but that are significantly up-regulated at four and seven days of 
hypoxia (Rustad et al., 2008).  
In addition, several EHR genes were found to show overlap between genes induced by 
nutrition deprivation and high temperature models (Rustad et al., 2008). Therefore, the 
analysis of these newly described genes of the EHR were considered interesting to offer 
insights into the hypoxic response of MTB and the resulting bacteriostasis.  In addition, 
EHR genes are also considered as potential drug targets (Murphy and Brown, 2008). EHR 

























Overall Aim  
This thesis presents the evaluation of in vitro human T cell reactivity of novel 
Mycobacterium tuberculosis antigens.   
The main focus of this thesis is the analysis of whole genome based, transcriptional 
profiles of Mycobacterium tuberculosis subject to 7 days of hypoxia (enduring hypoxic 
response) to guide antigen discovery, using bioinformatic analysis and empirical testing.  
Specific experiments directed to address the above aim are described in Chapters 5 and 6. 
The hypothesis include: 
1. Molecules highly induced when Mycobacterium tuberculosis was subject to 
hypoxia in vitro, may be expressed in vivo and thereby could be targets of immune 
response 
2. These molecules might provide further understanding in the biology of latent 
infection and may be preferentially recognized by the T cells during latent 
tuberculosis 
3. Genomic information from a pathogen might aid in antigen prediction 
4. Species specific genes of Mycobacterium tuberculosis are potential diagnostic 
targets. 
However, a preliminary comparison of various techniques and the performance of 
synthetic overlapping peptides in T cell assays are presented in Chapter 3.  
In addition, the T cell epitope mapping of previously described RD11-encoded Rv2654c 












Chapter 2: Materials and Methods 
 
The studies presented in this thesis, examine the in vitro reactivity of human T cells to 
antigens of Mycobacterium tuberculosis and bioinformatic analysis of hypoxia 
inducible MTB antigens. A detailed description of patients enrolled, as well as the 
immunological, microbiological and bioinformatic methodologies employed in these 
studies is described below. 
Ethical Approval 
The University of Cape Town research ethics committee approved these study 
(REC336/2004; REC 296/2007; REC 245/2009).  
Human Subjects 
Persons with active or latent tuberculosis were recruited at the Ubuntu clinic at 
Khayelitsha site B, South Africa. All were of Xhosa ethnicity (Chapter 4-7). In 
addition, 44 healthy volunt ers (laboratory and clinical staff) of mixed ethnicity, were 
enrolled in for the studies described in Chapters 3 and 4. 
Active tuberculosis (ATB) was defined by smear positivity for and/or culture of M. 
tuberculosis from one or more sputum specimens. Latent tuberculosis (LTBI) was 
defined by transverse TST reactivity of > 15 mm in response to 2 TU PPD (RT23) at 
48- 72 hours or an interferon-gamma (IFN-γ) Enzyme linked immunospot (ELISpot) 
response to ESAT-6 or CFP-10 of > 20 spot forming cells (SFC)/10
6
 PBMC in the 
absence of clinical symptoms or radiographic abnormality and with a negative sputum 











ATB patients were sampled prior to commencing anti-tubercular chemotherapy. 
Known immunosuppression for other reasons, age < 18 years and pregnancy formed 
other exclusion criteria. All persons underwent voluntary counseling and testing for 
HIV-1 infection and positivity was an exclusion criterion, with the exception 
described below.  
11 HIV-1 infected otherwise healthy persons, who were asymptomatic for any other 
infection, and naïve to anti retroviral therapy, were included in the study presented in 
Chapter 3. 19 HIV-1 infected persons who were starting combined anti-retroviral 
therapy (cART) and followed up for 36 weeks were included in the study presented in 
Chapter 6. 
Persons with ATB and / or HIV-1 infection were treated according to South African 
national guidelines. The baseline characteristics of subjects enrolled are described in 
the respective Chapters. 
Clinical Specimen 
Peripheral whole blood samples were used for all experiments presented in this thesis 
as described below. 
Heparinised peripheral whole blood 
30 ml of venous blood was obtained in tubes containing sodium heparin, from all 
patients enrolled in the studies presented in Chapters 3-6. They were transported to 














QuantiFERON-TB Gold In Tube 
Commercially available, QuantiFERON-TB Gold In Tube (QFT-GIT) tests were 
performed as per manufacturer‟s instructions, in studies described in Chapters 3 and 
4. One ml of whole blood is collected by venepuncture directly into each of the 
QuantiFERON
®
-TB Gold IT blood collection tubes [Nil Control (Grey cap), TB 
Antigen (Red cap) and Mitogen Control (Purple cap)] and mixed thoroughly (as 
antigens have been dried onto the inner wall of the blood collection tubes). 
In the peptide boosting experiments described in Chapter 4 the following modification 
was included: in addition to the three QFT-GIT, blood was also collected in an 
additional TB antigen and Nil tube, to which 5 g/ml of Rv2654c peptide covering 
region 51-65 was added. The tubes were transferred to a 37°C incubator within 4 
hours of collection and incubated for 16-20 hours. After incubation of the tubes at 
37°C, the plasma was harvested by centrifuging tubes for 15 minutes at 2000 to 3000 
RCF (g). The gel plug separates the cells from the plasma. The plasma was collected 
from over the gel plug and stored at -80°C for batched measurement by QFT ELISA. 
QuantiFERON TB Gold ELISA 
The QFT Gold ELISA was performed for the study presented in Chapter 3 and 4, 
according to manufactures instruction. All plasma samples and reagents, except for 
conjugate 100X concentrate, were brought to room temperature (22°C ±5°C) before 
use (at least 60 minutes for equilibration). The freeze dried Kit Standard was 
reconstituted with deionised or distilled water to a concentration of 8.0 IU/ml and 
mixed gently to minimize frothing and to ensure complete solubilisation.  Using the 
reconstituted kit standard, a 1 in 4 dilution series of IFN-γ in green diluent (GD) were 











(standard 3) contains 0.25 IU/ml, and S4 (standard 4) contains 0 IU/ml (GD alone)] 
and included in triplicates. The freeze-dried conjugate 100X was reconstituted with 
0.3ml of deionised or distilled water. The working strength of the conjugate was 
prepared according to the manufactures instruction (60 µl of conjugate in 6 mls of GD 
to be used for one plate (12 strips)). 50 µl of working strength conjugate was added to 
all the required wells. 50µl of test plasma (Nil, TB antigen and mitogen stimulated) 
and standards (S1-4) were added to respective wells. The plate was mixed thoroughly 
for 1 minute in a microplate shaker and incubated at room temperature for 2 hours. 
After incubation, the plates were washed with 400 µl of working strength wash 
buffer, and 100 µl of enzyme substrate solution was added to each well. Following 30 
minutes of incubation, 50 µl of enzyme stopping solution was added to stop the 
reaction and the optical density (OD) of each well was measured within 5 minutes 
using the Bio-Rad microplate reader, fitted with a 450nm and with a 655nm reference 
filters. The OD values are used to calculate results using QuantiFERON TB Gold 
analysis software v2.50. The cut-of for a positive result is defined by  >0.35 IU/ml of 
IFN-γ measured in TB antigen minus nil and as negative when <0.35IU/ml. The 
results for mitogen minus Nil <0.5IU/ml or Nil >8IU/ml of IFN-γ were considered 
indeterminate. 
Whole blood culture 
A diluted whole blood culture of 7 day incubation (Beveridge et al., 2008; Weir et al., 
1994) was performed for the study presented in Chapter 3. Whole blood was diluted 
1:10 in RPMI 1640 medium containing 1% L-Glutamine. A 48 well (flat bottom) 
plate was set up with the antigens and controls with a final volume of 1000µl. The 
antigens were reconstituted in the desired concentration with RPMI 1640 Medium 











included as a mitogen / positive control and RPMI 1640 medium with 1% L-
Glutamine as a negative control. 900 µl of diluted blood was added to the antigen 
plate and sealed with micro-pore tape, to avoid evaporation during incubation at 37°C 
with 5% CO2. After incubation for 7 days, the supernatants were harvested and stored 
at -20°C until used for IFN- γ ELISA. 
Peripheral Blood Mononuclear Cell (PBMC) Isolation 
Whole blood was diluted 1:1 with 1 X Dulbecco‟s Phosphate Buffered Saline (PBS) 
(Sigma®, UK) and slowly pipetted over a 10 ml layer of Ficoll-Paque PLUS (GE 
Healthcare Bio-Sciences AB) in a 50ml Falcon universal tube (Sterilin).  The tube 
was centrifuged at 1820 rpm for 20 minutes with the brakes off.  The whole blood 
separated into layers and the buffy layer was removed using a plastic pasture pipette.  
The buffy layer consisting of the PBMC was washed in RPMI-1640 Medium 
(Sigma®) without additives and centrifuged at 600 RCF for 10 minutes with the 
brakes on.  The RPMI was poured off leaving a pellet of PBMC behind.  This pellet 
was re-suspended in 10ml RPMI with 10% heat inactivated Fetal-Calf Serum (HI-
FCS) (RPMI/10%FCS) (Sigma), after which the number of PBMC was counted.  A 
1:1 dilution of PBMC in RPMI/10% FCS was added to a 0.4% trypan blue solution 
(Sigma®) and counted in a disposable, 10 chamber plastic counting slide.  PBMC 
were frozen in a 1:1 dilution of RPMI / 10% FCS and cell freeze medium (20% 
DMSO in FCS) in a stepwise manor using MrFrosty at -80ºC freezer overnight, then 
transferred to liquid nitrogen, and stored in vapour phase until used for the 













In house IFN-γ release assay 
In house ELISA were performed for the experiments described in chapter 3 as per the 
approved standard operating procedure of the Laboratory (Connell et al., 2007; 
Rangaka et al., 2007a). Plates (Costar 3590, 96 well EIA/RIA plate, high binding) 
were coated with captured antibody (Mouse anti-human IFN-γ monoclonal capture 
antibody (BD #551221) overnight at 4ºC. The plates were washed and blocked for 2 
hours at room temperature, and washed. 100 µl of samples and standards 
(recombinant human IFN-γ (BD #554617) were added to the respective wells and 
incubated overnight at 4ºC. Following incubation, the plates were washed and 100µl 
of biotinylated secondary antibody  (Biotinylated mouse anti-human IFN-γ detection 
antibody (BD#554550) added and incubated for 45 min at room temperature, washed 
and 100 µl of avidin peroxidase (sigma A3151) added and incubated at room 
temperature for 30 min. Following incubation, the plates were washed and 100µl of 
OPD solution (SigmaFast OPD tablet set) was added and incubated in dark for 5 min 
or until color develops. The reaction was stopped by 50µl of 2M H2SO4 (Sigma 
32,0501). The plates are read at 490nm with BioRad plate reader. The detection range 
of the ELISA was 0-3000 pg/ml of IFN-γ. 
Experimental procedures using PBMC  
Thawing and resting of PBMC 
Cryopreserved PBMC were thawed and rested overnight for all studies described in 
chapter 3-6. The cryovial containing the desired PBMC were transferred from liquid 
nitrogen to a 37ºC incubator (with the cap slightly loose to allow the nitrogen to 
escape during thawing). When the PBMC almost thawed (a small bit of ice remains), 











containing 10% FCS (37ºC) in a drop wise fashion with constant gently mix (1 ml cell 
suspension to 9 ml RPMI in a 50 ml Falcon centrifuge tube) and centrifuged at 1680 
rpm for ten minutes.  The supernatants are discarded and the pellet are suspended in 
10ml of RPMI containing 10% HI-FCS. Viable cell numbers are determined using the 
cell counting chamber with trypan blue stain, which differentiates dead and viable 
cells, (dead cell nucleus takes up the stain). The tubes containing the cell suspension 
are washed by centrifugation at 1680 rpm for 10 minutes and pellets are reconstituted 
at 10
6
 per ml with RPMI containing 10% FCS. The cell suspension is rested overnight 
at 37ºC with 5% CO2, with the lid slightly loose. After overnight resting (12-16 hrs), 
tubes are centrifuged at 1680 rpm for ten minutes and cells counted. The pellets were 
re-suspended at the required concentration for ELISpot, cell culture or FACS 
experiments. 
ELISpot assay 
The interferon-gamma ELISpot assay was performed in studies described in chapter 
3-6 (Wilkinson et al., 2009). Ninety-six well pre-coated ELISpot plates, mAb 1-D1K 
(Pre-coated One-step, Mabtech; 3420-2ATP-10) were washed 4 times with sterile 
PBS, blocked with RPMI with 10% FCS for ≥30 min at room temperature. The 
blocking medium was removed and the PBMC were set up with respective antigenic 
stimuli. Control stimuli for ELISpot included anti-CD3 mAb CD3-2 at 100 ng/ml 
final concentration and unstimulated wells. After incubation for 16-18 hours at 37ºC 
with 5% CO2, the cell free supernatants were collected and stored at -20ºC until used. 
The plates were washed 5 times with PBS, and 100µl of secondary antibody, mAb 7-
B6-1-ALP conjugate at 0.5mg/ml final concentration in PBS containing 0.5% FCS 











use substrate solution (BCIP/NBT-plus) was added and developed until spots 
emerged, washed with tap water and allowed to dry. 
IL-2 ELISpot was performed for studies described in chapter 5 and 6. 96- well 
polyvinylidene difluoride membrane based plates, type ELIIP (MAIPSWU10; 
Milipore Corp), were activated by a brief treatment for < 2 minutes with 70% ethanol, 
coated overnight at 4ºC with 15µg/ml of mAb IL2-I (Mabtech; 3440-2AW-Plus). The 
plates were then washed and blocked with R10 for ≥ 30 min. The blocking medium 
was removed and the PBMC were set up with respective antigenic stimuli. Control 
stimuli for ELISpot included anti-CD3 mAb CD3-2 at 100ng/ml final concentration 
and unstimulated wells. After 16-hours of incubation at 37ºC in 5% CO2, the plates 
were washed, 100µl of detection antibody (IL-2-II-biotin) at 1mg/ml in PBS 
containing 0.5% FCS added and incubated at room temperature. After 2 hrs, 100µl of 
Streptavidin-ALP 1:1000 in PBS-0.5% FCS was added and incubated at room 
temperature. After 1 hour, 100µl of substrate solution (BCIP/NBT-plus) was added 
and developed until distinct spots emerged. Plates were washed with tap water and 
allowed to dry. 
Spot forming cells were enumerated by immunospot counter (CTL, Cellular 
Technology Ltd) and confirmed by microscopy (X4).  Results are quoted as cytokine 
spot forming cells (SFC)/10
6
 PBMC. A positive score is defined as SFC score twice 
as that of the background or  2SD of the background response, below which is 
defined as a negative score. The assay is termed indeterminate when either the SFC 
response in the background is > 20 SFC/10
6
 PBMC or SFC response of positive 













 The cut-off for positive results for IFN-γ ELISpot were set to ≥15 SFC/10
6
 PBMC 
(above the background) for the study described in chapter 4. A cut of ≥20 SFC/10
6
 
PBMC (above the background) was set for both IFN-  and IL-2 ELISpot response in 
Chapter  5 and 6, however, the cut of was arbitrarily increased to ≥30 SFC/10
6
 PBMC 
(above the background) to define immunodominance for novel antigens in the study 
described in Chapter  5.  
The ELISpot (IFN-γ and IL-2) experiments described in Chapter 6, using live M. 
tuberculosis strains H37Rv (wild type), H37RvDRD2 (H37Rv RD2 knockout mutant) 
and H37RvDRD2::Rv1986 (H37Rv RD2 knockout mutant, complemented with 
Rv1986), were performed as described above. 200,000 PBMC/ well were co-cultured 
with 200,000 live bacteria / well for 16-18hrs (in duplicate wells). The counts from 
duplicate well were averaged and used for further analysis. 
Cell Culture 
In vitro cell cultures were performed for the studies presented in Chapter 3 and 6. 
200,000 - 250,000 PBMC were cultured with required concentration for 1 day, 3days, 
5 days and 7 days for experiments described in Chapter 3, at 37°C in 5% CO2. 
Control stimuli for cell culture included PHA at 5µg/ml final concentration and 
unstimulated wells. After incubation for the respective time points, the plates were 
centrifuged at 2000 rpm for 5 minutes and cell free supernatant were collected and 
stored at -20°C until used. 
Surface markers and Intracellular cytokine staining for flow cytometry 
Intracellular cytokine assay was performed for the experiments presented in Chapter 3 











For the experiments presented in Chapter 3, 200,000 PBMC were co-cultured with 
Purified Protein Derivative (PPD) (2µl; 1000U/ml final concentration) and controls 
including Staphylococcal Enterotoxin B (SEB) as positive control at 10µg/ml and 
unstimulated cells as negative control at 37°C with 5% CO2. After 2 hrs, Brefeldin A 
at 5µg/ml (Sigma, St. Louis, MO) was added to capture the newly formed cytokines 
in the golgi apparatus. After 16 h incubation (in total), the cells were washed with 
PBS (1X), stained for the surface marker CD3 (FITC) and CD4 (PerCp) (3µl of 
surface Ab each) for 30 minutes at 4°C. The cells were then fixed and permeabalised 
with BD Cytofix/Cytoperm for 20 minutes at 4°C, after which the cells were stained 
with intra cellular stain for IFN-γ (APC) (10 µl of 1:10 of diluted antibody in perm 
wash) for 30 minutes at 4°C. After incubation, the cells were washed, and pellets re-
suspended in 150µl perm wash buffer and a minimum of 20,000 cells was acquired on 
BD FACS Calibur. The data was analysed with Flow Jo (Tree Star).  
For the experiments presented in Chapter 6, 1.5-2 x 10
6
 PBMC were incubated with 
the two Rv1986 peptides (residues 61-80 and 161-180) at 10 µg/ml each (i.e., 20 
µg/ml peptide in total) or a pool of 21 peptides from CFP-10 and ESAT-6 at 2µg/ml 
each (i.e, 42 µg/ml peptides in total) at 37°C. Control stimuli included SEB as 
positive control at 10 µg/ml and unstimulated cells as negative control. After 2 hrs, 
Brefeldin A at 5µg/ml (Sigma, St. Louis, MO) was added to capture the newly formed 
cytokines in the golgi apparatus. After 16 h incubation (in total), the cells were 
washed with PBS (1X). For 8 colour surface and intracellular staining the cells were 
first permeabilized, and fixed using Cytoperm/cytofix buffer (BD) for 20 min at 4°C, 
washed with BD Perm/wash and stained with antibody cocktail in BD perm/wash for 
1 hr at 4°C. The antibodies used were as follows: CD3-Pacific Blue (1µl/tube), CD4 











FITC (5µl/tube), TNF Cy7PE (5µl/tube), CD45RA- APC (3µl/tube), CD27-PE 
(3µl/tube), all of which were purchased from BD BioSciences. 
10
6
 cells were acquired on the LSR II flow cytometer (BD Bioscience). Cell doublets 
were excluded using forward scatter area vs. forward scatter height parameters. 
Unstained cells and single-stained mouse calibration beads were used to calculate 
compensations for every run. Data analysis was performed using FlowJo v 8.8.2 (Tree 
Star), Pestle v 1.6.1 (NIH) and Spice v 5.05013 (NIH). T cell phenotypes were 
defined based on the surface markers CD45RA and CD27: Central memory cells 
(TCM) as positive for CD27 and negative for CD45RA; effector memory (TEM) are 
negative for both CD27 and CD45RA and Terminally differentiated T cells (Tdiff) 
are negative for CD27 and positive for CD45RA. The results are expressed as the 
percentage of CD3+ CD4+ T cells. 
Multiplex cytokine analysis 
Multiplex cytokine analysis was performed as per manufacturer‟s instructions, for the 
experiment described in Chapter 6. Bioplex, mixed-to-order panel  (premixed 
multiplex panel) from Bio-Rad was used for multiplex cytokine analysis. The assay 
was carried out according to the manufacturer‟s instructions as follows: the 96- well 
filter plate was pre- wet with 150µl of Bio-Rad assay buffer and the buffer removed 
by vacuum filtration. 50µl of multiplex bead working solution was added to the wells 
and the buffer removed. 100µl of Bioplex wash buffer was added to each well and 
washed twice and the buffer removed. 50µl of standard and sample was added to the 
respective wells, the plate was sealed and then covered by aluminium foil and placed 
over a microplate shaker. The speed of the shaker was increased to 1100 RPM for 30 











incubation, the plates were washed 3 times with Bioplex wash buffer. 25 µl of 
Bioplex detection antibody working solution was added, and incubated for 30 min as 
above on the microplate shaker at room temperature. The plates were washed 3 times 
with Bioplex wash buffer and 50 µl of streptavidin-PE was added, and incubated for 
10 min, washed 3 times with Bioplex wash buffer. Beads were re-suspended with 125 
µl of Bioplex assay buffer, mixed over the micro-plate shaker at room temperature at 
1100 rpm for 30 sec and read on the Bioplex suspension array system. 
Microbial culture conditions, hypoxia model and microbial RNA analysis 
The results of experiments performed in the Seattle Biomedical Research Institute, 
Seattle, Washington, USA formed the basis for our studies presented in Chapter s 5-6. 
These techniques have previously been extensively described (Rustad et al., 2008). 
Briefly, exponential phase cultures grown in rolling culture to an OD600 of 0.3 were 
diluted to a starting OD of 0.1 with warm media.  500 mL of this starting culture was 
transferred to a constantly stirred one litre flask.  Hypoxia was generated by 
introducing a constant flow of nitrogen with trace amounts of oxygen (0.2% O2), 
leading to bacteriostasis.  Samples were taken before hypoxia, at four hours, and after 
1, 4, and 7 days of exposure to hypoxia.  RNA was isolated from these samples using 
bead beating in the presence of Trizol, followed by chloroform extraction and 
precipitation of RNA.  The RNA was further cleaned using an RNeasy kit (Qiagen).  
Approximately 3 µg of purified RNA was converted to cDNA using Superscript III 
(Invitrogen).  Aminoallyl dUTP was included in the cDNA reaction, and subsequently 
conjugated to reactive Cy dye esters.  The aerobically growing transcriptional profiles 
were directly compared to each subsequent hypoxic time point by co-hybridization on 











Pathogen Functional Resource Centre at the J. C. Ventner Institute as part of their 
NIAID contract N01-AI-15447.  Slides were scanned with a GenePix 4000B 
purchased from Axon Technologies. Raw background subtracted intensities were 
normalized to SigA to provide approximate measure of transcript abundance. 
The lists of genes and their fold induction and normalised intensity measures at 4 
hours, 24 hours, 96 hours and 168 hours were obtained collaboratively and analysed 
the using bio-informatic techniques with the results presented in Chapter 5. 
Bioinformatics evaluation 
Bioinformatics analysis formed the major part of the evaluation presented in Chapter  
5 and 6. The results are discussed in detail in respective chapters. 
TubercuList (http://genolist.pasteur.fr/TubercuList/ or http://tuberculist.epfl.ch/) and 
TB database (TBDB) (http://www.tbdb.org/) were used to interrogate Enduring 
Hypoxic Response genes; coding and protein sequence for each of the genes were 
obtained for further evaluation. 
NCBI BLAST (http://www.ncbi.nlm.nih.gov/BLAST/Blast.cgi) was used to find 
regions of high similarity in biological sequence with the sequences in nucleotide and 
protein database. In addition, Local BLAST applications available at the TB database 
were also used for evaluation of protein sequences with the protein database (TB 
genome). 
ProPred (Singh and Raghava, 2001) (http://www.imtech.res.in/raghava/propred/), a 
web-based server was used to predict MHC class II binding regions in an antigen 
sequence. The analysis was carried out with a threshold of 1% (high stringency) in all 











of highest binding score any peptide could attain for that particular allele, was 
calculated for each allele per protein. 
Pubmed (http://www.ncbi.nlm.nih.gov/pubmed/) was used for extensive literature 
search and to review all existing literature, if available, for the EHR genes. 
Information on their antigenicity, whether they are known to induce any immune 
response; whether the genes are essential (Sassetti et al., 2003) and the distribution of 
MHC class 2 allelic frequency in South African Population (du Toit et al., 1988) were 
obtained from literature. 
Antigen Preparation 
Studies described in this thesis used synthetic overlapping peptides (Chapter  3-6) and 
recombinant  (chapter 3) proteins of Mycobacterium tuberculosis. The synthetic 
overlapping peptides used were 15-20 mers as the focus of the studies presented in 
this thesis were to study the CD4 response. The purity of the synthetic peptides 
purchased ranges between >90-95 %. 
Tuberculin Purified Protein derivative (PPD) was obtained from Evans Vaccines, 
Liverpool, UK. 10,000U/ml stock in PBS were stored at -80°C and used at 1000 U/ml 
final concentration was used in experiments described in chapter 3. 
Recombinant ESAT-6 and CFP-10, obtained collaboratively from Apronex, Czech 
Republic were used in experiments presented in Chapter 3. Recombinant proteins 
were reconstituted with PBS- 2% BSA and were used at a final concentration of 5 
µg/ml (Table 5 and 6). 












Overlapping peptides covering, ESAT-6 and CFP-10 used in experiments described in 
Chapter 3 and 4 were 15-mers overlapping by 10 residues, obtained from Peptide 
Protein Research Ltd, Oxford, UK. Mixtures were prepared in DMSO and PBS and 
the final dilution of each peptide was 3 µg/ml (Table 5 and 6). 
20-mers overlapping by 10  residues covering the entire length of Rv2654c and 
Rv1733c; and 15-mer truncated peptides for Rv2654c, were used in experiments 
presented in Chapter 4. These were synthesized by the Research Group of Peptide 
Chemistry, Hungarian Academy of Sciences, Eotvos Lorand University, Budapest, 
Hungary, within a joint, Hungary-South Africa research cooperation programme, 
funded by the National Research Foundation of South Africa. The peptides were 
dissolved in DMSO (0.1-0.3% final concentration) and PBS with 2% BSA and stored 
at -20 C until used (Table 9 and 10). Peptides were used at a final concentration of 3 
µg/ml. 
ESAT-6, CFP-10 and Acr-1 used in experiments presented in Chapter 5-6, obtained 
collaboratively from Veterinary Laboratories Agency, were 16-mers overlapping by 8 
. The peptide mixtures, were prepared in DMSO (0.1% final concentration) and 
PBS, Stocks of 2 mg/ml were stored at -80C until used (Appendix A.1). Peptides 
mixtures were used at a final concentration of 10µg/ml. 
All synthetic peptides used in experiments presented in Chapters 5-6 were 20-mer 
peptides overlapping by 10 residues and were purchased from Peptide Protein 
Research Ltd, Oxford, UK and from Pepscan Presto B.V, Netherlands. The peptide 
mixtures were prepared with DMSO (final concentration of 0.1-0.2%) and PBS and 











Recombinant MTB strains 
Recombinant strains described in the experiment presented in Chapter 6 were 
obtained collaboratively from Dr. Marcel Behr‟s lab at McGill University Health 
Centre, Montreal Canada. Briefly, the MTB H37Rv∆RD2 strain (RD2 mutant) was 
prepared using homologous recombination and sucrose counter-selection as 
previously described (Sherman et al., 2001). This mutant was then electroporated with 
either the empty plasmid pMV306 or the same plasmid into which Rv1986 from 
H37Rv had been cloned. This gene was expressed under its native promoter. This 
resulted in the MTB H37Rv∆RD2::pMV control (RD2 muta t) and MTB 
H37Rv∆RD2::Rv1986 (RD2 mutant complemented with Rv1986) strains, which were 
grown in 7H9 + ADC + 0.05% Tween 80 + Kanamycin (25mg/ml)  and glycerol 
stocks were prepared.  
Colony forming units were determined. 200,000 bacilli were used at a final volume of 
10µl and co-cultured with 200,000 PBMC.  
Modifications include, treatment with Isoniazide treatment (Isonicotinic acid 
hydrazide, Sigma I-3377), at a final concentration of 1µg/ml and heat killing at 56°C 
for 30 minutes in a water bath. 
Statistical analysis 
The normality of data was assessed by the D‟Agostino and Pearson omnibus test 
using Graphpad Prism 5.0 software (www.graphpad.com). Parametric continuous 
variables were assessed by student‟s paired and unpaired t-tests, and non-parametric 
by Wilcoxon matched pairs, Kruskal Wallis test with Dunn‟s post test correction or 
Mann Whitney U tests. Contingency analysis was by Fisher‟s exact test of 
probability: kappa statistics was used to test the agreement between two tests.  











Chapter 3: Comparison of various techniques and performance 
of peptides in in vitro blood cultures 
Abstract 
Studies on antigens of Mycobacterium tuberculosis are of wide interest to improve vaccine 
efficacy and to define a biomarker for diagnosis and monitoring of treatment. The 
methodologies used for these investigations differ greatly between laboratories and the 
discrepancies between results are inevitable. The following investigations are addressed in 
this chapter. 
Firstly, IFN-  response to well characterized MTB proteins was evaluated in HIV-1 
infected and uninfected persons, by 3 different techniques: Overnight IFN-  ELISpot and 
FACS analysis; and 7 day PBMC culture. Findings show that HIV-1 infected persons, have 
a lower ability to induce an immune response to MTB proteins, by all 3 techniques and 
suggests that the proportion of terminally differentiated activated T cells, effector memory 
and central memory differ between HIV-1 infected and HIV-1 uninfected. Poor correlation 
between the techniques suggests phenotypic heterogeneity between what is measured by 
specific readouts.  
Secondly, discrepancies in IFN-  response between short and prolonged in vitro culture 
systems and the performance of synthetic peptide mixtures and recombinant proteins were 
studied in the context of whole blood cultures. The results suggest that recombinant 
proteins perform well in prolonged in vitro whole blood cultures, whilst the peptide pools 
perform poorly. The activity of peptides and recombinant proteins do not differ in short 
term or long-term PBMC culture assays. In addition, results provide evidence that the use 
of DMSO (up to 0.3% final concentration) to dissolve synthetic peptides do not affect the 
viability or the activity of the antigens. Further findings suggest that peptides are degraded 












In vitro studies on antigens of M. tuberculosis are a research priority, to discover new 
immunododminant targets to improve immuno diagnosis and vaccines. Various 
laboratories use different techniques and read out methods to compare the performance of 
new candidates.  
The measurement of Mycobacterium tuberculosis antigen specific T cell Interferon-gamma 
(IFN-γ) production has received great attention and is used widely for determination of 
immune recognition in antigen discovery. First generation IFN-γ release assays used 
purified protein derivate of MTB, which has also been used in Mantoux test (Tuberculin 
Skin Test) for over one hundred years. The specificity of these assays were highly 
compromised, due to the cross reactivity of immune response to homologous proteins in 
tuberculous, non tuberculous and environmental mycobacteria.   
New generation IFN-γ release assays were developed which use MTB specific ESAT-6 
and CFP-10, a co-expressed immunodominant antigen encoded by the region of difference 
(RD)-1. These antigens were first evaluated in a 6-day lymphocyte stimulation test (LST) 
and found to be highly specific for the diagnosis of tuberculosis (Arend et al., 2000b; Ravn 
et al., 1999). IFN-γ release assays were subsequently developed that differed from the 
classical LST with respect to the following described in Table 1. 
Studies have shown that T cell responses to MTB specific antigens: recombinant ESAT-6 
and CFP-10 correlated with the respective mixture of synthetic overlapping peptides when 
PBMC of MTB specific cell lines were used (Arend et al., 2000b), IFN-  results from short 
term (24- 72 hours) PBMC and whole blood cultures found to correlate (Scholvinck et al., 











immune response between short term and long-term culture conditions (Beveridge et al., 
2008; Leyten et al., 2007).  
Table 1 Various formats of techniques used in immunodiagnosis and antigen screening 

















- 24 hours 
- 48 hours 
- 72 hours 





In this chapter, the following investigations, were performed within the context of the 
techniques involved in the antigen screening and are described in two groups of 
experiments:  
In the first group of experiments, 
1. Evaluation and comparison of IFN-  response to MTB proteins measured by 3 
techniques: Overnight (16-18 hour) T cell ELISpot and FACS analysis, and 7 day 
PBMC culture and ELISA. This was evaluated in HIV-1 infected and HIV 
uninfected person with latent tuberculosis. 
2. The ability to induce an IFN-  response, between HIV-1 infected and HIV 
uninfected were compared. 
3. Correlation of IFN-  response detected by 3 techniques was assessed. 
In the second group of experiments: 











5. Comparison of short term commercial QuantiFERON TB Gold In Tube (QFT –
GIT) assay with prolonged (7 day) in house in vitro culture assays using ESAT-6 
and CFP-10 to induce an IFN-  response.  
6. Performance of MTB antigens in the form of synthetic overlapping peptide 
mixtures and recombinant proteins in long term whole blood culture assay system. 
Due to the exploratory nature of the experiments presented in this chapter, the results 











Results and Discussion 
Comparison of PPD specific IFN-γ production in HIV-1 infected and HIV uninfected 
persons using various techniques 
A study was designed to compare IFN-γ production in HIV uninfected and HIV-1 infected 
persons using 3 different techniques: the overnight ELISPOT assay, measurement of 
CD4+IFN- + T cells by intracellular flow cytometry (IC-FACS) and the 7 day PBMC 
culture method, using ELISA to quantitative secreted IFN-γ in the culture supernatant (7d-
IFNGRA).  
Twenty-four healthy patients were recruited from Khayelitsha township near Cape Town, 
South Africa. Thirteen were HIV uninfected (median age 25±6 years), and eleven people 
were HIV-1 infected (median age 30±4 years, median CD4 count 391±243) (Table 3).  
23/24 patients ascertained to be latently M. tuberculosis infected based on a positive 
response to either ESAT-6 or CFP-10, or a positive tuberculin skin test reaction (TST) 
(defined by >5mm for HIV-1 infected and >15mm for HIV uninfected), were included in 
the final analysis. 
Table 2 Demographic detail of persons included in Chapter 3 part 1 
 HIV Uninfected HIV-1 Infected 
Number 12 11 
Median Age (IQR) 25 (22-33) 30 (28-33) 
Sex: M/F 8M/5F 4M/7F 
Median TST  (IQR) 18 mm (9-20) 16 mm (0-22) 











IFN-  analysis by ELISpot 
The IFN-γ producing capacity of T cells in HIV uninfected and HIV-1 infected patients 
was first evaluated using ELISpot. The largest interferon gamma ELISpot response in the 
HIV uninfected group was to CFP-10 (372 SFC/10
6
 PBMC, IQR 7-1151) and this response 
was significantly greater than that in the HIV-1 infected group (5 SFC/10
6
 PBMC, IQR 0-
24; p=0.03). In the HIV-1 infected group the highest response was to PPD (36 SFC / 10
6
 
PBMC, IQR 4-104). In addition to CFP-10, the IFN-γ responses to ESAT-6 and PPD were 
higher in HIV uninfected when compared to HIV-1 infected group (54 SFC/10
6
 PBMC, 
IQR 30-90 vs. 20 SFC/10
6
 PBMC, IQR 0-75; p=0.13 and 88 SFC / 10
6
 PBMC, IQR 0-262 
vs. 36 SFC / 10
6
 PBMC, 4-104; p=0.29) respectively (Figure 7 A).  
The ELISpot response was also analysed by the sum of responses to ESAT-6 and CFP-10, 
which was significantly higher in HIV uninfected compared to HIV-1 infected group (398 
SFC / 10
6
 PBMC, IQR 57-1245 vs. 24 SFC / 10
6
 PBMC, IQR 8-90; p=0.006 respectively) 
(Figure 7 A).  
When analysed by the frequency of response (defined as >20 SFC/10
6
 PBMC of IFN- ), 
there was no significant difference observed in the IFN-  response between the two groups. 
ESAT-6 (83%) was highly recognized by HIV uninfected persons, while ESAT-6 and PPD 
(63%) were highly recognized by HIV-1 infected persons. However, the most frequently 
recognized response was to sum of ESAT-6 and CFP-10, by both groups (Figure 7 B).  
ELISpot enumerates the number of cytokine secreting cells and the responses were 
predominantly attributable to the effector cells responding to the stimuli (Wilkinson et al., 
2005b). These findings suggest that the HIV-1 infected persons have effector T cells, that 
have a reduced ability to induce an immune response, however, the percentage scored 
positive, do not differ between HIV-1 infected and HIV uninfected persons.  However, 
previous report from the same population suggest that ELISpot results are unaffected in 

























Figure 7 IFN-γ ELISpot response to antigens in HIV uninfected and HIV-1 infected persons 
Panel A shows the spot forming cells (SFC) in patients with HIV uninfected () and HIV-1 infected ().  
The strongest response in HIV uninfected group was to CFP-10.  The strongest response in HIV-1 infected 
was to PPD. HIV uninfected persons had higher IFN-  response than HIV-1 infected persons, and was 
significantly higher for CFP-10 and sum of CFP-10 and ESAT-6.  
Panel B shows the frequency of response, defined by >20 SFC/10
6
 PBMC. Higher frequency of response was 
observed for sum of ESAT-6 and CFP-10 in both groups. There was no significant difference observed 











As there were only limited cells available, all antigen stimulation for all 3 techniques was 
not possible. PPD induced the largest IFN-γ response amongst the HIV-1 infected persons. 
Hence, PPD specific IFN-γ response was compared in FACS and 7 day in house PBMC 
culture - ELISA. 
Intracellular FACS analysis 
IFN-γ production by CD4+ T cells in response to PPD stimulation by intra cellular-FACS 
were analysed in both HIV-1 infected and HIV uninfected persons. PBMC were stimulated 
overnight (16 hrs) with BFA added 2 hours after stimulation. After incubation at 37ºC with 
5% CO2, the cells were washed, fixed, permeabilized and stained for surface markers 
(CD3-FITC and CD4-PerCp) and intracellular stain for IFN-γ (APC). Stained cells were 
acquired on FACS calibur (minimum of 20,000 cells/test) and results were analysed with 






















Results indicated a higher percentage of lymphocytes and PPD specific IFN-γ producing 
CD4+ T cells in HIV uninfected group when compared to the HIV-1 infected group: 
median percentage of lymphocytes 75% vs. 46 %; p=0.004 and median CD4+ IFN-γ+ T 
cells 0.73% vs. 0.11%; p=0.0002 respectively. Similar trend was observed when analyzed 
by the number of cells per million: a median 1189/10
6
 (IQR 833-1679) CD4+IFN- + T 
cells in the HIV uninfected group, compared to 400/10
6
 (IQR 263-935) CD4+IFN- + T 
cells in the HIV-1 infected group (p=0.05, Mann-Whitney U) (Figure 9 A-C).  
IC- FACS measures the cytokine expressing T cells. The CD4 phenotypes that are 
responsible for these responses can be both memory and effector T cells. These findings 
suggest that HIV-1 infected persons might have lower proportions of functional memory T 
cells.  
 
Figure 9 FACS Analysis 
Panel A shows percentage of lymphocytes of the total PBMC acquired. HIV uninfected in blue and 
HIV-1 infected in red. Total lymphocytes were defined on the basis of side scatter that defines the 
granularity or the complexity of the cells and forward scatter that defines approximate size of cells. 
Panel B shows the percentage of CD4+T cell that produce IFN-γ to PPD stimulation.  












7 day PBMC culture and ELISA 
One way of evaluating the functionality of memory T cells is to assess their proliferative 
capacity. An indirect way to assess this is the prolonged (7 day) cell culture of PBMC 
combined with evaluation of the IFN-γ response of the proliferating memory cells. In this 
assay, the stimulations included PPD, the control antigen: PHA as the positive control and 
media as the negative control. The cell free supernatants were collected at the end of 7 
days of incubation and IFN-γ was measured using in house ELISA, as per the standard 
laboratory protocol.   
PPD specific IFN-γ levels were higher in HIV uninfected (mean 3214 SEM±497pg/ml 
IFN-γ) compared to the HIV-1 infected group (999±373 pg/ml IFN-γ; p=0.002) (Figure 
10). The results indicate that HIV-1 infected memory T cells have lesser IFN-γ producing 




                      Figure 10 IFN-γ response by 7 day PBMC culture 
Shows the IFN-γ 
response in pg/ml in 
HIV uninfected and 














Correlation of responses between ELISpot, FACS and ELISA 
The correlation of PPD specific IFN-γ response measured by the three techniques was 
analysed. In the HIV uninfected group, no correlation was observed amongst the three 
techniques. The correlation co-efficient (rho) for ELISpot vs. ELISA was 0.24 (p=0.24); 
FACS vs. ELISpot - 0.228  (p=0.5) and ELISA vs. FACS was -0.010  (p=0.97).  
In the HIV-1 infected group also, no correlation was observed amongst the three 
techniques: ELISpot vs. ELISA -0.01 (p=0.97), ELISpot vs. FACS -0.5 (p=0.12) and 
FACS vs. ELISA -0.38 (p=0.24). These finding suggest that there was poor correlation 
between the techniques irrespective of the immune status of the patients and might also 
reflect on the heterogeneity of the patient population tested.  
In conclusion, these investigations provide further insight in addition to the findings 
available in the literature. There is poor correlation between the IFN-γ read out by various 
techniques in both HIV uninfected and HIV-1 infected persons, suggests phenotypic 
heterogeneity between what is measured by specific readouts. In addition, HIV-1 infected 
persons have reduced ability, to induce an immune response to MTB protein as measured 













Evaluation and comparison of whole blood culture assays in HIV uninfected adults 
Comparison of short and prolonged in vitro Whole blood culture  
This study was designed to compare the commercially available overnight QuantiFERON 
TB Gold in Tube (QFT-GIT) with the widely used 7 day diluted whole blood assay 
(Beveridge et al., 2008; Hanekom et al., 2008).  In this evaluation, 29 healthy laboratory 
and clinical staff (volunteers) who reported some exposure to tuberculosis during their 
lives were included. No TST or HIV-1 testing was performed. None of the volunteers had 
symptoms of active TB or of being HIV-1 seropositive.  The demographic details of those 
included in this evaluation are described in Table 3. Of the volunteers, 10 were male and 
19 were female; median age was 27 years and 25 were BCG vaccinated. 17 of the 29 
persons reported work related contact with tuberculosis patients (clinicians). 
 
Table 3 Demographic details of persons included in the study described in Chapter 3 part 2 
 Latent TB 
Number 29 
Sex 10M/19F 
Median Age 27 years 
BCG vaccinated 
25 vaccinated 














Blood sample was collected by venepuncture in Sodium Heparin tube and 3 QFT tubes 
[(1ml of blood per tube (Nil, Antigen and Mitogen tubes)]. QFT tubes were incubated 
overnight and the plasma was harvested and stored at -80°C until assayed. 1 ml of 1:10 
diluted whole blood (in RPMI) was used to set up the in house 7day culture assay 
(Beveridge et al., 2008; Black et al., 2002; Weir et al., 1994). MTB specific antigens 
(ESAT-6 and CFP-10) were used as stimulants either as peptide pools (3µg/ml of each 
peptide) or recombinant proteins (5 µg/ml). After 7 days of Incubation at 37°C in the 
presence of 5% CO2, the supernatants were harvested and an in-house IFN-γ ELISA was 
performed. This assay has a dynamic range of approximately 10-3000 pg/ml. The lowest 
sensitivity of the assay was 14 pg/ml and calculated values below this were reassigned 
„zero‟. 
Of 29 QFT-GIT tests, 14 were positive (48%). 10/29 donors (34%) responded (> 14 pg/ml) 
to any of the two-peptide mixtures in the 7 day diluted whole blood assay. However, when 
recombinant antigens were used as stimulants, 22/29 (90%) donors responded to either 
recombinant ESAT-6 or CFP-10 (Figure 11). 
Kappa statistics were calculated to compare agreement between short term QFT-GIT and 
7day (peptide and recombinant stimulated) cultures. When QFT-G IT was compared to any 
response by peptides in 7 day culture, agreement was 59%; Kappa 0.16 (i.e. SLIGHT) and 
to response by recombinant antigen, agreement was 55%; Kappa 0.13 (i.e. SLIGHT).  
Appendix Figure C.1 describes direct comparison of 7 day whole blood assay response to 















Figure 12 Percentage positivity for IFN-γ 
response 
Shows frequency of response to IFN- , as 
defined by ≥0.035 IU/ml for QFT-GIT; 
≥14pg/ml for peptide pool or recombinant 
antigen. 
 
Figure 11 IFN-γ response measured by 
QFT-GIT 
Shows the IFN-γ response measured by 
QFT-GIT and represented as IU/ml.  
Subjects with a negative QFT –GIT and a 
postive response in ELISpot with 
recombinant protein are shown in orange. 
Dotted line indicates the cut off for a 
positive response (0.35IU/ml). Solid line 












Table 4 Correlation between QFT -GIT and IFN-γ response in 7 day Whole blood culture 
 
I further analyzed the qualitative responses (figure 12 and 14) by correlating the absolute 
values in pg/ml with the IU/ml in the QFT-GIT. Although there was only slight agreement 
between QFT-G IT and In house IFN-γ release assay, there was significant correlation 
between QFT-GIT with In house IFN-γ response to peptide pool of ESAT-6 (r=0.45; 
p=0.02) and the IFN-γ response to the recombinant CFP-10 (r=0.6; p=0.001). The 
spearman rho and associated p values are as follows (Table 4).  
The performance of peptide mixtures are inferior to that of recombinant proteins in 
prolonged whole blood culture 
A large difference in the IFN-γ response was observed between synthetic peptides and 
recombinant ESAT-6 and CFP-10 (Figure 14) in the 7 day whole blood culture assay. 
However, the peptide mixtures and recombinant proteins perform at a similar manner in 
overnight assays (as depicted in Figure 13) and long term cultures using PBMC as found in 
the literature (Arend et al., 2000b).  
Parameter PP ESAT-6 PP CFP-10 Rec ESAT-6 Rec CFP-10 
n* 28 28 28 28 













0.0165 0.4537 0.0857 0.001 
* 1 person had QFT-GIT IFN-γ response >10 IU/ml and therefore excluded from this 












Figure 13 IFN-  response to peptide pools and recombinant protein in overnight ELISpot 
Shows IFN-  SFC/10
6 
PBMC measured by overnight ELISpot. “PP” indicates the peptide pools 
and R indicates recombinant proteins of ESAT-6 and CFP-10. When analysed by Wilckoxons 
matched pair T test, there was no significant difference found between the peptide pool and 
recombinant protein.  
By contrast, the IFN-γ response to recombinant proteins: ESAT-6 and CFP-10 were 
significantly higher than to the corresponding peptide pools. (ESAT-6 peptide pool median 
of 0 pg/ml vs. recombinant 1878 pg/ml; p= <0.0001 and CFP-10 peptide pool 0 pg/ml vs. 
recombinant 305pg/ml) (Figure 14). 10/29 donors (34%) responded (> 14 pg/ml) to any of 
the two peptide mixtures. 22/29 (90%) donors responded > 100 pg/ml to either 
recombinant ESAT-6 or CFP-10 and this difference was significant (p≤0.0001 Fisher‟s 













Shows IFN-  response measured by ELISA on a 7 day diluted whole blood culture supernatant. 
“PP” indicates peptide pool and “R” indicates the recombinant proteins. Recombinant proteins 
induced significantly higher response than the peptide pools in the 7 day diluted whole blood 
culture (p<0.0001 for both ESAT-6 and CFP-10). IFN-  levels are shown as pg/ml. Lines indicate 
median response. 
 
In order to further investigate, first, I re-assayed IFN-γ response to peptide pools in a   high 
sensitivity ELISA (lowest standard that was measurable was 6 pg/ml). With the high 
sensitivity ELISA, the percentage positivity (response >6 pg/ml) to any peptide mixture 
increased to 66% (19/29). However, the median IFN-γ response to either ESAT-6 (peptide 
pool 4 pg/ml vs. recombinant 1878 pg/ml; p= <0.001) or CFP-10 (14 pg/ml vs. 304 pg/ml; 
p=0.001) was significantly lower than recombinant proteins (Figure 15).  
 












Figure 15 IFN-γ responses to peptide pool and recombinant ESAT-6 and CFP-10 (high 
sensitivity ELISA) 
Shows IFN-γ response measured by ELISA on a 7 day diluted whole blood culture supernatant, 
assayed on a high sensitivity ELISA. “PP” indicates peptide pool and “R” indicates the 
recombinant proteins. Recombinant proteins induced significantly higher response than the peptide 
pools in the 7 day diluted whole blood culture (p<0.0001 for both ESAT-6 and CFP-10). IFN-γ 
levels are shown as pg/ml. Lines indicate median response. 
 
Considering the high purity of the recombinant proteins, and clear negative responses 
observed, the possibility of contamination in the recombinant protein to induce higher IFN-
γ response was ruled out. In addition, there was no significant difference observed, in 
overnight ELISpot assay using PBMC from the same persons.  
Since this observation seemed to be biologically very interesting, I further investigated the 











DMSO in peptide mixture is not toxic 
The peptide mixtures were prepared in 0.1% to 0.3% final concentration of DMSO and 
PBS/ 2% BSA, whereas the recombinant proteins were dissolved either in PBS or PBS / 
2% BSA. In order to rule out the possible toxic effect of DMSO in the peptide mixture to 
the cells in the whole blood culture, I tested PBMC from 4 volunteers, stimulated with 
recombinant ESAT-6 and CFP-10 in parallel with and without DMSO in overnight 
ELISpot assay.  3% DMSO was added to recombinant proteins. Positive controls included 
were anti CD-3 (MabTech) and unstimulated well. The experiment was set in duplicate 
well and the average spot forming cell counts were analyzed.  
The median SFC response to recombinant ESAT-6 (without DMSO) (67 SFC/10
6 
PBMC, 
IQR 17-70) and recombinant ESAT-6 with DMSO were similar (61 SFC/10
6 
PBMC, IQR 
16-66; p=0.2 by Wilcoxon signed rank paired t test). Similar results were observed for 
recombinant CFP-10 as well (61 SFC/10
6 
 PBM , IQR 13-298 vs. 60 SFC/10
6 
PBMC, IQR 
13-280 for CFP-10 with DMSO; p=0.5) (Figure 16). These finding confirmed that DMSO 
upto 0.3% final concentration used in the peptide mixture as not toxic to the culture system 
and ruled out the toxic effect of DMSO as the reason for the reduced level of interferon 
gamma observed with the peptides. 
 











Figure 16 Effect of DMSO 
PBMC from 4 persons were tested for IFN-γ response to recombinant proteins: ESAT-6 and CFP-
10, with or without DMSO. E and C refer to recombinant ESAT-6 or CFP-10 respectively; ED and 
CD refers to DMSO in addition to recombinant ESAT-6 and CFP-10 respectively. Bars indicate 
IFN-γSFC response per person. The IFN-  levels were at similar levels. 
 
Peptide and recombinant proteins perform similarly in prolonged PBMC cultures 
In addition, I evaluated the PBMC cell culture with various time points of incubation: 1 
day, 3 days, 5 days and 7 days, to study its performance.   I hypothesized that there will be 
no / less effect of peptide degradation by protease activity, as in the whole blood culture.  
250,000 PBMC were cultures with appropriate stimuli (peptide pool or recombinant 
protein) and controls in four sets. These were incubated at 37°C with 5%CO2 for 1 day, 3 
days, 5 days and 7 days. At the end of each incubation time point, the cell free supernatant 
was collected and stored at -20°C until ELISA was performed.  
The results (shown in Figure 17) suggest, that both peptide and recombinant form of 
ESAT-6 and CFP-10 induce similar levels of IFN-γ production during the time course of 
the experiments. Therefore, these results are comparable in terms of response between 
peptide and recombinant  protein to the overnight ELISpot  (Figure 15), and suggest that 
peptides and recombinant proteins have similar activity in prolonged PBMC based 
cultures. This might also suggest that the PBMC probably have less proteases compared to 













PBMC from 2 persons were cultured with peptide and recombinant proteins at 250,000 cells/well 
(200ml) and incubated for 1, 3, 5 and 7 days. PE and PC denote, response from peptides of ESAT-
6 and CFP-10 respectively; RE and RC denotes, recombinant proteins. There was no significant 
difference in the response between the activity of peptide and recombinant proteins. 
 
IFN-γ response after seven days results from the daughter cells of those cells that initially 
proliferated rather than from the initially activated cells. For this purpose, the prolonged 
culture assay would depend on enough intact peptide being around during the course of the 
culture. The peptides have a greater sensitivity than recombinant proteins to degradation by 
proteases present in the whole blood (Nusslein et al., 2006; Yeaman et al., 2002). 
Therefore, I hypothesized that in-sufficient peptide was present to last for 7 days of culture 
to stimulate the proliferating T cells.  











Peptides degrade in prolonged whole blood culture 
In order to further test the hypothesis of possible peptide degradation or protease activity in 
the whole blood culture, we collaboratively investigated the nature of peptide mixtures and 
recombinant proteins in the supernatants of whole blood cultures at the point of setting up 
(day 0) and at the end of 7 days of incubation using SELDI analysis at Imperial College 
London.  
1:10 diluted whole blood cultures were set up, and the supernatants were harvested at the 
respective time points and evaluated by SELDI. Protein Chip N20 arrays which mimic 
normal-phase chromatography with silicate functionality, broad protei  binding chip were 
used. 15 µl of the culture supernatant was used for the analysis.  
The peptides ESAT-6 and CFP-10 produced peaks at Day 0 (Figure 18) but the peaks were 
absent or dramatically reduced by Day 7. This finding further supports the hypothesis that 
degradation of these peptides is taking place and therefore might contribute to the reduced 











Table 5 ESAT-6 peptide and recombinant sequence and predicted molecular mass 
Peptide number Sequence Molecular Mass 
ESAT-6 1 MTEQQWNFAGIEAAA 1667 
ESAT-6 2 WNFAGIEAAASAIQG 1506 
ESAT-6 3 IEAAASAIQGNVTSI 1445 
ESAT-6 4 SAIQGNVTSIHSLLD 1555 
ESAT-6 5 NVTSIHSLLDEGKQS 1628 
ESAT-6 6 HSLLDEGKQSLTKLA 1640 
ESAT-6 7 EGKQSLTKLAAAWGG 1517 
ESAT-6 8 LTKLAAAWGGSGSEA 1419 
ESAT-6 9 AAWGGSGSEAYQGVQ 1467 
ESAT-6 10 SGSEAYQGVQQKWDA 1654 
ESAT-6 11 YQGVQQKWDATATEL 1738 
ESAT-6 12 QKWDATATELNNALQ 1703 
ESAT-6 13 TATELNNALQNLART 1630 
ESAT-6 14 NNALQNLARTISEAG 1572 
ESAT-6 15 NLARTISEAGQAMAS 1520 
ESAT-6 16 ISEAGQAMASTEGNV 1465 
ESAT-6 17 QAMASTEGNVTGMFA 1515 
 
ESAT-6 Recombinant protein Sequence: Predicted weight: 11800 Da 
M T V H M T E Q Q W N F A G I E A A A S A I Q G N V T S I H  
S L L D E G K Q S L T K L A A A W G G S G S E A Y Q G V Q Q  
K W D A T A T E L N N A L Q N L A R T I S E A G Q A M A S T  












Table 6 CFP-10 peptide and recombinant protein sequence and predicted molecular mass 
Peptide number Sequence Molecular 
Mass CFP-10 1 MAEMKTDAATLAQEA 1581 
CFP-10 2 TDAATLAQEAGNFER 1594 
CFP-10 3 LAQEAGNFERISGDL 1620 
CFP-10 4 GNFERISGDLKTQID 1693 
CFP-10 5 ISGDLKTQIDQVEST 1634 
CFP-10 6 KTQIDQVESTAGSLQ 1605 
CFP-10 7 QVESTAGSLQGQWRG 1604 
CFP-10 8 AGSLQGQWRGAAGTA 1431 
CFP-10 9 GQWRGAAGTAAQAAV 1415 
CFP-10 10 AAGTAAQAAVVRFQE 1490 
CFP-10 11 AQAAVVRFQEAANKQ 1631 
CFP-10 12 VRFQEAANKQKQELD 1804 
CFP-10 13 AANKQKQELDEISTN 1689 
CFP-10 14 KQELDEISTNIRQAG 1702 
CFP-10 15 EISTNIRQAGVQYSR 1722 
CFP-10 16 IRQAGVQYSRADEEQ 1750 
CFP-10 17 VQYSRADEEQQQALS 1752 
CFP-10 18 ADEEQQQALSSQMGF 1669 
 
CFP-10 Recombinant protein Sequence Predicted weight: 12600 Da 
M T V H M A E M K T D A A T L A Q E A G N F E R I S G D L K T Q I D  
Q V E S T A G S L Q G Q W R G A A G T A A Q A A V V R F Q E  
A A N K Q K Q E L D E I S T N I R Q A G V Q Y S R A D E E Q  
























Shows the SELDI analysis of ESAT-6 (A) and CFP-10 (B) peptides in the supernatants at the time 
of set up (day 0) and at the end of the incubation (day 7). Day 0 results shows peaks with respective 
masses in both ESAT-6 and CFP-10 (table 6 and 7). The peaks were either reduced or not present 
at day 7. 
 
By contrast, recombinant ESAT-6 and CFP-10 produced peaks both at Day 0 and Day 7 
(Figure 19 and 20). Interestingly, the peaks produced by recombinant ESAT-6 and CFP-10 
at Day 7 showed a shift to a lower molecular mass suggestive of some protease activity or 
cleavage of the protein. 















Shows the SELDI analysis of ESAT-6 recombinant protein in the supernatants at the time of set up 
(day 0) and at the end of the incubation (day 7). Day 0 results shows peaks with respective masses 
in both ESAT-6 (table 6). At day 7 a peak was detected. However these peaks showed a shift 
towards a lower molecular weight.  































Shows the SELDI analysis of CFP-10 recombinant protein in the supernatants at the time of set up 
(day 0) and at the end of the incubation (day 7). Day 0 results shows peaks with respective masses 
in both ESAT-6 (table 6). At day 7 a peak was detected. However these peaks showed a shift 
towards a lower molecular weight.  














The recombinant proteins are of higher molecular weight than that of the native protein. 
The theoretical molecular weight of ESAT-6 is 9.9-kDa and the recombinant CFP-10 is 
11.8-kDa.  The differences in the molecular weight are due to the flanking sequences from 




For recombinant ESAT-6 the predicted molecular weight is 11kDa. The Day 0 SELDI m/z 
showed peaks at 11.7 kDa (3000 laser) and day 7 SELDI showed peak at 10.8kDa, a shift 
of 841 Da. Further analysis reveled that cleavage of  “ H H H H H H “ produces a protein 
that would shift a protein peak by 841 Da.   
Similarly recombinant CFP-10 (predicted molecular mass:12.6 kDa), Day 0 SELDI m/z 
showed peak at 12.5kDa (2500 laser) and Day 7 showed a peak at 10.8kDa. The cleavage 
of  “ G F H V Q L E H H H H H H “ produces a protein that would shift a protein peak by 
1652 Da. 













These findings provide evidence that the peptides are degraded by day 7, and therefore not 
available to stimulate the proliferating T cells and therefore, most probably responsible for 
the reduced response observed.  Similarly, this investigation also provide evidence 
suggestive of that even recombinant proteins may also be subject to exo-peptidase activity 
during or at 7 days of whole blood culture. This empirical data whereby the recombinant 
proteins stimulate a recall response after 7 days suggests that these cleavages do not affect 
the antigenic activity.  However, further confirmation of these findings need to be 
performed with antibody depletion of the respective proteins. 
In conclusion, the discrepancy in response between short and prolonged in vitro culture 
systems using whole blood cultures was investigated. The commercially available QFT-
GIT assay was found to be less sensitive than the 7day whole blood culture with 
recombinant antigens for detection of latent tuberculosis (48 % vs. 90% positivity 
respectively) (Figure 12).  This could be entirely attributed to the variation in the length of 
incubation of these assays: where the long term assay being more sensitive, due to the IFN-
 response from both effector and memory T cells, while the short term incubation assay 
being less sensitive as it detects only effector T cell response. 
In addition, these investigations led to uncover the mystery of reduced performance of the 
peptide mixtures over the recombinant proteins of RD1-encoded antigens in prolonged 
whole blood culture, which has not been reported elsewhere. In long-term whole blood 
culture system, the recombinants perform better. The activity of peptide and recombinant 
proteins do not differ in short term or long-term PBMC cultures. The use of DMSO (up to 
0.3% final concentration) was found not to affect the viability or the activity of the 
antigens. The decreased performance of peptides was found to be due to degradation 
during the course of incubation in whole blood culture system. In addition, these finding 
also suggest the possibility of exo-peptidase activity on recombinant proteins in the 











Chapter 4: Mapping T cell antigenic determinants of novel 




Species specific and stress-induced genes of MTB are considered as excellent targets 
to improve the diagnostic tests for tuberculosis and develop post exposure vaccine 
candidates. RD11 encoded Rv2654c and dosR encoded Rv1733c were previously 
described as dominant targets in active and latent tuberculosis respectively. T cell 
antigenic determinants of Rv2654c and Rv1733c were mapped in a high tuberculosis 
endemic area. Rv2654c and Rv1733c induced T cells IFN-γ response from persons 
with active and latent tuberculosis. Rv2654c showed focused dominant epitope 
region, while Rv1733c, a degenerate pattern of epitope spread throughout the length 
of the antigen. The most striking discovery however was that commercially used p38-
55 peptide of Rv2654c is not immunodominant in this population, and the  region 
covering p51-65 of Rv2654c was the dominant target. In addition, preliminary results 
show that adding p51-65 to the QFT-GIT TB Ag tube, increases the percentage 













The lack of a quick and reliable clinical laboratory test for early stage and latent 
tuberculosis has long represented a diagnostic dilemma. The tuberculin skin test 
(TST), using purified protein derivative (PPD), is largely utilized for both diagnosis 
and screening. The greatest drawback of using PPD is its broad cross-reactivity with 
antigens derived from several mycobacterial species (Borsuk et al., 2009) and greatly 
decreased specificity in patients with advanced disease or with immunodeficiency 
such as HIV-1 infection. The control strategies of tuberculosis, however depend 
largely on the partially effective vaccine, BCG and diagnosis and treatment of those 
who are at high risk of developing active disease (Maartens and Wilkinson, 2007). 
Therefore a diagnostic test, which is specific to MTB infection, is urgently needed 
(Bakir et al., 2009; Roupie et al., 2007). 
Recent genome driven advances in MTB antigen discovery have identified genes that 
are absent from the vaccine strain of M. bovis BCG described as the regions of 
difference (RD) on the MTB chromosome (Behr et al., 1999; Brosch et al., 2002; 
Mahairas et al., 1996). These genes offer the advantage to distinguish between 
infection with MTB and prior vaccination with BCG.  Two antigens encoded by RD1 
(ESAT-6 and CFP-10) were found to be immunodominant and studied in much detail 
and have been included in the two recently commercialised blood based 
immunodiagnostic tests for TB (T-SPOT.TB and QuantiFERON (QFT) (Lalvani and 
Pareek, 2009b; Pai et al., 2008; Richeldi et al., 2009).  
Recent studies of genes other than RD1-encoded immunodominant targets revealed 
RD11-encoded, Rv2654c. Rv2654c has been previously described and mapped in a 











dominant for IFN-γ response in 7 out of 9 persons with active tuberculosis as opposed 
to those with latent infection or BCG vaccinated controls in the tested Danish 
population (Aagaard et al., 2004; Brock et al., 2004). 
Based on these promising yet limited data, one peptide of Rv2654c (termed p4) was 
included in the whole blood based IFN-γ release assay QuantiFERON TB-Gold In-
tube (QFT-G-IT) in addition to ESAT-6 and CFP-10 (Aagaard et al., 2004; Brock et 
al., 2004), and shown to increase the sensitivity and specificity of those 3rd 
generation tests to detect active tuberculosis (Parkash et al., 2009).  
In vitro studies exploring the conditions which MTB is thought to encounter in vivo, 
during the course of latent infection have described the dosR regulon, which is 
induced and regulates a group of genes when MTB cultures were exposed to 2 hours 
of Hypoxia (Roberts et al., 2004; Rustad et al., 2009; Sherman et al., 2001). Hypoxia 
has been shown to be a condition that is present within the granulomas, which are the 
hallmark of the tuberculosis infection (Via et al., 2008). DosR encoded proteins have 
been well evaluated, and there are claims that these antigens are preferentially 
recognized in those with latent infection (Black et al., 2009; Goletti et al., 2009; 
Leyten et al., 2006; Schuck et al., 2009). One such well evaluated candidate Rv1733c 
has been shown to be promising in animal models to induce protective immune 
response (Roupie et al., 2007). Therefore, Rv1733c has the potential to be developed 
into a post exposure vaccine (Bivas-Benita et al., 2009; Black et al., 2009; Leyten et 
al., 2006; Roupie et al., 2007) but has never been mapped for human T cell epitopes.  
Rv2654c and Rv1733c have been previously described, to be preferentially 
recognized in persons with active and latent disease respectively based on a prolonged 











the clinical and research settings for operational reasons, as the results could be 
available faster (Pai et al., 2009). These candidates (Rv2654c and Rv1733c) have 
neither been mapped nor evaluated in short term culture conditions, despite Rv2654c 
(p4) being predominantly used in short-term whole blood assay (Brock et al., 2004).  
Therefore, I was interested to evaluate the pattern of T cell determinants of species 
specific Rv2654c and dosR (infection stage specific) Rv1733c antigens in a high 
tuberculosis endemic setting, to evaluate the performance in a short term in vitro cell 
culture assay and to determine the pattern of immunodominant epitopes, which could 












29 Healthy laboratory and clinical volunteers, with latent TB infection, and no 
symptoms of active tuberculosis, who agreed to participate, were included. 
Participants self reported on BCG, TST and HIV-1 infection status. Latent 
tuberculosis (LTBI) was defined by an interferon-gamma enzyme linked immunospot 
(ELISpot) response to ESAT-6 or CFP-10 of > 20 spot forming cells (SFC)/10
6 
PBMC. In addition, 10 persons with active tuberculosis (ATB) were recruited from 
the Ubuntu clinic in Khayeltisha and were defined by a positive culture of M. 
tuberculosis from one or more sputum specimens. ATB patients were sampled prior 
to commencing antitubercular chemotherapy. Known immunosuppression for HIV-1 
and other reasons, age < 18 years and pregnancy formed other exclusion criteria. The 
baseline characteristics of subjects enrolled to the study are shown in Table 7. 
Table 7 Demographic details of persons included Chapter 4 
 Latent TB Active TB 
Number 29 10 
Sex 10M:21F 6M:4F 
Median Age 27 years 27 years 
BCG vaccinated 27 vaccinated 
1 not vaccinated 
3 Unknown 
2 vaccinated 
4 not vaccinated 
4 Unknown 
TB smear/culture positive NA 5 smear and culture +;   
1 smear -, culture +; 












IFN-γ analysis of Rv2654c in active and latent tuberculosis 
To determine if there was evidence of preferential recognition, I analyzed the pattern 
of recognition as a pool of peptides covering the whole protein in those with active 
TB (n=10) and latent TB (n=26). The median background IFN-  ELISpot response 
were 5 SFC/10
6 
PBMC (IQR: 0-10) in those with latent TB and 0 SFC/10
6 
PBMC 




When analyzed as the SFC response, the IFN-  responses were weak and were similar 
between the two groups. Although persons with active TB tend to have slightly higher 
median response when compared to those with latent TB (10 SFC/10
6 
PBMC, IQR: 6-
25 vs. 4 SFC/10
6 
PBMC, IQR:0-25; p=0.3194), however, this difference in the median 
response was not statistically significant (Figure 22A). When analyzed by the 
proportion of responders, Rv2654c was recognized (>15 SFC/10
6 
PBMC) in 4/10 
persons with ATB (40%) while 8/26 persons with LTBI (31%) (Figure 22 B). 
 
Panel A shows the IFN-γ SFC/10
6 
PBMC to Rv2654c peptide pool in persons with latent and 
active tuberculosis. The median response was not significantly different between the two 
groups. Panel B shows the frequency of response to Rv2654c in latent and active tuberculosis.   











Peptide map of IFN-γ response to Rv2654c 
PBMC from 26 persons with LTBI was used to map seven peptides, covering the 
entire region of Rv2654c (Figure 23).  In addition 10 persons with active tuberculosis 
were also mapped (Figure 24) to evaluated differential patterns were to be found. The 
peptide sequences used in this evaluation are described in Table 9.  
All persons with latent tuberculosis responded to ESAT-6 or CFP-10 with >15 
SFC/10
6 
PBMC of IFN-γ response. Overall, the responses to ESAT-6 and CFP-10 
were higher than that of any peptide or peptide pool in both active and latent 
tuberculosis (p<0.0001).  
When analysed by the proportion of responders, >15% responded (>15 SFC/10
6 
PBMC) with IFN-γ response to every peptide tested in both groups with the exception 
of peptide covering the  region 11-30 (latent and active) and 41-60 (only active 
disease). Over all the responses were moderate with the highest median response 
being 8 SFC/10
6 
PBMC in latent tuberculosis and 18 SFC/10
6 
PBMC in active 
tuberculosis (p= 0.179) for the peptide covering the region 61-81 and the peptide pool 
of Rv2654c (Figure 23A and 24 A).  
When analyzed by the frequency of response (defined by >15 SFC/10
6 
PBMC), 
Rv2654c pooled peptides were recognized by 31% and 40% in latent and active 
tuberculosis respectively.  
Peptides covering the region 61-81 were the most recognized in 35% and 50%; 51-70 
(27% and 30%) in latent and active tuberculosis respectively; peptides covering 
region 1-20 was recognized by 31% only in latent tuberculosis. All other peptides had 














Table 8 Peptide Sequence of Rv2654c 
Rv2654c sequence 
P1 (1-20) MSGHALAARTLLAAADELVG 
P2 (11-30) LLAAADELVGGPPVEASAAA 
P3 (21-40) GPPVEASAALAGDAAGAWR 
P4 (31-50) LAGDAAGAWRTAAVELARAL 
P5 (41-60) TAAVELARALVRAVAESHGV 
P6 (51-70) VRAVAESHGVAAVLFAATAA 













Figure 23 Peptide map of Rv2654c in Latent tuberculosis 
Panel A shows IFN-γ SFC response to the 20 mer peptide. Bars indicate median response. 















Figure 24 Peptide map of Rv2654c in Active tuberculosis 
Panel A shows IFN-γ SFC response to the 20 mer peptide. Bars indicate median response. 














In order to further study the epitopic targets within the highly recognized peptide 
regions, 15-mer truncated peptides with 10  overlap were synthesized. In addition, 
the previously described, immunodominant and preferentially recognized (in ATB) 
peptide covering the 38-55 (p4) (Aagaard et al., 2004), was also synthesized to be 
tested in this setting. Origins of the truncated peptides are described in Figure 25. 
 
 
Panel A shows the original peptide sequence, with highlights on highly recognized sequence 
Panel B shows truncated peptides originating from the highly recognized sequence. Arrow 
(yellow) indicates previously described immunodominant peptide covering  region 38-55 
of Rv2654c. 
 











The IFN-γ responses to the truncated peptides in 10 persons with active tuberculosis 
in addition to 7 further persons (truncated peptides) with latent tuberculosis. Due to 
the limited availability of cells, peptide 1-15, 6-20, 31-45 and 36-50 were tested in 10; 
38-58 and 51-65 in 14 and 55-70 in 26 LTBI persons. 
The response in those with active tuberculosis was tending to be slightly higher than 
those with latent tuberculosis, although the overall response was weak. The highest 
IFN-γ SFC response was to peptide sequence covering the  region 51-65 in persons 
with ATB and LTBI (n=9) (25 SFC/10
6 
PBMC vs. 16 SFC/10
6 
PBMC respectively; 
p=0.6) but the responses were not significantly different (Figure 26 A and B).  All 
other peptides had lower response in both clinical groups with the exception of 61-81 
and 55-70 (18 SFC/10
6 
PBMC and 10 SFC/10
6 
PBMC) in ATB and 61-81 (8 SFC/10
6 
PBMC) in LTBI.   
When analyzed by the frequency of responders, the peptide sequence covering the 
region 51-65 had the highest response in both active (67%) and latent (50%) disease, 
the difference being not significant (p=0.7) (Figure 26. C and D). All other peptide 
sequences were less recognized. The peptide sequence covering the region 38-55 was 
recognized by only 20% and 14% in active and latent tuberculosis respectively.  
 
Figure 26 IFN-γ analysis of Rv2654c in active and latent tuberculosis 
Panel A and B shows the IFN-γ SFC response in LTBI (Blue) and active TB (red) to the 
peptides of Rv2654c, represented as SFC/10
6 
PBMC. Bars indicate median response. Dotted 
lines indicate 15 SFC/10
6 
PBMC, the cut-off for a positive response. 
Panel C and D shows the frequency of response in LTBI (blue) and Active TB (red) to the 








































































Comparison of responses between 4 peptides covering the  region 38-55, 51-70, 
51-65 and 55-70 
The striking finding in this study was the dominant IFN-γ response to peptide region 
covering the region 51-65 in both active and latent disease. It was also found that 
adding 5  (p51-70) at the C terminal reduces the response, while removing 5  
from the N-terminal (p55-70) also reduces the response (Figure 27 and 28), 
suggesting that the epitope core of this peptide is present within the region p55-65. 
The previously described immunodominant region covering peptide sequence 38-55 
performed poorly with only a moderate median response of 5 and 3 SFC/10
6 
PBMC 
(p=0.7) and recognized in 20% and 14% in ATB and LTBI respectively. 
 
Figure 27 IFN- response to peptides of Rv2654c in active and latent tuberculosis 
Panel A and C shows the SFC/10
6
 PBMC response in LTBI and ATB for peptide regions 38-
55, 51-70, 51-65 and 55-70.  
Panel B and D shows frequency of responders. Peptide covering the region 51-65 had both the 












     Figure 28 Likely epitope core of Rv2654c. 
IFN-γ response of ESAT-6, CFP-10 and Rv2654c 
In light of these findings, I compared the IFN-γ response between commercial QFT- 
GIT  (obtained at recruitment) with the in house ELISpot response to ESAT-6, CFP-
10 and Rv2654c peptide pool. By QFT- GIT, 14 persons scored a positive response  
(defined by ≥0.35 IU/ml) for IFN-γ. However, 26 of the 29 recruits had a positive 
response (defined by ≥20 SFC/10
6
 PBMC) by ELISpot. The frequency of response to 
sum of ESAT-6, CFP-10 and Rv2654c by ELISpot was significantly higher than the 
frequency of positive response by QFT- GIT assay (90 % vs. 45%; p=0.001), although 
the test for agreement (kappa statistics) between these two assays was fair (k=0.310, 













QFT boosting experiment 
I reasoned that the lower positive responses in QFT as opposed to the ELISpot with 
ESAT-6, CFP-10 and Rv2654c (Figure 26) might be due to the absence of the 
immunodominat peptide of Rv2654c p51-65 in the QFT, which contains only p38-55 
of Rv2654c. Therefore, I reasoned that it would be interesting to investigate whether 
adding p51-65 of Rv2654c to QFT-GIT tubes would increase the proportion of results 
positive of these assay.  
Blood from 15 volunteers was obtained, and were set up with normal (Nil, TB Ag and 
Mitogen) tubes and in addition, Nil and TB antigen tube to which 5 µg/ml of p51-65 











was added and incubated as that of normal QFT-GIT. Supernatant were collected and 
QFT ELISA were performed to measure IFN-γ (IU/ml).  
8 out of 15  (53%) had a positive response to TB Ag- Nil. However, boosting with 
p51-65 increased the proportion of responders to 12 out of 15 (80%). 4 people 
remained negative (Figure 30). This finding suggests, recognition of a different region 
of the antigen Rv2654c in different populations, and that boosting QuantiFERON 
Gold In Tube with the immunodominat peptide (p51-65) increases the proportion 










Shows the IFN-γ IU/ml before  (TB AG) and after adding peptide 51-65  (TB AG +TB 7.7 p51-65) to 
the TB antigen tube of QFT –GIT. The results are corrected for the background. The QFT ELISA was 
repeated for those who score >10 IU/ml with diluted sample, and the values were extrapolated using 
the standard curve.  











 IFN-γ analysis of Rv1733c in active and latent tuberculosis 
Rv1733c, a dosR encoded antigen has been described to be preferentially recognised 
in those with latent infection as opposed to those with active tuberculosis disease 
(Leyten et al., 2006). Its potential as a post exposure vaccine has also been exploited 
in animal models and found to be promising (Bivas-Benita et al., 2009; Roupie et al., 
2007). 
The ability of pooled peptides of Rv1733c to restimulate IFN-γ in 10 persons with 
active tuberculosis was analyzed, and compared it with the responses in those with 
latent tuberculosis (n=25).  
The median SFC response induced by Rv1733c was tended to be slightly higher in 
those with latent disease when compared to those with active disease (12 SFC/10
6
 
PBMC, IQR 5-38 vs. 7 SFC/10
6
 PBMC, IQR 0-34; p=0.29), however this difference 
was not significantly different (Figure 31). The reverse pattern in RD1-encoded 
antigens (ESAT6+CFP-10) was also noted, where the SFC responses were higher in 
those with active disease (109 SFC/10
6
 PBMC, IQR 36-163 vs. 20 SFC/106 PBMC, 
IQR 24-176; p=0.71). Although there was no evidence of significant difference in the 
preferential recognition in those with latent tuberculosis, these findings are similar to 



























Shows the IFN-γ SFC/ 10
6
 PBMC response to persons with active (n=10) or latent (n=25) 
tuberculosis to Rv1733c and ESAT-6+CFP-10. The lines indicate median response. Active 
TB are shown in red () and latent tuberculosis in blue () 
Rv1733c induced a slightly higher (not different) median response in those with latent 
tuberculosis, whereas ESAT-6 and CFP-10 induced a higher (not different) response in those 
with active disease. However, these differences were not statistically significant.  












Peptide map of Rv1733c 
Therefore, I proceeded to determine dominant peptides in Rv1733c using peptide 
mapping. As this antigen was described to be preferentially recognized in latent 
infection, persons with active TB were not recruited to map T cell epitopes for 
Rv1733c. IFN-γ responses to the peptides of Rv1733c, was evaluated in 26 healthy, 
RD1 positive volunteers using ELISpot assay. Every peptide stimulated a response in 
at least 5 donors.  
When analysed by the median IFN-γ response, the highest response was to the pooled 
peptides of Rv1733c (median 33 SFC/10
6
 PBMC, IQR 8-70), which was greater (not 
significantly) than that of the ESAT-6 (15 SFC/10
6
 PBMC, IQR 0-70; p= 0.7) and 
CFP-10 (17 SFC/10
6
 PBMC, IQR 0-146; p=0.7).   
Amongst the peptide sequences, the highest median responses were from  region 
covering 171-190  (11 SFC/10
6
 PBMC, IQR 1-37) and 41-60 (10 SFC/10
6
 PBMC, 
IQR 1-20).  However there was no peptide residue with dominant SFC response 
(Figure 32 A). 
When analyzed by the frequency of response (>15 SFC/ 10
6
 PBMC), all peptides 
were recognized by >20% of the donors. The peptides with  region 51-60, 101-121 
and 151-170 were recognized by >40% of the donors and 71-90,171-190 and 191-210 
were recognized by 50% of the donors.  The highest frequency of response was 
however to the peptide pool of Rv1733c (63%) (Figure 32 B). There was no dominant 
pattern of recognition, and the epitope targets seem to be dispersed throughout the 











Table 9 Peptide sequence of Rv1733c 
Rv1733c sequence 
P1 (1-20) MIATTRDREGATMITFRLRL 
P2 (11-30) ATMITFRLRLPCRTILRVFS 
P3 (21-40) PCRTILRVFSRNPLVRGTDR 
P4 (31-50) RNPLVRGTDRLEAVVMLLAV 
P5 (41-60) LEAVVMLLAVTVSLLTIPFA 
P6 (51-70) TVSLLTIPFAAAAGTAVQDS 
P7 (61-81) AAAGTAVQDSRSHVYAHQAQT 
P8 (71-90) RSHVYAHQAQTRHPATATVI 
P9 (81-100) TRHPATATVIDHEGVIDSNT 
P10 (91-110) DHEGVIDSNTTATSAPPRTK 
P11 (101-121) TATSAPPRTKITVPARWVVNG 
P12 (111-130) ITVPARWVVNGIERSGEVNA 
P13 (121-140) GIERSGEVNAKPGTKSGDRV 
P14 (131-150) KPGTKSGDRVGIWVDSAGQL 
P15 (141-160) GIWVDSAGQLVDEPAPPARA 
P16 (151-170) VDEPAPPARAIADAALAALG 
P17 (161-180) IADAALAALGLWLSVAAVAG 
P18 (171-190) LWLSVAAVAGALLALTRAIL 
P19 (181-200) ALLALTRAILIRVRNASWQH 












Panel A shows the IFN-γ SFC/106 PBMC for peptide of Rv1733c, ESAT-6 and CFP-10. 
Dotted line indicates the cut off for a positive response15 SFC / 10
6
 PBMC. 
Panel B shows the frequency of recognition of peptides of Rv1733, and peptide pools of 
Rv1733, and sum of ESAT-6 and CFP-10. 












As species specific and infection stage specific immunodominant targets of M. 
tuberculosis are important in considering potential candidates to improve 
immunodiagnosis of tuberculosis and developing post exposure vaccines, T cell targets of 
Rv2654c and Rv1733c were evaluated, in a setting of high tuberculosis endemicity. 
Rv2654c and Rv1733 re-stimulate T cells from persons in active and latent tuberculosis. 
Although there was slightly higher median SFC response in persons with active and latent 
tuberculosis for Rv2654c and Rv1733c respectively, these differences were not statistically 
significant.  
Rv2654 had focused dominant epitope region, whereas, in Rv1733, there was a degenerate 
pattern of epitopes spread through-out the length of the antigen. The most striking finding 
however is the immunodominant region covering p51-65 of Rv2654c, and that the 
previously described dominant epitope covering the region p38-55 was recognized poorly 
by those with active and latent disease in this population. Preliminary data suggesting a 
boosting effect of p51-65 in the QFT TB Gold in tube assay (QFT-GIT) is also described.  
Synthetic overlapping peptides are as efficient in detecting T-cell responses as recombinant 
proteins, with the advantage of faster production and lower costs and in the same time 
allow mapping of the epitope regions, enabling a focus on the immunodominat  regions as 
potential candidates for vaccine development (Jurcevic et al., 1996). Evaluation of T cell 
epitopes is highly influenced by the MHC II allelic polymorphism present within different 
populations, and the infection pressure in people living in low and high endemic areas may 
contribute to the different patterns of recognition in different populations (Ovsyannikova et 
al., 2008).  There is also evidence of discrepancy in the responses between short and 
prolonged incubation time in assays, due to difference in the phenotype of T cells 











Chapter 3. Studies on species-specific genes of MTB have been very attractive for their 
specificity and are considered to be appropriate candidates for development of diagnostics. 
Recent interest in defining LTBI, based on immune response to the antigens which are 
differentially expressed during stress related conditions, led to the discovery of interesting 
immunodominat antigens. These formed the basis of selection of Rv2654c and Rv1733c 
for evaluation.  
Rv2654c, is RD-11 encoded phiRv2 phage insert, which are absent in strains other than M. 
tuberculosis (especially in M. bovis and in all BCG vaccine strains). The specificity of 
Rv2654c is greater than RD1-encoded CFP-10 or ESAT-6 such that it is only present 
within the M. tuberculosis species, whereas RD1-encoded genes are also shared amongst 
some environmental Mycobacteria. Therefore, an immune response to this antigen 
suggests exposure and infection purely by MTB, and not merely due to BCG vaccination 
or exposure to environmental Mycobacteria. The limitation however was that no group of 
person without tuberculosis disease or latent infection was included. This is due to the high 
tuberculosis endemic setting in which this study was done. 
The promising evidence of the immunodominance of Rv2654c is based on prolonged 
proliferative assay, and based on this evidence, a peptide has been included in the 
commercial whole blood based IFN-γ response assay QFT-GIT (Aagaard et al., 2004; 
Brock et al., 2004; Lalvani and Pareek, 2009b; Leyten et al., 2007; Pai et al., 2008) which 
is an overnight, short term assay.  The sensitivity and specificity of QFT has been 
evaluated with much variable results on the positive predictive value.  In my own 
experience, there was relatively poor agreement for detection of prevalent TB when QFT-
GIT or Mantoux  (TST) was compared to sputum culture for MTB in HIV-infected people 
recruited from the same population (Gideon HP et al, abstract presented at the 5th IAS 
Conference on HIV-1 Pathogenesis, Treatment and Prevention, Cape Town, July 2009) 











epitope in this population is different (p51-65 as opposed to 38-55 in QFT-G IT), and that 
there is a boosting effect in response upon addition of p51-65.  
Rv1733c is a DosR-encoded immunodominat antigen, with promising experimental 
evidence in mice (Roupie et al., 2007). The pattern of T cell epitope recognition is found to 
be similar to that of the well known RD-1 encoded antigen ESAT-6 (Pathan et al., 2001). 
Human and animal studies have described the potential of this antigen to be included in 
development of post exposure vaccine candidate.  However, concerns have also been 
raised due to the cross reactive immune response to this antigen in individuals infected 
with other Mycobacteria (Lin et al., 2009a). Further studies are required to validate its 
contribution and influence in the potential novel TB vaccines. 
In summary, both Rv2654c induced an IFN-  response in both active and latent 
tuberuclosis. No evidence of stage specific recognition was observed. Rv2654c has a 
focused T cell epitope, which is different from what is previously described. This may be 
due to the MHC polymorphism present in different population, rendering binding of 
different regions of the protein. The out come of this study would be to evaluate whether 
adding p51-65 to QFT-GIT TB Ag tube would increase the percentage positivity of the test 
in HIV-1 infected persons. Rv1733c is a potential antigen; further studies are required to 











Chapter 5: Bioinformatic and empirical analysis of novel 
hypoxia-inducible targets of the human anti-tubercular T cell 
response 
Abstract 
Hypoxia is a relevant stimulus that Mycobacterium tuberculosis encounters in vivo. 
Therefore whole genome based transcriptional profiles of M. tuberculosis subject to 
prolonged hypoxia (described as the Enduring hypoxic response (EHR)) were analyzed, to 
guide the discovery of novel potential antigens, by a combined bioinformatic and empirical 
approach. Analysis included fold induction of 100 highly induced genes at 7 days of 
hypoxia, their transcript abundance, population specific MHC class II-peptide binding 
prediction (ProPred), and a literature search. 26 candidate genes were selected by 
bioinformatic prediction and evaluated empirically using IFN-γ and IL-2 ELISpot using 
well-described immunodominant antigens (Acr-1, CFP-10, ESAT-6) as references. 23 of 
26 proteins induced an IFN-γ response in PBMC of persons with active or latent 
tuberculosis; of that 10 proteins induced a dominant IFN-γ response in >50% of the 
donors. Five novel immunodominant proteins: Rv1957, Rv1954c, Rv1955, Rv2022c and 
Rv1471, showed responses similar to CFP-10 and ESAT-6 in both magnitude and 
frequency. Only moderate evidence of infection stage specific recognition of antigens was 
observed. IL-2 responses were of lower magnitude than that of IFN-γ and the antigenic 
repertoire far more focused. Reconciliation of bioinformatic and empirical hierarchies of 
immunodominance revealed that antigens could, to an extent, be predicted providing 
transcriptomic data was coupled to population specific MHC-peptide binding prediction. 
These findings revealed that a number of genes induced by hypoxia are in fact potent T-
cell targets and therefore offers general support to the important role of hypoxia in the 
natural course of tuberculosis infection. The approach described for antigen discovery 













Mycobacterium tuberculosis remains a major threat to global health with an estimated 10 
million incident cases of tuberculosis (TB) that causes around 1.3 million deaths per year 
(WHO, 2010).  Furthermore, one third of the world‟s population is considered latently 
infected: a reservoir from which active TB disease will continue to develop for the 
foreseeable future and thus forming a major obstacle to achieve global control. The 
existence of so many with latent infection highlights that the partially effective vaccine: 
Mycobacterium bovis Bacille Calmette Guérin (BCG) does not prevent such infection 
(Maartens and Wilkinson, 2007).  
Studies of MTB genomic deletions (encoded by the region of difference 1, RD-1) led to 
the discovery of highly immunodominant, co-regulated, secreted, species specific proteins 
CFP-10 and ESAT-6 (Berthet et al., 1998; Sorensen et al., 1995). This use of genomic 
information has paved the way to the development of in vitro assays that measure T cell 
release of Interferon-gamma (IFN-γ) which have operational advantages and improve the 
specificity and possibly sensitivity of tuberculosis immunodiagnosis (Pai et al., 2008). An 
alternative genome based strategy is to relate what is highly expressed by bacilli in vivo or 
in vitro (and thereby potentially available as an antigen) (Sidders et al., 2008) to what is 
recognized in vivo.   
Multiple in vitro and in vivo studies increasingly indicate adaptation of M. tuberculosis via 
oxygen limitation into a non-replicating persistent state (Rustad et al., 2009). These 
observations have led to the models of latency and reactivation that suggests a prominent 
role of oxygen status (Boshoff and Barry, 2005; Gomez and McKinney, 2004; Rao et al., 
2008; Via et al., 2008). These in vitro culture models represent proxies of conditions that 
tubercle bacilli are thought to encounter in vivo during persistence in immunocompetent 











expressed as a part of the initial adaptation to hypoxia in MTB, are up regulated in vitro in 
IFN-γ activated MTB infected murine macrophages (Schnappinger et al., 2003; Shi et al., 
2003; Timm et al., 2003), have increased level of RNA in human lung tissue in patients 
with active TB (Timm et al., 2003), and are found to encode a number of MTB antigens 
with the potential to induce a strong T cell and IFN-γ  responses (Black et al., 2009; 
Demissie et al., 2006; Leyten et al., 2006; Roupie et al., 2007; Wilkinson et al., 1998b).  
The dosR regulon is also induced in response to nitric oxide, in standing cultures  (which 
generates a hypoxic gradient), and following infection of macrophage, mice and guinea 
pigs (Sharma et al., 2006; Voskuil et al., 2003; Voskuil et al., 2004). Some of these 
conditions are marked by significant bacterial replication, suggesting that the role of dosR 
may not be specific to latency and that other factors may also be involved. This lead to 
further characterization of the hypoxic response in more depth revealing that the initial 
hypoxic conditions regulated by dosR contributes modestly to the survival under hypoxic 
conditions in vitro and it is dispensable for the virulence in mice (Rustad et al., 2008).   
Recent whole genome based transcriptional analysis of MTB under similar in vitro 
hypoxic conditions, revealed that induction of the dosR regulon is somewhat transient, 
with expression of nearly half of the genes returning to baseline by 24 hours (1 day). An 
additional more prolonged transcriptional response to hypoxia was noted, which increased 
until 96 hours (4 days) and then stabilized around an enduring hypoxic response (EHR) at 
168 hours (7 days) (Rustad et al., 2008).  
Based on these findings 100 highly induce EHR genes were considered for evaluation. 
Since empirical screening of all the 100 genes is a considerable undertaking, a 











In this chapter describes evaluation of EHR encoded genes as potential antigens. I present 
the analysis of whole genome based transcriptional profiles of M. tuberculosis subject to 
prolonged hypoxia by a combined bioinformatic and immunological approach.  
The hypothesise addressed in this chapter includes the following: 
1. Molecules highly induced when MTB was subject to hypoxia in vitro, may be 
expressed in vivo and there by could be targets of the immune response.  
2. These molecules might provide further understanding in the biology of latent 
infection and may be preferentially recognized by T cells during latent tuberculosis 
infection.   














Bioinformatic evaluation and selection of candidate antigens 
Fold Expression and SigA normalized intensity in EHR 
 Whole genome based transcriptional data of MTB was analyzed, using fold induction  
(mean >2 log fold induction) and transcript levels (normalized to median SigA intensity) 
during the hypoxic time course (4 hours, 1 day, 4 days and at 7 days) as described 
previously (Rustad et al., 2008) (Appendix B.1 and B.2). EHR genes were ranked based on 
the fold induction at 7 days of hypoxia (Table 10): 100 genes with highest fold induction 
levels were selected for further evaluation. A qualitative score was assigned to aid 
prediction of candidates. The genes were ranked, ranging from rank 1 (highest fold 
induction) to rank 100 (lowest) and referred as R(FI) (Table 10). The transcript levels at 4 
and 7 days were also ranked from 1 to 100, and the average of ranks at 4 and 7 days were 
calculated; the average rank was further ranked and referred to as R(NI) (Table 10).  
 
Table 10 M. tuberculosis transcript levels: Fold induction at day 7, Normalized intensity at 
day 4 and 7 with respective ranks 
      Fold Induction 
(FI) 




























































































1 Rv0140 Rv0140 3.180 47 1.26 5.10 46 13 29.
5 
26 
2 Rv0188 Rv0188 2.638 76 2.10 2.78 26 26 26 22 
3 Rv0233 nrdB 2.492 86 1.21 1.76 51 51 1 50 
4 Rv0251
c 




3 3 3 2 
5 Rv0268
c 














clpB 2.941 63 1.25 1.58 47 54 50.
5 
49 
9 Rv0474 Rv0474 3.390 33 4.37 4.84 7 15 11 9 
10 Rv0520 Rv0520 3.296 38 0.48 0.63 83 84 83.
5 
85 















3.056 54 0.54 0.65 80 82 81 80 
13 Rv0766
c 





Rv0767c 4.019 19 3.49 2.63 10 28 19 18 
15 Rv0791
c 
Rv0791c 3.040 56 0.89 0.96 61 70 65.
5 
71 
16 Rv0793 Rv0793 2.730 72 0.47 0.44 84 92 88 89 
17 Rv0826 Rv0826 3.477 31 3.43 3.07 11 25 18 16 
18 Rv0846
c 
Rv0846c 3.538 30 0.51 0.65 82 83 82.
5 
83 
19 Rv0847 lpqS 5.564 1 21.7
5 
9.97 1 5 3 3 
20 Rv0848 cysK2 4.040 17 2.68 1.82 18 48 33 29 
21 Rv0849 Rv0849 2.592 83 0.46 0.46 87 91 89 90 
22 Rv0940
c 
Rv0940c 2.684 73 0.85 2.01 65 41 53 55 




2 2 2 1 
24 Rv0976
c 
Rv0976c 3.105 51 0.65 0.52 73 90 81.
5 
81 










Rv0991c 5.230 2 5.16 6.96 6 11 8.5 5 
28 Rv1169
c 
PE11 3.224 44 0.70 2.52 70 33 1.
5 
51 
29 Rv1221 sigE 2.771 70 3.98 26.1
6 
8 1 4.5 4 
30 Rv1284 Rv1284 3.107 50 0.58 0.62 77 86 81.
5 
82 
31 Rv1285 cysD 2.403 92 1.27 1.03 44 68 56 61 
32 Rv1403
c 
Rv1403c 3.984 20 0.92 1.34 60 62 61 64 
33 Rv1405
c 
Rv1405c 3.370 34 1.55 1.90 34 44 39 36 





Rv1587c 2.313 100 2.49 2.05 20 40 30 27 
36 Rv1738 Rv1738 4.987 4 0.54 1.40 79 58 68.
5 
75 
37 Rv1806 PE20 4.393 9 0.39 2.22 89 37 63 68 
38 Rv1813
c 
Rv1813c 4.029 18 2.02 1.38 30 60 45 40 
39 Rv1875 Rv1875 3.745 24 0.86 9.15 64 6 35 32 
40 Rv1909
c 





Rv1954c 2.678 74 0.42 0.22 88 99 93.
5 
94 
42 Rv1955 Rv1955 4.383 10 5.36 3.84 5 19 12 12 
43 Rv1956 Rv1956 3.115 49 2.34 2.53 22 32 27 23 
44 Rv1957 Rv1957 3.542 28 1.04 1.80 56 49 52.
5 
53 
45 Rv1986 Rv1986 3.058 53 2.10 1.35 25 61 43 39 
46 Rv1990
c 
Rv1990c 3.151 48 1.25 1.75 48 52 0 48 
47 Rv1994
c 
Rv1994c 3.220 45 1.46 8.08 38 8 23 20 
48 Rv1995 Rv1995 2.317 98 0.27 0.29 95 97 96 96 
49 Rv1996 Rv1996 2.945 62 0.38 0.60 92 88 90 91 
50 Rv2007
c 
fdxA 2.623 81 0.65 1.15 72 64 68 74 
51 Rv2011
c 
Rv2011c 2.906 66 1.11 1.67 53 53 53 56 
52 Rv2012 Rv2012 3.317 36 1.10 1.77 54 50 52 52 
53 Rv2021
c 





Rv2022c 2.948 61 0.74 0.85 69 73 71 76 
55 Rv2025
c 










hspX 4.217 14 0.63 1.40 75 57 66 72 
58 Rv2032 acg 3.210 46 0.17 0.38 97 95 96 97 
59 Rv2034 Rv2034 4.997 3 3.37 7.18 14 9 11.
5 
11 
60 Rv2035 Rv2035 3.828 23 2.24 3.68 23 20 21.
5 
19 
61 Rv2036 Rv2036 3.310 37 0.87 1.89 63 45 4 58 















rpiB 2.994 57 1.00 2.24 58 36 47 45 
64 Rv2466
c 
Rv2466c 4.153 15 3.29 10.8
1 
16 4 10 6 
65 Rv2504
c 
scoA 2.669 75 0.75 3.29 68 24 46 44 
66 Rv2517
c 
Rv2517c 2.633 78 1.50 4.94 36 14 25 21 
67 Rv2558 Rv2558 3.636 27 2.03 1.82 29 47 38 35 
68 Rv2617
c 
Rv2617c 2.482 88 1.23 3.63 50 21 35.
5 
33 










Rv2627c 3.280 40 0.12 0.40 10
0 
94 97 98 
72 Rv2628 Rv2628 2.427 91 0.52 0.81 81 74 77.
5 
79 
73 Rv2642 Rv2642 4.741 7 3.42 7.14 12 10 11 10 
74 Rv2643 arsC 3.729 25 0.60 2.38 76 34 5 59 
75 Rv2658
c 





Rv2659c 3.286 39 1.47 0.72 37 79 58 62 
77 Rv2660
c 
Rv2660c 2.471 89 0.33 0.28 93 98 95.
5 
95 
78 Rv2662 Rv2662 3.348 35 0.30 0.95 94 71 82.
5 
84 
79 Rv2663 Rv2663 2.901 67 0.76 2.57 67 31 49 47 
80 Rv2664 Rv2664 2.762 71 0.69 1.56 71 55 63 69 
81 Rv2693
c 










Rv2699c 2.633 77 0.39 0.66 90 81 85.
5 
86 










Rv2962c 2.334 97 0.38 0.42 91 93 92 93 
87 Rv2963 Rv2963 3.069 52 1.40 0.74 40 78 9 63 
88 Rv3130
c 
Rv3130c 3.712 26 2.07 2.65 27 27 27 24 
89 Rv3131 Rv3131 2.368 93 0.47 0.62 85 87 86 87 










lat 3.224 43 2.37 8.68 21 7 14 13 
93 Rv3334 Rv3334 3.399 32 2.51 2.01 19 42 30.
5 
28 





fdxD 2.552 84 1.26 0.75 45 77 61 65 
96 Rv3515
c 
fadD19 2.990 58 0.97 1.09 59 65 62 66 
97 Rv3536
c 
Rv3536c 3.887 22 1.28 3.40 43 23 33 30 
98 Rv3597
c 
lsr2 2.345 95 2.04 2.58 28 30 29 25 
99 Rv3681
c 





whiB6 4.301 12 3.38 4.14 13 18 15.
5 
14 














MHC class II- binding peptide prediction 
Using ProPred (Singh and Raghava, 2001), MHC class II (MHCII)-binding peptide 
prediction was performed for the following HLA 51 allelic variants as described in the 
methods (Chapter 2): DR1 (2 allelic variants), DR3 (7), DR4 (9), DR 7 (6), DR8 (9), 
DR11(9), DR13 (11) and DR15(3) (Table 11). Instead of selecting only the predicted 
binding regions of the proteins, a rational approach was undertaken. A novel protocol was 
developed for scoring, which allowed ranking of the prediction, and prioritization of the 
gene products.  
ProPred analysis defines the binding peptide sequences for all 51 HLA allelic variants and 
provides the binding score attained by that peptide sequence. In addition, it also provides 
the highest binding score that could be attained by any peptide to that allele. In the scoring 
protocol that was developed, the number of peptide regions with a score higher than 30% 
of the highest binding score attainable by any peptide for all the 51 HLA allelic variants 
was calculated. This score was then summed and corrected for the number of allelic 
variants of each allele, and referred as the MHC II binding peptide prediction score (Table 
11). 
Table 11 MHC II binding peptide prediction: number of peptide sequence with >30 % of 
highest binding score 
    MHC class II binding peptide prediction score 
(number  of alleles scored >30% of highest binding score) 
S.No Name DR1 DR3 DR4 DR7 DR8 DR11 DR13 DR15 
1 Rv0140 0.00 2.00 1.90 2.00 0.60 0.20 1.18 1.30 
2 Rv0188 3.00 2.20 3.20 5.00 3.50 3.20 4.07 4.90 
3 Rv0233 0.50 1.64 2.00 5.00 1.30 1.90 2.47 2.60 
4 Rv0251c 1.50 2.28 0.30 1.00 1.66 2.00 2.36 3.90 
5 Rv0268c 0.50 1.40 0.00 1.00 1.50 1.60 2.17 1.60 
6 Rv0327c 3.00 4.95 4.70 5.00 5.20 4.90 4.68 4.90 
7 Rv0350 1.50 4.54 3.20 5.00 3.10 2.90 3.60 2.70 
8 Rv0384c 4.00 4.94 5.36 5.00 4.30 4.00 4.13 4.90 
9 Rv0474 0.00 2.57 0.10 2.00 1.00 0.76 0.16 1.60 
10 Rv0520 0.00 1.70 0.30 3.50 1.46 0.60 0.63 2.00 
11 Rv0521 0.50 1.70 2.40 5.00 2.10 3.40 3.69 3.60 











13 Rv0766c 3.00 4.70 3.20 5.00 4.76 4.20 4.70 4.90 
14 Rv0767c 2.50 3.08 1.80 5.00 1.80 2.84 3.45 1.09 
15 Rv0791c 3.50 4.10 4.30 5.00 3.30 2.80 3.40 5.00 
16 Rv0793 0.50 1.14 0.30 1.00 3.40 1.20 1.70 2.00 
17 Rv0826 2.50 3.14 1.60 5.00 4.30 3.40 4.08 4.90 
18 Rv0846c 1.00 4.78 4.50 5.00 5.80 3.30 4.60 4.20 
19 Rv0847 0.50 1.84 1.80 3.00 1.60 0.90 1.50 2.30 
20 Rv0848 0.50 4.28 4.10 5.00 3.32 3.30 3.56 1.07 
21 Rv0849 1.50 2.70 2.70 6.00 3.60 3.60 3.63 5.00 
22 Rv0940c 1.50 0.12 2.30 5.00 3.72 3.10 4.18 5.00 
23 Rv0967 0.50 0.57 2.10 3.00 0.60 0.20 1.18 3.00 
24 Rv0976c 3.00 4.99 6.10 5.00 4.46 3.60 2.80 5.00 
25 Rv0986 3.00 4.40 3.20 5.00 1.66 2.50 2.98 4.60 
26 Rv0990c 4.00 4.54 3.80 5.00 2.80 3.90 4.03 1.00 
27 Rv0991c 0.00 1.14 1.30 2.00 0.90 0.50 0.27 0.60 
28 Rv1169c 0.50 0.50 2.50 5.00 0.00 0.20 0.50 3.00 
29 Rv1221 0.50 4.60 3.34 5.00 4.10 3.00 3.40 4.30 
30 Rv1284 2.00 3.54 2.50 5.00 2.50 2.60 3.30 4.00 
31 Rv1285 2.00 4.00 3.10 5.00 4.10 3.40 2.49 4.60 
32 Rv1403c 3.00 3.55 2.10 4.00 0.60 1.70 2.09 1.00 
33 Rv1405c 2.00 3.99 3.40 3.00 3.10 3.10 2.90 4.30 
34 Rv1471 1.50 1.14 1.15 2.00 0.80 0.60 0.89 3.30 
35 Rv1587c 0.50 1.70 2.80 5.00 2.30 3.40 3.69 3.60 
36 Rv1738 0.00 0.14 0.70 3.00 1.30 0.30 1.09 1.30 
37 Rv1806 4.00 1.70 2.60 8.00 1.60 1.00 1.08 4.00 
38 Rv1813c 0.50 3.00 0.80 4.00 3.10 2.30 2.56 1.09 
39 Rv1875 1.00 2.70 2.50 4.00 2.10 2.90 3.10 1.18 
40 Rv1909c 1.50 2.80 1.40 2.00 1.83 1.00 1.80 1.30 
41 Rv1954c 1.00 1.20 1.10 3.00 3.32 1.40 2.18 3.30 
42 Rv1955 1.00 3.95 1.00 2.00 1.96 2.29 2.76 3.00 
43 Rv1956 0.50 3.40 0.70 0.00 2.10 1.50 1.48 1.30 
44 Rv1957 3.00 3.28 1.80 5.00 2.50 3.40 3.79 4.30 
45 Rv1986 5.00 4.80 4.40 3.00 4.76 4.10 4.50 5.20 
46 Rv1990c 0.00 2.54 1.70 4.00 0.83 0.60 1.72 1.00 
47 Rv1994c 0.50 1.14 1.30 3.00 1.16 0.60 1.30 0.30 
48 Rv1995 1.00 4.10 2.50 4.00 3.00 2.20 2.80 4.30 
49 Rv1996 3.00 4.80 3.90 5.00 2.10 2.00 2.60 3.00 
50 Rv2007c 0.50 2.60 0.10 2.00 0.00 0.30 0.00 0.00 
51 Rv2011c 0.00 4.43 1.74 2.00 2.50 1.44 3.55 2.33 
52 Rv2012 0.00 2.14 0.70 0.00 3.80 2.90 3.17 2.20 
53 Rv2021c 0.00 3.24 1.70 5.00 2.46 2.50 2.68 4.00 
54 Rv2022c 1.50 1.70 0.70 3.00 1.30 1.30 1.81 1.30 
55 Rv2025c 5.00 5.60 4.60 5.00 4.90 4.70 3.89 4.90 
56 Rv2030c 4.00 4.70 4.20 5.00 4.90 4.00 4.40 3.96 
57 Rv2031c 1.00 1.90 1.10 3.00 0.80 1.40 1.17 4.30 
58 Rv2032 2.00 4.98 3.70 5.00 3.60 3.20 3.18 4.30 
59 Rv2034 1.00 2.20 0.80 0.00 1.30 0.60 0.70 0.60 
60 Rv2035 1.00 1.00 0.80 1.00 1.60 0.80 1.60 0.72 
61 Rv2036 0.00 1.28 0.90 3.00 4.76 2.90 3.90 4.60 
62 Rv2050 0.00 1.70 0.30 1.00 0.60 0.30 0.09 1.00 











64 Rv2466c 0.00 1.57 1.80 4.50 2.16 2.16 2.45 2.20 
65 Rv2504c 1.00 2.80 2.20 5.00 2.16 1.50 2.56 4.30 
66 Rv2517c 0.00 0.00 0.60 3.00 0.60 0.80 0.09 2.00 
67 Rv2558 1.50 2.80 1.70 5.00 1.70 1.40 1.79 3.30 
68 Rv2617c 4.00 1.78 3.10 5.00 3.16 2.10 3.36 4.90 
69 Rv2623 2.00 4.57 2.50 5.00 2.00 1.10 1.79 3.30 
70 Rv2626c 1.50 2.28 2.60 2.00 2.46 2.60 3.20 1.60 
71 Rv2627c 3.50 3.28 2.80 5.00 3.90 3.90 4.60 4.60 
72 Rv2628 0.00 0.14 0.40 5.00 0.76 0.60 1.69 1.00 
73 Rv2642 1.00 2.00 2.00 1.00 2.20 2.00 3.80 0.80 
74 Rv2643 3.50 3.14 3.30 0.00 3.60 4.60 5.36 1.45 
75 Rv2658c 0.50 1.57 1.20 1.00 0.50 0.20 0.80 0.60 
76 Rv2659c 1.50 2.57 3.10 5.00 3.66 3.20 3.08 4.00 
77 Rv2660c 0.00 0.00 0.00 0.00 0.00 0.00 0.18 0.00 
78 Rv2662 0.50 0.42 0.90 0.00 0.76 0.50 0.80 1.30 
79 Rv2663 0.00 1.20 0.40 1.00 2.10 1.00 1.45 1.30 
80 Rv2664 0.00 0.94 4.40 0.00 0.30 0.70 0.76 1.00 
81 Rv2693c 3.00 5.20 6.50 5.00 5.00 4.80 5.93 5.00 
82 Rv2694c 1.00 2.00 1.70 2.00 3.00 2.93 3.50 1.20 
83 Rv2699c 0.00 1.27 0.40 3.00 3.80 1.20 2.07 1.60 
84 Rv2780 3.50 5.10 3.70 7.00 5.20 4.30 5.40 6.30 
85 Rv2913c 5.50 4.40 3.60 8.00 2.76 7.40 4.88 9.30 
86 Rv2962c 3.50 5.00 4.14 4.50 4.90 5.40 5.39 4.20 
87 Rv2963 1.50 4.28 3.40 1.00 4.30 2.10 2.58 1.20 
88 Rv3130c 4.00 5.30 5.34 6.50 4.80 2.90 3.62 4.90 
89 Rv3131 3.00 4.04 4.60 5.00 3.33 4.71 3.45 4.00 
90 Rv3269 0.00 0.43 0.77 1.00 3.17 1.28 1.64 0.67 
91 Rv3288c 2.00 2.40 2.00 5.00 1.32 2.30 2.85 5.00 
92 Rv3290c 1.00 3.70 2.70 2.00 3.43 4.50 4.66 7.30 
93 Rv3334 1.00 1.70 2.10 6.00 2.96 1.20 1.20 3.60 
94 Rv3406 1.50 4.50 3.90 5.00 3.80 4.40 4.24 4.30 
95 Rv3503c 1.00 1.80 0.10 1.00 0.50 0.40 0.09 2.60 
96 Rv3515c 2.50 0.43 3.40 4.00 4.96 4.20 4.35 3.00 
97 Rv3536c 1.00 3.27 1.80 5.00 2.66 1.80 2.18 0.90 
98 Rv3597c 0.00 0.85 0.30 0.00 0.96 0.50 1.18 0.00 
99 Rv3681c 0.50 0.28 0.00 0.00 1.60 0.50 1.18 0.00 
100 Rv3862c 0.50 0.70 1.70 3.00 0.33 0.80 1.18 1.60 
 
[Represented as the average number of peptide sequence with >30% of the highest peptide binding score 
achievable for each allele] 
 
HLA allelic polymorphism in the human population, are known to influence the peptide 
recognition by MHC II. To account for this, the MHCII binding peptide prediction score 











population (in which the empirical evaluation was to be carried out), available from the 
literature (Appendix B.3)(du Toit et al., 1988). The correction was performed, by 
multiplying the prediction score for each allele (eg: score for DR1= 2) with its allelic 
frequency (af) (eg: af of DR1= 0.0839) within the population. The resulting score is 
referred as the population specific (corrected) MHCII binding peptide as presented in the 
Table 12.  
In order to rank and prioritize gene products: minimum, median and maximum score (of all 
alleles) attained by each protein was calculated. The median score was then ranked 
(highest to lowest) and assigned rank numbers 1-100. This population specific MHCII 
binding prediction rank was referred as R(cPP) (Table 12).  

















































































1 Rv0140 0.0000 0.8386 0.2537 0.2858 0.0074 0.0627 0.3885 0.2826 0.0000 0.8386 0.2681 71 
2 Rv0188 0.2517 0.9225 0.4272 0.7145 0.0434 1.0038 1.3398 1.0653 0.0434 1.3398 0.8185 19 
3 Rv0233 0.0420 0.6877 0.2670 0.7145 0.0161 0.5960 0.8131 0.5652 0.0161 0.8131 0.5806 42 
4 Rv0251c 0.1259 0.9560 0.0401 0.1429 0.0206 0.6274 0.7769 0.8479 0.0206 0.9560 0.3852 58 
5 Rv0268c 0.0420 0.5870 0.0000 0.1429 0.0186 0.5019 0.7144 0.3478 0.0000 0.7144 0.2454 74 
6 Rv0327c 0.2517 2.0755 0.6275 0.7145 0.0645 1.5371 1.5407 1.0653 0.0645 2.0755 0.8899 10 
7 Rv0350 0.1259 1.9036 0.4272 0.7145 0.0384 0.9097 1.1851 0.5870 0.0384 1.9036 0.6507 36 
8 Rv0384c 0.3356 2.0713 0.7156 0.7145 0.0533 1.2548 1.3596 1.0653 0.0533 2.0713 0.8904 6 
9 Rv0474 0.0000 1.0776 0.0134 0.2858 0.0124 0.2384 0.0533 0.3478 0.0000 1.0776 0.1459 85 
10 Rv0520 0.0000 0.7128 0.0401 0.5002 0.0181 0.1882 0.2074 0.4348 0.0000 0.7128 0.1978 80 
11 Rv0521 0.0420 0.7128 0.3204 0.7145 0.0260 1.0666 1.2147 0.7826 0.0260 1.2147 0.7137 31 
12 Rv0754 0.2098 2.0546 0.5474 0.7145 0.0508 0.8784 0.9876 0.6087 0.0508 2.0546 0.6616 35 
13 Rv0766c 0.2517 1.9707 0.4272 0.7145 0.0590 1.3175 1.5472 1.0653 0.0590 1.9707 0.8899 9 
14 Rv0767c 0.2098 1.2914 0.2403 0.7145 0.0223 0.8909 1.1357 0.2370 0.0223 1.2914 0.4774 48 
15 Rv0791c 0.2937 1.7191 0.5741 0.7145 0.0409 0.8784 1.1193 1.0870 0.0409 1.7191 0.7964 21 
16 Rv0793 0.0420 0.4780 0.0401 0.1429 0.0422 0.3764 0.5596 0.4348 0.0401 0.5596 0.2597 73 
17 Rv0826 0.2098 1.3166 0.2136 0.7145 0.0533 1.0666 1.3431 1.0653 0.0533 1.3431 0.8899 7 











19 Rv0847 0.0420 0.7715 0.2403 0.4287 0.0198 0.2823 0.4938 0.5000 0.0198 0.7715 0.3555 63 
20 Rv0848 0.0420 1.7946 0.5474 0.7145 0.0412 1.0352 1.1720 0.2326 0.0412 1.7946 0.6309 38 
21 Rv0849 0.1259 1.1321 0.3605 0.8574 0.0446 1.1293 1.1950 1.0870 0.0446 1.1950 0.9722 4 
22 Rv0940c 0.1259 0.0503 0.3071 0.7145 0.0461 0.9725 1.3761 1.0870 0.0461 1.3761 0.5108 46 
23 Rv0967 0.0420 0.2390 0.2804 0.4287 0.0074 0.0627 0.3885 0.6522 0.0074 0.6522 0.2597 72 
24 Rv0976c 0.2517 2.0923 0.8144 0.7145 0.0553 1.1293 0.9218 1.0870 0.0553 2.0923 0.8681 12 
25 Rv0986 0.2517 1.8449 0.4272 0.7145 0.0206 0.7843 0.9810 1.0000 0.0206 1.8449 0.7494 29 
26 Rv0990c 0.3356 1.9036 0.5073 0.7145 0.0347 1.2234 1.3267 0.2174 0.0347 1.9036 0.6109 40 
27 Rv0991c 0.0000 0.4780 0.1736 0.2858 0.0112 0.1569 0.0889 0.1304 0.0000 0.4780 0.1436 87 
28 Rv1169c 0.0420 0.2097 0.3338 0.7145 0.0000 0.0627 0.1646 0.6522 0.0000 0.7145 0.1871 82 
29 Rv1221 0.0420 1.9288 0.4459 0.7145 0.0508 0.9411 1.1193 0.9348 0.0420 1.9288 0.8247 17 
30 Rv1284 0.1678 1.4843 0.3338 0.7145 0.0310 0.8156 1.0864 0.8696 0.0310 1.4843 0.7651 27 
31 Rv1285 0.1678 1.6772 0.4139 0.7145 0.0508 1.0666 0.8197 1.0000 0.0508 1.6772 0.7671 26 
32 Rv1403c 0.2517 1.4885 0.2804 0.5716 0.0074 0.5333 0.6874 0.2174 0.0074 1.4885 0.4068 54 
33 Rv1405c 0.1678 1.6730 0.4539 0.4287 0.0384 0.9725 0.9547 0.9348 0.0384 1.6730 0.6944 33 
34 Rv1471 0.1259 0.4780 0.1535 0.2858 0.0099 0.1882 0.2930 0.7174 0.0099 0.7174 0.2370 75 
35 Rv1587c 0.0420 0.7128 0.3738 0.7145 0.0285 1.0666 1.2147 0.7826 0.0285 1.2147 0.7137 32 
36 Rv1738 0.0000 0.0587 0.0935 0.4287 0.0161 0.0941 0.3588 0.2826 0.0000 0.4287 0.0938 94 
37 Rv1806 0.3356 0.7128 0.3471 1.1432 0.0198 0.3137 0.3555 0.8696 0.0198 1.1432 0.3513 64 
38 Rv1813c 0.0420 1.2579 0.1068 0.5716 0.0384 0.7215 0.8428 0.2370 0.0384 1.2579 0.4043 55 
39 Rv1875 0.0839 1.1321 0.3338 0.5716 0.0260 0.9097 1.0205 0.2565 0.0260 1.1321 0.4527 51 
40 Rv1909c 0.1259 1.1740 0.1869 0.2858 0.0227 0.3137 0.5926 0.2826 0.0227 1.1740 0.2842 68 
41 Rv1954c 0.0839 0.5032 0.1469 0.4287 0.0412 0.4392 0.7177 0.7174 0.0412 0.7177 0.4339 52 
42 Rv1955 0.0839 1.6562 0.1335 0.2858 0.0243 0.7184 0.9086 0.6522 0.0243 1.6562 0.4690 49 
43 Rv1956 0.0420 1.4256 0.0935 0.0000 0.0260 0.4706 0.4872 0.2826 0.0000 1.4256 0.1880 81 
44 Rv1957 0.2517 1.3753 0.2403 0.7145 0.0310 1.0666 1.2477 0.9348 0.0310 1.3753 0.8247 16 
45 Rv1986 0.4195 2.0126 0.5874 0.4287 0.0590 1.2862 1.4814 1.1305 0.0590 2.0126 0.8589 13 
46 Rv1990c 0.0000 1.0650 0.2270 0.5716 0.0103 0.1882 0.5662 0.2174 0.0000 1.0650 0.2222 76 
47 Rv1994c 0.0420 0.4780 0.1736 0.4287 0.0144 0.1882 0.4280 0.0652 0.0144 0.4780 0.1809 83 
48 Rv1995 0.0839 1.7191 0.3338 0.5716 0.0372 0.6901 0.9218 0.9348 0.0372 1.7191 0.6309 39 
49 Rv1996 0.2517 2.0126 0.5207 0.7145 0.0260 0.6274 0.8559 0.6522 0.0260 2.0126 0.6398 37 
50 Rv2007c 0.0420 1.0902 0.0134 0.2858 0.0000 0.0941 0.0000 0.0000 0.0000 1.0902 0.0277 98 
51 Rv2011c 0.0000 1.8569 0.2329 0.2858 0.0310 0.4531 1.1672 0.5073 0.0000 1.8569 0.3695 60 
52 Rv2012 0.0000 0.8973 0.0935 0.0000 0.0471 0.9097 1.0436 0.4783 0.0000 1.0436 0.2859 67 
53 Rv2021c 0.0000 1.3585 0.2270 0.7145 0.0305 0.7843 0.8823 0.8696 0.0000 1.3585 0.7494 28 
54 Rv2022c 0.1259 0.7128 0.0935 0.4287 0.0161 0.4078 0.5959 0.2826 0.0161 0.7128 0.3452 66 
55 Rv2025c 0.4195 2.3481 0.6141 0.7145 0.0608 1.4744 1.2806 1.0653 0.0608 2.3481 0.8899 8 
56 Rv2030c 0.3356 1.9707 0.5607 0.7145 0.0608 1.2548 1.4485 0.8609 0.0608 1.9707 0.7877 24 
57 Rv2031c 0.0839 0.7967 0.1469 0.4287 0.0099 0.4392 0.3852 0.9348 0.0099 0.9348 0.4069 53 
58 Rv2032 0.1678 2.0881 0.4940 0.7145 0.0446 1.0038 1.0469 0.9348 0.0446 2.0881 0.8247 18 
59 Rv2034 0.0839 0.9225 0.1068 0.0000 0.0161 0.1882 0.2304 0.1304 0.0000 0.9225 0.1186 92 











61 Rv2036 0.0000 0.5367 0.1202 0.4287 0.0590 0.9097 1.2839 1.0000 0.0000 1.2839 0.4827 47 
62 Rv2050 0.0000 0.7128 0.0401 0.1429 0.0074 0.0941 0.0296 0.2174 0.0000 0.7128 0.0671 95 
63 Rv2465c 0.0000 0.6290 0.0534 0.2858 0.0223 0.0314 0.1975 0.4348 0.0000 0.6290 0.1255 90 
64 Rv2466c 0.0000 0.6583 0.2403 0.6431 0.0268 0.6776 0.8065 0.4783 0.0000 0.8065 0.5607 43 
65 Rv2504c 0.0839 1.1740 0.2937 0.7145 0.0268 0.4706 0.8428 0.9348 0.0268 1.1740 0.5925 41 
66 Rv2517c 0.0000 0.0000 0.0801 0.4287 0.0074 0.2510 0.0296 0.4348 0.0000 0.4348 0.0549 96 
67 Rv2558 0.1259 1.1740 0.2270 0.7145 0.0211 0.4392 0.5893 0.7174 0.0211 1.1740 0.5142 44 
68 Rv2617c 0.3356 0.7464 0.4139 0.7145 0.0392 0.6588 1.1061 1.0653 0.0392 1.1061 0.6866 34 
69 Rv2623 0.1678 1.9162 0.3338 0.7145 0.0248 0.3451 0.5893 0.7174 0.0248 1.9162 0.4672 50 
70 Rv2626c 0.1259 0.9560 0.3471 0.2858 0.0305 0.8156 1.0534 0.3478 0.0305 1.0534 0.3475 65 
71 Rv2627c 0.2937 1.3753 0.3738 0.7145 0.0484 1.2234 1.5143 1.0000 0.0484 1.5143 0.8573 14 
72 Rv2628 0.0000 0.0587 0.0534 0.7145 0.0094 0.1882 0.5563 0.2174 0.0000 0.7145 0.1235 91 
73 Rv2642 0.0839 0.8386 0.2670 0.1429 0.0273 0.6274 1.2510 0.1739 0.0273 1.2510 0.2205 77 
74 Rv2643 0.2937 1.3166 0.4406 0.0000 0.0446 1.4430 1.7645 0.3152 0.0000 1.7645 0.3779 59 
75 Rv2658c 0.0420 0.6583 0.1602 0.1429 0.0062 0.0627 0.2634 0.1304 0.0062 0.6583 0.1367 89 
76 Rv2659c 0.1259 1.0776 0.4139 0.7145 0.0454 1.0038 1.0139 0.8696 0.0454 1.0776 0.7921 23 
77 Rv2660c 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0593 0.0000 0.0000 0.0593 0.0000 100 
78 Rv2662 0.0420 0.1761 0.1202 0.0000 0.0094 0.1569 0.2634 0.2826 0.0000 0.2826 0.1385 88 
79 Rv2663 0.0000 0.5032 0.0534 0.1429 0.0260 0.3137 0.4773 0.2826 0.0000 0.5032 0.2128 79 
80 Rv2664 0.0000 0.3941 0.5874 0.0000 0.0037 0.2196 0.2502 0.2174 0.0000 0.5874 0.2185 78 
81 Rv2693c 0.2517 2.1804 0.8678 0.7145 0.0620 1.5058 1.9519 1.0870 0.0620 2.1804 0.9774 3 
82 Rv2694c 0.0839 0.8386 0.2270 0.2858 0.0372 0.9191 1.1522 0.2609 0.0372 1.1522 0.2733 69 
83 Rv2699c 0.0000 0.5325 0.0534 0.4287 0.0471 0.3764 0.6814 0.3478 0.0000 0.6814 0.3621 61 
84 Rv2780 0.2937 2.1384 0.4940 1.0003 0.0645 1.3489 1.7777 1.3696 0.0645 2.1384 1.1746 2 
85 Rv2913c 0.4615 1.8449 0.4806 1.1432 0.0342 2.3214 1.6065 2.0218 0.0342 2.3214 1.3748 1 
86 Rv2962c 0.2937 2.0965 0.5527 0.6431 0.0608 1.6940 1.7744 0.9131 0.0608 2.0965 0.7781 25 
87 Rv2963 0.1259 1.7946 0.4539 0.1429 0.0533 0.6588 0.8493 0.2609 0.0533 1.7946 0.3574 62 
88 Rv3130c 0.3356 2.2223 0.7129 0.9289 0.0595 0.9097 1.1917 1.0653 0.0595 2.2223 0.9193 5 
89 Rv3131 0.2517 1.6952 0.6141 0.7145 0.0413 1.4779 1.1372 0.8696 0.0413 1.6952 0.7921 22 
90 Rv3269 0.0000 0.1797 0.1024 0.1429 0.0393 0.4008 0.5387 0.1449 0.0000 0.5387 0.1439 86 
91 Rv3288c 0.1678 1.0063 0.2670 0.7145 0.0164 0.7215 0.9382 1.0870 0.0164 1.0870 0.7180 30 
92 Rv3290c 0.0839 1.5514 0.3605 0.2858 0.0425 1.4117 1.5341 1.5870 0.0425 1.5870 0.8861 11 
93 Rv3334 0.0839 0.7128 0.2804 0.8574 0.0367 0.3764 0.3950 0.7826 0.0367 0.8574 0.3857 57 
94 Rv3406 0.1259 1.8869 0.5207 0.7145 0.0471 1.3803 1.3958 0.9348 0.0471 1.8869 0.8247 15 
95 Rv3503c 0.0839 0.7547 0.0134 0.1429 0.0062 0.1255 0.0296 0.5652 0.0062 0.7547 0.1047 93 
96 Rv3515c 0.2098 0.1803 0.4539 0.5716 0.0615 1.3175 1.4320 0.6522 0.0615 1.4320 0.5128 45 
97 Rv3536c 0.0839 1.3711 0.2403 0.7145 0.0330 0.5647 0.7177 0.1957 0.0330 1.3711 0.4025 56 
98 Rv3597c 0.0000 0.3564 0.0401 0.0000 0.0119 0.1569 0.3885 0.0000 0.0000 0.3885 0.0260 99 
99 Rv3681c 0.0420 0.1174 0.0000 0.0000 0.0198 0.1569 0.3885 0.0000 0.0000 0.3885 0.0309 97 












Final Ranking for informatics prediction 
The overall qualitative score was calculated by summing the ranks: R(FI), R(NI) and 
R(cPP). The summed score was in turn ranked (R) from the lowest to highest and the gene 
with the lowest score was assigned the highest rank (rank 1) for being the best candidate 
and the highest score with the lowest rank (rank 100), as the worst candidate (Table 13). 
Table 13 Overall score and ranking 
S.No Name Gene name R(FI) R(cPP) R(NI) Over all Score R 
1 Rv0140 Rv0140 47 71 26 144 46 
2 Rv0188 Rv0188 76 19 22 117 27 
3 Rv0233 nrdB 86 42 50 178 73 
4 Rv0251c hsp 16 58 3 77 7 
5 Rv0268c Rv0268c 69 74 67 210 87 
6 Rv0327c cyp135A1 65 7 100 172 67 
7 Rv0350 dnaK 96 36 7 139 40 
8 Rv0384c clpB 63 6 49 118 30 
9 Rv0474 Rv0474 33 85 10 128 36 
10 Rv0520 Rv0520 38 80 85 203 82 
11 Rv0521 Rv0521 99 31 88 218 91 
12 Rv0754 PE_PGRS11 54 35 80 169 63 
13 Rv0766c cyp123 55 8 57 120 33 
14 Rv0767c Rv0767c 19 48 18 85 10 
15 Rv0791c Rv0791c 56 21 71 148 49 
16 Rv0793 Rv0793 72 73 89 234 95 
17 Rv0826 Rv0826 31 9 16 56 1 
18 Rv0846c Rv0846c 30 20 83 133 38 
19 Rv0847 lpqS 1 63 2 66 3 
20 Rv0848 cysK2 17 38 29 84 9 
21 Rv0849 Rv0849 83 4 90 177 72 
22 Rv0940c Rv0940c 73 46 55 174 69 
23 Rv0967 Rv0967 5 72 1 78 8 
24 Rv0976c Rv0976c 51 12 81 144 47 
25 Rv0986 Rv0986 85 28 92 205 84 
26 Rv0990c Rv0990c 21 40 41 102 16 
27 Rv0991c Rv0991c 2 87 5 94 13 
28 Rv1169c PE11 44 82 51 177 70 
29 Rv1221 sigE 70 15 4 89 11 
30 Rv1284 Rv1284 50 27 82 159 58 
31 Rv1285 cysD 92 26 61 179 74 
32 Rv1403c Rv1403c 20 54 64 138 39 
33 Rv1405c Rv1405c 34 33 36 103 17 
34 Rv1471 trxB1 8 75 31 114 26 
35 Rv1587c Rv1587c 100 32 27 159 57 
36 Rv1738 Rv1738 4 94 75 173 68 
37 Rv1806 PE20 9 64 68 141 43 
38 Rv1813c Rv1813c 18 55 40 113 25 
39 Rv1875 Rv1875 24 51 32 107 22 











41 Rv1954c Rv1954c 74 52 94 220 93 
42 Rv1955 Rv1955 10 49 12 71 6 
43 Rv1956 Rv1956 49 81 24 154 52 
44 Rv1957 Rv1957 28 16 53 97 15 
45 Rv1986 Rv1986 53 13 39 105 19 
46 Rv1990c Rv1990c 48 76 48 172 65 
47 Rv1994c Rv1994c 45 83 20 148 48 
48 Rv1995 Rv1995 98 39 97 234 96 
49 Rv1996 Rv1996 62 37 91 190 77 
50 Rv2007c fdxA 80 98 74 252 98 
51 Rv2011c Rv2011c 66 60 56 182 75 
52 Rv2012 Rv2012 36 67 52 155 55 
53 Rv2021c Rv2021c 87 29 54 170 64 
54 Rv2022c Rv2022c 61 66 76 203 81 
55 Rv2025c Rv2025c 68 10 42 120 32 
56 Rv2030c Rv2030c 60 24 99 183 76 
57 Rv2031c hspX 14 53 72 139 42 
58 Rv2032 acg 46 17 96 159 59 
59 Rv2034 Rv2034 3 92 11 106 20 
60 Rv2035 Rv2035 23 84 19 126 35 
61 Rv2036 Rv2036 37 47 58 142 44 
62 Rv2050 Rv2050 41 95 15 151 50 
63 Rv2465c rpiB 57 90 45 192 78 
64 Rv2466c Rv2466c 15 43 6 64 2 
65 Rv2504c scoA 75 41 44 160 60 
66 Rv2517c Rv2517c 78 96 21 195 80 
67 Rv2558 Rv2558 27 44 35 106 21 
68 Rv2617c Rv2617c 88 34 33 155 53 
69 Rv2623 TB31.7 42 50 77 169 62 
70 Rv2626c Rv2626c 6 65 46 117 29 
71 Rv2627c Rv2627c 40 14 98 152 51 
72 Rv2628 Rv2628 91 91 79 261 99 
73 Rv2642 Rv2642 7 77 9 93 12 
74 Rv2643 arsC 25 59 59 143 45 
75 Rv2658c Rv2658c 13 89 70 172 66 
76 Rv2659c Rv2659c 39 22 62 123 34 
77 Rv2660c Rv2660c 89 100 95 284 100 
78 Rv2662 Rv2662 35 88 84 207 85 
79 Rv2663 Rv2663 67 79 47 193 79 
80 Rv2664 Rv2664 71 78 69 218 90 
81 Rv2693c Rv2693c 94 3 34 131 37 
82 Rv2694c Rv2694c 79 69 8 156 56 
83 Rv2699c Rv2699c 77 61 86 224 94 
84 Rv2780 ald 90 2 17 109 24 
85 Rv2913c Rv2913c 29 1 73 103 18 
86 Rv2962c Rv2962c 97 25 93 215 88 
87 Rv2963 Rv2963 52 62 63 177 71 
88 Rv3130c Rv3130c 26 5 87 118 31 
89 Rv3131 Rv3131 93 23 23 139 41 
90 Rv3269 Rv3269 64 86 60 210 86 
91 Rv3288c usfY 82 30 43 155 54 
92 Rv3290c lat 43 11 13 67 5 
93 Rv3334 Rv3334 32 57 28 117 28 
94 Rv3406 Rv3406 11 18 37 66 4 
95 Rv3503c fdxD 84 93 65 242 97 
96 Rv3515c fadD19 58 45 66 169 61 











98 Rv3597c lsr2 95 99 25 219 92 
99 Rv3681c whiB4 81 97 38 216 89 
100 Rv3862c whiB6 12 70 14 96 14 
*selected proteins are in bold 
 
Selection of candidates for empirical evaluation 
I selected genes that were:  
(i) Species specific: especially if they are absent from M. bovis and the commonly used 
BCG vaccine strains (described and presented in Chapter 6) 
(ii) Based on the overall prediction score (R) (Table 14): both high and low ranking 
candidates were included in order to aid relating bioinformatic and empirical hierarchies. 
(iii) Genomic organisation (e.g. predicted operons) 
(iv) Genes that are also induced in other stress conditions, such as nutrition starvation and 
heat shock.  











The fold induction and sigA normalized transcript intensity over a time course of 168 hrs 
hypoxia for the selected EHR genes (and of Acr1, CFP-10 and ESAT-6) were analyzed.  
The fold induction and the sigA normalized transcript intensity for the EHR and dosR 
regulated Acr1 genes increased over a time course of 168 hours (Figure 33 A and B). 
Interestingly, whilst the fold induction (Figure 33 A) for the RD1 encoded genes fell, the 
normalized intensity remained at a similar absolute level to that of both EHR and the dosR 











Figure 33 was generated from the data obtained from (Rustad et al., 2008) (Appendix B.1 
and B.2)  
 




Figure 33 M. tuberculosis transcript levels from bacilli exposed to 7 days of hypoxia 
Panel A Shows the fold induction over hypoxic time course with reference to phase of aerobic 
cultures. There is a relative increase in the transcripts of EHR genes and Acr1 (Rv2031c) and a fall 
for those of CFP-10 (Rv3874) and ESAT-6 (Rv3875). 
Panel B Shows the median transcript intensity normalized to SigA. There is a very rapid peak in 
Acr1 levels followed by a decline; a sustained increase in EHR genes; and a fall in CFP-10 and 
ESAT-6. However overall abundance is similar at 168 hours for CFP-10 and ESAT-6 as that of 
other EHR genes. 
 
Evaluation of regions of similarity between biological sequences  
The nucleotide and protein sequence of selected EHR candidate genes (n=26) were further 
analysed for regions of similarity with sequences in the nucleotide and protein databases 
(and with reference to TB genome). Similarity was represented as the percentage identity 
with respect to MTB H37Rv strain. Results are summarised as the percentage similarity 
(≥50%) with the H37Rv sequence as the reference in Table14 (protein) and Table 15 
(nucleotide). Bacterial strains presented in the table can be largely classified as strains of 
tuberculous and non-tuberculous mycobacteria and environmental bacteria that are 











sequence, 18 and 11 EHR gene candidates shared regions of similarity only within the M. 






































































































































































































M. tuberculosis H37Ra  100 100 100 100 100 100 100 100 100 100  100 100 100 100 100  100 100 100 100 100 100 100 100 100 
M. tuberculosis 
CDC1551  
100 100 100 99  100 100 99 100 100  100 100 99 100 100  99 100  100 100 100 100 100 100 
M. tuberculosis F11  100 100 100 99 100 100 100 100 100 100  100 100 100 100 100 100  100  100 100 100 100 100 100 
M. tuberculosis C  100 100 100 99 100 100 100 99 100   100 100 100 100 60 97  100  100 100 100 100 100 100 
M. tuberculosis Haarlem 
(draft)  
100 100 100 99  100 100 100 100 100  100 100 99 100 100 100  100 100 100 100 100 100 100 100 
M. bovis AF2122/97  100 100 99 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 64 100 100 
M. bovis BCG  100 100 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 64 100 100 
M. leprae TN         87  57       80       85   
M. avium 104   74 84    73 80 80 71       82      71 83  78 
M. avium k10  100 74 84    73 80 80 71       82 66     71 82   
M. abscessus   60 68  56  57 68 66 62       77      54 78  52 
M. gilvum PYR-GCK   62 66  62  63 71 77 63       77      65 78  56 
M. marinum   74 87 63 75 80 72 83 84 72       86      81 83  84 
M. smegmatis MC2 155   70 72    63 72 79 68       78      61 81  60 
M. sp. KMS   66 70  64  62 75 78 73       81      67 80  57 
M. sp. MCS   66 66  64  62 75 78 73       81      67 80  57 
M. ulcerans Agy99    87 62 73 79 70 83 85              80 83  84 
M. vanbaalenii PYR-1   60 69  63  61 72 78 70       75      66 79   
C. diphtheriae NCTC 
13129  
         53       57          
C. efficiens YS-314                  52          
C. glutamicum ATCC 
13032   
                55          
C. jeikeium K411                  52          
R. sp. RHA1    61     63 77 60       72      53 68  57 
R. sphaeroides 2.4.1                         57   
S. avermitilis MA-4680         58 52        57       68   
S. coelicolor A3(2)         58 53        55       66   
N. farcinica IFM 10152         68  63       74       62  54 
P. acnes KPA171202         55                60   





































































































































































































M. tuberculosis H37Ra 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
M. tuberculosis 
CDC1551 
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
M. tuberculosis F11 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
M. tuberculosis KZN 
1435 
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100       100 100 
M. tuberculosis sequence 
from clone y223 
                  100 100 100 100     
M. bovis subsp. bovis 
AF2122/97  
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 96 100 100 100 100 100 100 100 
M. bovis BCG Pasteur 
1173P2 
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 96 100 100 100 100 100 100 100  
M. bovis BCG str. Tokyo 
172 DNA 
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 96 100 100 100 100 100 100 100 
M. leprae Br 4923                        100   
M. leprae strain TN                            100   
 M. avium 104                    95      89   99 
 M. avium subsp. 
paratuberculosis str. K10 
                95      89    
M. gilvum PYR-GCK     82                         
M. kansasii strain                            
M. marinum M                   99       99  98 
M. riyadhense strain                           
M. smegmatis str. MC2 
155   
100         81                 
M. sp KMS               59                 
M. sp. MCS             59                 
M. sp.JLS              59                 
M. ulcerans Agy99                    99  99     98  83 
M. vanbaalenii PYR-1     83   53            92          
N. farcinica IFM 10152 
DNA    
    82                      












Functional Categories of Enduring hypoxic genes 
The genes with the highest fold induction during hypoxia time course were assigned a 
functional category. As previously described (Rustad et al., 2008), the 100 highly induced 
genes featured a larger percentage of putative regulatory and a high proportion of genes of 
unknown function when compared with the whole genome of Mycobacterium tuberculosis. 
Table 16 describes the percentage of genes according to the functional category. 
Additional properties of these candidate genes are summarized in Appendix B.4. Figure 34 
presents a graphical representation of percentage gene distribution according to the 
functional category, in the repertoire of EHR (Panel B, C, D) in relation to the whole 
genome (Panel A) of MTB. 
 
Figure 34: Distribution in MTB according to functional category  
Shows the percentage distribution of genes according to the functional categories in whole genome 
of MTB and in various repertoire of EHR. 
Panel A represents the whole genome of MTB; Panel B represents the described 230 EHR genes 
(Rustad et al., 2008); Panel C represents highly induced 100 EHR genes, that were selected for the 
study and Panel D represents 30 EHR genes (includes Acr1) selected for empirical evaluation. 
The functional categories were obtained for the whole genome (panel A) and the 100 highly 
induced EHR genes (Panel C and including panel D) from the TubercuList. For the complete EHR 

































































Genes tested empirically 
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Empirical evaluation of EHR proteins 
Human Subjects 
Patients with active or latent tuberculosis were recruited at the Ubuntu clinic at 
Khayelitsha site B, South Africa. All were of Xhosa ethnicity.  Latent tuberculosis is 
described as a positive TST (≥15mm) or ≥20 SFC/10
6
 PBMC IFN-γ response to ESAT-6 
or CFP-10. Active tuberculosis is defined by a sputum smear or sputum culture positive for 
M. tuberculosis. The baseline characteristics of subjects enrolled to the study are shown in 
Table 17. There was a significant difference in the median age between the two clinical 
groups. However, this difference did not affect the magnitude or frequency of response. 
Table 17 Characteristic of persons recruited for study 
 Active tuberculosis Latent tuberculosis 
Significance, 
p 
Number 37 40  
Median age (Range) 36 20 <0.0001 
Sex (Male: Female) 26M:11F 11M:32F  
Sputum smear positive 





Sputum culture positive 




11 vaccinated; 11 Not 
vaccinated;  
15 Don‟t know/ data 
unavailable 
20 vaccinated 
16 Not vaccinated 
4 Don‟t know/ data 
unavailable 
 





















Synthetic peptides of 20 amino acid length overlapping by 10 amino acid, dissolved in 
DMSO (<0.2%) were used in the study.  Antigenic stimuli were in the form of pools (each 
of the peptide pool contained minimum of 7 to maximum of 14 peptides per pool) for 
respective proteins with each peptide used at a final concentration of 10µg/ml. Control 
stimuli for ELISpot included anti-CD3 mAb CD3-2 (Mabtech) at 100 ng/ml final 
concentration and unstimulated wells. In addition 3 antigens were included as references: 
RD-1 encoded ESAT-6 and CFP-10; and DosR encoded Acr1 (which was also present 








Shows the frequency of response (described as response ≥ 30 SFC/10
6
 PBMC above background) 
of Acr-1, CFP-10 and ESAT-6. There was no significant difference across two rounds of 
evaluation for all three control antigens. 
 
 













Due to the limitation of availability of cells, the assays were done in two rounds. Three 
reference antigens: ESAT-6, CFP-10 and Acr-1 were used in both rounds. Since, there was 
no significant difference in the response to these 3 internal controls between the two 
rounds of evaluation (Figure 35), the results are described together.  
Immunodominance was assessed both quantitatively (median SFC/10
6
 PBMC) and as 
frequency of positive response. A positive response was defined by >20 SFC/10
6
 PBMC 
for IL-2 and since IFN-γ response was primarily used to define the immunodominance, it 
was arbitrarily increased to > 30 SFC/10
6
 PBMC of IFN-γ. The background response for 
IFN-  and IL-2 were 6 SFC/10
6
 PBMC and 8 SFC/10
6
 PBMC respectively. Results 
presented are corrected for background.  
The SFC responses were analyzed both as peptide pools and as proteins (summed response 
of respective peptide pools per protein) and described as response to proteins unless 
specified otherwise. 
IFN-γ analysis of active and latent tuberculosis 
IFN-γ ELISpot was performed in a total of 77 persons with active (37) or latent (40) 
tuberculosis. Each antigen was tested in at least 20 latent and 17-20 active tuberculosis 
persons. 
When analyzed quantitatively, the highest IFN-γ SFC response in persons with latent 
disease was to CFP-10 (median 84 SFC/10
6
 PBMC, IQR 36-234), which was higher than 
most (not all) EHR proteins and Acr-1 (p≤ 0.034). The exception were 7 EHR proteins: 















In persons with active tuberculosis, the highest response was to Rv1957 (136 SFC/10
6
 
PBMC, IQR 45-328), with the exception of Rv1954c, CFP-10 and ESAT-6 (p ≥ 0.205), the 
response was higher than all other EHR proteins and Acr-1 (p ≤ 0.04).   
Amongst EHR proteins, Rv1955, Rv1471, Rv2022, Rv1954, Rv1284 and Rv0990 had 
dominant IFN-γ SFC response in persons with either latent or active tuberculosis; 
Rv0826c, Rv0849 and Rv2780 were recognized better by those with latent disease. All the 
other proteins evoked moderate levels of IFN-γ SFC response similar to that of Acr-1 or 
lower (Table 18; Figure 36, 41A).  
When analyzed by the frequency of response, the highest response in those with latent and 
active disease was to CFP-10 (78%) and Rv1957 (88%) respectively. Rv1954, Rv1955 and 
Rv2022 were recognized at a similar frequency (>70%) as CFP-10 and ESAT-6 in both 
latent and active disease, while Rv0849 (70%) only in those with latent infection.  
Rv0826, Rv0990, Rv1284 and Rv1471 were recognized >50% of those tested in both 
latent and active disease, while Rv2693 and Rv2780; and Rv2466 recognized only in latent 
and active disease respectively. All other antigens were recognized similar to that of Acr-1 
or lower (Table 18; Figure 37, 41B).   
 
Figure 36 Interferon-gamma analysis of  EHR antigens in active and latent tuberculosis  
Shows the spot forming cells (SFC) in patients with latent (blue) and active (red) tuberculosis 
represented as Box and whiskers (minimum to maximum, with median and IQR). The strongest 
response in latent disease was to CFP-10. The strongest response in active disease was to Rv1957. 
Peptide pool Rv2021c was preferentially recognized by latently infected persons (p = 0.02). 
 
Figure 37 Interferon-gamma analysis of EHR antigens by frequency of response in active and 












Shows the frequency of responders (defined by a response of ≥ 30 SFC/106 PBMC above 
background). No pool was preferentially recognized by either clinical group. The most frequent 





















































































































































Preferential recognition in latent tuberculosis 
When analyzed as proteins, Rv2021c, evoked a significantly higher response in those with 
latent tuberculosis (median 0 SFC/106 PBMC, IQR 0-7 in latent disease vs. 0 SFC/106 
PBMC, IQR 0-0; p=0.02). However this response was very modest. None of the other 
antigens had significantly higher IFN-γ SFC in either of clinical groups.  
However, when analyzed as peptide pools, peptide pools Rv0849-2 and Rv2693-1 were 
preferentially recognized by persons with latent infection (14 SFC/10
6
 PBMC, IQR 1-23 in 
latent disease vs. 0 SFC/10
6
 PBMC, IQR 0-11 in active disease; p=0.04) and 16 SFC/10
6
  
PBMC, IQR 5-65 vs. 6 SFC/10
6
 PBMC, IQR 0-12; (p=0.04) respectively (Figure 38). 
However, when analyzed by the frequency of response, none of the antigens were 
preferentially recognized by latent or active disease groups.  
Figure 38 Interferon-gamma analysis of peptide pools that are preferentially recognized by latent disease 
Spot forming cells (SFC) in patients with latent (L) and active (A) tuberculosis are shown as Box and whiskers 
(minimum to maximum, with median and IQR). The strongest response in latent disease was to CFP-10. With the 
exception of ESAT-6 all other responses were significantly lower (p ≤ 0.007). The strongest response in active 
disease was to ESAT-6. With the exception of CFP-10 all other responses were significantly lower (p ≤ 0.002). 
Peptide pool Rv0849-2, Rv2693-1 and Rv2021c were preferentially recognised by latently infected persons (p = 
0.04, p=0.4 and p=0.02 respectively). However, the magnitude of the response was low and when analysed by the 













IL-2 analysis of active and latent tuberculosis 
IL-2 ELISpot was performed in the same persons as IFN-γ ELISpot, however complete 
data were not available for all subjects and all antigens/peptide pools, due to the limitation 
in cell numbers, and non specific binding of some peptides to the membrane and activation 
of the ALP-substrate complex (data not shown) which were excluded from the analysis. 
Whilst the IFN-γ responses were spread amongst the EHR proteins tested, IL-2 responses 
were generally of lower magnitude and more focused, by both quantitative and frequency 
of response analysis (Figure 41).  
Rv0826c dominated the IL-2 responses in both latent and active disease (median 276 
SFC/10
6
 PBMC, IQR 44-669 and 153 SFC/10
6
 PBMC, IQR 5-575) and Rv2780 in latent 
disease (114 SFC/10
6
 PBMC, IQR 9-761), both of which were dominant over CFP-10 and 
ESAT-6. All other antigens induced modest levels of IL-2, which were similar to that of 
Acr-1 or lower (Table 18).   
All antigens induced similar numbers of IL-2 SFC amongst the two clinical groups with 
the exception of Rv2780, which induced higher numbers of IL-2 SFC in latent compared to 
active disease, however this difference did not attain statistical significance (Table 10; 
Figure 39, 41C). 
When analyzed by the frequency of response, Rv0826 was the most frequently recognized 
antigen amongst those with latent infection (85%) with, Rv1284 greatest amongst those 
with active disease (73%). However, none of the antigens were preferentially recognized 





















Figure 39 IL-2 analysis of EHR antigens in active and latent tuberculosis  
Shows IL-2 spot forming cells (SFC) in patients with latent (L) and active (A) tuberculosis 
represented as Box and whiskers (minimum to maximum, with median and IQR). The strongest 
response in both active and latent disease was to Rv0826. All other responses with the exception of 
CFP-10, ESAT-6, Rv2780 and Rv1284 were lower.  No protein was preferentially recognized by 
latently infected persons.  
 
Figure 40 IL-2 analysis of EHR antigens by frequency of response in active and latent 
tuberculosis  
Shows the frequency of responders (defined by a response ≥ 20 SFC/106 PBMC above 
background). No pool was preferentially recognized by either clinical group. The most frequent 




















































































































































Figure 41 Summary of interferon-gamma and IL-2 analysis of active and latent 
tuberculosis  
Panel A shows the spot forming cells (SFC) in patients with latent (L) and active (A) tuberculosis 
represented as Box and whiskers (minimum to maximum, with median and IQR). The strongest 
response in latent disease was to CFP-10. The strongest response in active disease was to Rv1957. 
Peptide pool Rv2021c was preferentially recognized by latently infected persons (p = 0.02). 
Panel B shows the frequency of responders (defined by a response of ≥ 30 SFC/10
6
 PBMC above 
background). No pool was preferentially recognized by either clinical group. The most frequent 
response in active disease was to Rv1957 (88%) and in latent disease was to CFP-10 (78%). 
Panel C shows IL-2 spot forming cells (SFC) in patients with latent (L) and active (A) tuberculosis 
represented as Box and whiskers (minimum to maximum, with median and IQR). The strongest 
response in both active and latent disease was to Rv0826. All other responses with the exception of 
CFP-10, ESAT-6, Rv2780 and Rv1284 were lower.  No protein was preferentially recognized by 
latently infected persons.  
Panel D shows the frequency of responders (defined by a response ≥ 20 SFC/10
6
 PBMC above 
background). No pool was pr ferentially recognized by either clinical group. The most frequent 







































































































Table 18 Summary of quantitative and Frequency of response of EHR antigens including 
Acr1, CFP-10 and ESAT-6 
 
Medians (SFC/106 PBMC) (IQR) Proportion of responders 





















































Acr-1 16 (4-40) 12 (0-70) 0.59 8(0-24) 8 (0-25) 0.68 33 38 0.64 26 30 0.78 
CFP-10 84 (37-234) 124 (26-408) 0.87 64 (8-184) 20 (0-140) 0.06 78 73 0.79 68 52 0.28 
ESAT-6 72 (28-223) 123 (43-410) 0.20 52 (13-132) 32 (10-80) 0.25 73 78 0.60 71 63 0.58 
Rv0188 4 (0-25) 6 (0-23) 0.55 NA NA NA 20 18 1.00 NA NA NA 
Rv0767 c 7 (1-38) 5 (0-23) 0.44 0 (0-4) 0 (0-8) 0.87 30 12 0.25 12 0 0.49 
Rv0826 46 (25-130) 28 (13-46) 0.15 276 (44-669) 153 (5-575) 0.42 65 35 0.11 86 58 0.19 
Rv0847 12 (0-16) 6 (0-43) 0.80 0 (0-4) 0 (0-12) 0.49 10 35 0.13 8 0 1.00 
Rv0849 54 (15-76) 22 (12-68) 0.19 0 (0-7) 12 (1-44) 0.05 70 35 0.06 14 33 0.37 
Rv0967 20 (4-125) 14 (5-58) 0.41 0 (0-5) 5 (0-9) 0.15 45 30 0.51 14 17 1.00 
Rv0990c 32 (4-192 46 (11-85) 0.77 5 ( 0-40) 11 (0-40) 0.74 55 59 1.00 29 40 0.71 
Rv0991c 12 (4-32) 4 (0-16) 0.09 0  (0-105) 0 (0-4) 0.78 30 10 0.24 21 8 0.60 
Rv1284 57 (11-286) 80  (14-168) 0.89 20 (0-53) 27 (16-52) 0.34 60 59 1.00 53 73 0.29 
Rv1471 66 (17-188) 75 (11-245) 0.84 4 (0-8) 10 (0-25) 0.18 75 59 0.48 12 33 0.21 
Rv1954c 60 (20-470) 72 (27-210) 0.89 4 (0-86) 10 (0-30) 0.89 70 76 0.72 41 33 0.73 
Rv1955 68 (25-367) 60 (6-151) 0.29 8 (0-104) 15 (0-32) 0.63 75 71 1.00 47 47 1.00 
Rv1956 12 (6-38) 16 (5-75) 0.98 0 (0-8) 0 (0-12) 0.85 30 35 1.00 18 20 1.00 
Rv1957 48 (18-454) 136 (45-328) 0.41 0 (0-18) 5 (0-10) 0.54 65 88 0.14 24 20 1.00 
Rv2021c 0 (0-7) 0 (0-0) 0.02 Not tested Not tested NA 15 0 0.23 NA NA NA 
Rv2022c 64 (29-228) 65 (29-124) 0.66 8 (0-30) 6 (0-15) 0.58 75 76 1.00 29 13 0.40 
Rv2466c 15 (1-51) 40 (6-71) 0.18 12 (2-28) 20 (15-29) 0.16 30 53 0.19 35 53 0.48 
Rv2517c 4 (0-12) 0 (0-4) 0.12 0 ( 0-12) 2 (0-7) 0.77 10 10 1.00 0 8 0.46 
Rv2660c 14 (1-40) 6 (0-25) 0.34 0 (0-5) 4 (0-11) 0.30 30 20 0.72 7 8 1.00 
Rv2662 0 (0-0) 0 (0-0) 0.91 Not tested Not tested NA 0 0 NA NA NA NA 
Rv2663 0 (0-0) 0 (0-0) 0.84 Not tested Not tested NA 0 0 NA NA NA NA 
Rv2664 0 (0-0) 0 (0-0) 0.35 Not tested Not tested NA 0 0 NA NA NA NA 
Rv2693c 28 (9-102) 16 (1-56) 0.16 0 (0-4) 0 (0-10) 0.72 50 35 0.52 7 17 0.58 
Rv2780 46 (16-110) 24 (5-101) 0.87 114 (9-761) 26 (0-319) 0.20 60 45 0.53 71 58 0.68 
Rv3334 0 (0-0) 0 (0-0) 0.85 0 (0-2) 0 (0-0) 0.79 5 12 0.58 6 0 1.00 















Responses of adjacent gene products: Rv1954c-Rv1957 
 Four adjacent genes: Rv1954-Rv1957 covering 2 predicted operons (Rv1954c-Rv1955 
and Rv1956-Rv1957) were amongst the 100 highly induced EHR genes. IFN-γ responses 
to these antigens, with the exception of Rv1956 were similar in magnitude (Rv1954c: p ≥ 
0.579; Rv1955: p ≥ 0.242; Rv1957: p≥ 0.781) and frequency of recognition (p ≥ 0.787) as 
that of CFP-10 and ESAT-6 (Figure 42 A and B). However, responses to Rv1956 were 
moderate and at similar levels of Acr-1 (p=1.000) and significantly lower than CFP-10 and 
ESAT-6 (p≤0.0001). Rv1957 (77%) was recognized with greater frequency (not 
significantly different) than either CFP-10 (75%) or ESAT-6 (75%) (Figure 42 B). The IL-
2 responses to these antigens were however very modest.   
 
Figure 42 IFN-  analysis of Rv1954c, Rv1955, Rv1956 and Rv1957 
Panel A shows IFN-γ spot forming cells (SFC) in combined patient group (latent and active disease) are represented as Box 
and whiskers (minimum to maximum, with median and IQR). 
Panel B shows frequency of recognition by IFN-γ response, and arranged according to the increase in frequency response to 












Intramolecular influence on the phenotype of T cell response 
Rv0826c, a relatively large molecule of 351 amino-acids, had to be divided into 3 peptide 
pools for empirical testing. Pools 1 and 2  (covering the  region 1-120 (Pool-1) and 111-
240 (pool 2) were moderate stimulants of an IFN-γ response that was of similar order of 
magnitude (not significantly higher) to the response to Acr1 (p=0.055). However, pool 3 
(  231-350) induced significantly lower IFN-γ when compared to Pool 1 and 2 
(p=0.008). By contrast, peptide pools 1 and 2 induced lower levels IL-2 response, while 
the C-terminal peptides (peptide pool 3) induced a strong IL-2 response that was 
significantly greater than pool 1 and 2 and Acr-1 (p ≤ 0.007). The levels of IL-2 tended to 
be higher than the response to CFP-10 and ESAT-6 (p=0.07) (Figure 43). 
 
 
Figure 43 Intramolecular influence on the phenotype of T cell response  
The IFN-γ  (Panel A) (n=40) and IL-2  (Panel B) (n=27) response  (median SFC response with 
IQR) to 3 pools of Rv0826 is shown. Since there was no significant difference between active and 
latent disease groups, the results are represented for combined groups. Pools 1 and 2 of Rv0826 
were moderate stimulants of the Interferon-gamma response that was of similar order of magnitude 
to Acr1. By contrast peptide pools 1 and 2 poorly stimulated an IL-2 response but the C-terminal 




























Reconciliation of bioinformatic prediction with empirical findings 
I next evaluated hierarchies of immunodominance (empirical testing) by both quantitative 
(Median SFC) and Frequency of response (>30 SFC/10
6
 PBMC) measures and reconciled 
with hierarchies of informatic prediction. Only IFN-γ ELISpot results were used for this 
analysis, as it formed the most complete data set. The median SFC and frequency of 
response to EHR proteins were independently ranked from 1-26 by clinical groups 
(persons with latent and active disease), and since there was no significant difference in the 
responses between the 2 clinical groups, the average rank of clinical groups were 
calculated and represented as average rank for each protein (Table 19; Figure 44).   
For hierarchies of informatic prediction, existing ranks were extracted from rank list: 
R(FI), R(NI)  and R(cPP); and re-assigned (adjusted) ranks (iR(FI), iR(NI)  and iR(cPP)) 
between 1-26 for every category. Adjusted ranks, with combinations (as described in Table 
19) were used to test the correlation between informatic prediction and empirical findings. 
Non parametric Spearman‟s correlation was used to test the correlation between empirical 
ranks (median and proportion of responders) against informatic ranks (individual and 
combination ranks) of iR(FI)  ,iR(NI)  and iR(cPP) (Table19 and Table 20). 
 
When empirical ranking was correlated with bioinformatic prediction, there was no 
correlation of ranks based on fold induction (iR(FI); r=0.1; p=0.5); normalized intensity 
(iR(NI); r=-0.1;p=0.7); combined ranks of normalized intensity or population specific 
MHC-peptide binding prediction (iR(NI) + iR(cPP); r=0.2; p=0.23). However, significant 
correlation was found with the combined fold induction and population specific MHC-

















Table 19 Ranks of Empirical and Informatic analysis  
* There was no significant difference observed in the IFN-γ response between active and latent 
tuberculosis. Therefore, those with latent and active tuberculosis were combined for this analysis. 
(a) Hierarchy defined by the Median IFN-γ ELISpot response. IFN-γ median SFC/ 10
6
 PMBC 
responses of all the proteins were ranked. The ranks ranged from 1 to 26 (highest response to 
lowest response). 
(b) Hierarchy defined by Frequency of response. IFN-γ Frequency of response (defined as >30 
SFC/10
6
 PBMC of IFN-γ) of all the proteins were ranked.  The ranks ranged from 1 to 26 (highest 
response to lowest response). 
(c) Hierarchy defined by Fold induction of EHR proteins (iR(FI)). The ranks from R(FI) were 
extracted and re-assigned as per hierarchy of informatics as referred as iR(FI). 
(d) Hierarchy defined by sigA normalized transcript levels of EHR proteins (iR(NI)). The ranks 
from R(NI) were extracted and re-assigned as per hierarchy of informatics as referred as iR(NI). 
(e) Hierarchy defined by population specific MHCII binding peptide prediction (iR(cPP)). The 
ranks from R(cPP) were extracted and re-assigned as per hierarchy of informatics as referred as 
iR(cPP).  
(f) Hierarchy defined by combined score: iR(FI)+ iR(cPP). Hierarchy defined by Fold induction of 
EHR proteins (iR(FI)) was complemented with hierarchy of population specific MHCII binding 
peptide prediction(iR(cPP)).  
(g) Hierarchy defined by combined score: iR(NI)+ iR(cPP). Hierarchy defined by sigA normalized 
transcript levels of EHR proteins (iR(NI)) was complemented with hierarchy of population specific 






























Rv0188 20 20 20 10 7 15 5 
Rv0767c 19 18 8 8 12 8 10 
Rv0826 10 10 11 6 4 2 2 
Rv0847 17 17 1 2 16 4 6 
Rv0849 9 9 22 24 3 12 14 
Rv0967 13 14 3 1 18 9 8 
Rv0990c 8 7 9 16 10 7 12 
Rv0991c 18 19 2 3 23 13 13 
Rv1284 6 6 15 22 8 10 17 
Rv1471 3 5 4 13 19 11 18 
Rv1954c 2 3 19 25 14 19 23 
Rv1955 5 4 5 5 13 6 7 
Rv1956 15 15 14 11 22 21 19 
Rv1957 1 2 10 18 6 3 11 
Rv2021c 23 23 23 19 9 18 16 
Rv2022c 4 1 16 21 17 20 21 
Rv2466c 14 13 7 4 11 5 3 
Rv2517c 21 21 21 9 25 25 20 
Rv2660c 16 16 24 26 26 26 26 
Rv2662 24 24 13 23 24 22 25 
Rv2663 25 25 17 17 21 24 22 
Rv2664 26 26 18 20 20 23 24 
Rv2693c 12 12 26 14 2 17 4 
Rv2780 7 8 25 7 1 14 1 
Rv3334 22 22 12 12 15 16 15 




















Figure 44 Hierarchy of immunodominance amongst EHR antigens  
Panel A shows hierarchies of immunodominance by quantitative response (Median SFC/10
6
 PBMC of 
IFN- ). Bars indicate median response. 
Panel B shows hierarchies of immunodominance by frequency of recognition (>30 SFC/10
6
 PBMC of 












Figure 45 Reconciliation of bioinformatic prediction and empirical evaluation (Median response) 
A-D shows correlation of empirical ranking by median response against informatic ranks: iR(FI) (A) ,iR(NI) (B) , 
iR(FI) +iR(cPP) (C) and iR(NI)+iR(cPP) (D).  
Panel A shows the correlation between the hierarchies defined by the median response and fold induction iR(FI) . The 
spearman‟s rho = 0.14 (p=0.49). 
Panel B shows the correlation between the hierarchies defined by the median response and normalised transcript 
levels iR(FI) .The spearman‟s rho = -0.09 (p=0.67). 
Panel C shows the correlation between the hierarchies defined by the median response and Fold induction, 
complemented with the population specific MHCII binding peptide prediction (iR(NI)+iR(cPP)). There was significant 
correlation: spearman‟s rho = 0.47 (p=0.01).   
Panel D shows the correlation between the hierarchies defined by the median response and Normalised transcript 
levels, complemented with the population specific MHCII binding peptide prediction (iR(NI)+iR(cPP)). There was no 


















Figure 46 Reconciliation of Bioinformatics prediction and empirical evaluation (Frequency of response) 
A-D shows correlation of empirical ranking by frequency of response against informatics ranks: iR(FI) (A) ,iR(NI) (B) , iR(FI) 
+iR(cPP) (C) and iR(NI)+iR(cPP) (D).  
Panel A shows the correlation between the hierarchies defined by the frequency of response and Fold induction iR(FI) . The 
spearman‟s rho = 0.14 (p=0.51). 
Panel B shows the correlation between the hierarchies defined by the frequency of response and normalised transcript levels iR(NI) 
.The spearman‟s rho = -0.10 (p=0.63). 
Panel C shows the correlation between the hierarchies defined by the frequency of response and Fold induction, complemented 
with the population specific MHCII binding peptide prediction (iR(NI)+iR(cPP)). There was significant correlation: spearman‟s rho 
= 0.47 (p=0.02).   
Panel D shows the correlation between the hierarchies defined by the median response and Normalised transcript levels, 
complemented with the population specific MHCII binding peptide prediction (iR(NI)+iR(cPP)).  There was no correlation. The 













Table 20 Correlation of Empirical and Informatic prediction 
 Rank by Median  Rank by Proportion of response 
Parameter Spearman r P value Summary Spearman r P value  Summary 
iR(FI) 0.14 0.49 ns 0.14 0.51 ns 
iR(NI) -0.09 0.67 ns -0.10 0.63 ns 
iR(FI)+ iR(cPP) 0.47 0.01 * 0.47 0.02 * 















Several, novel immunodominant T cell targets induced during enduring hypoxic response of 
Mycobacterium tuberculosis have been discovered by a combined approach, utilizing 
bioinformatic prediction algorithms and empirical evaluation.  
Whole genome based transcriptional profiles of M. tuberculosis subject to prolonged hypoxia 
to guide the discovery of novel and potential antigens were analyzed. Based on the discovery 
of ~230 genes, significantly induced at four and seven days of hypoxia, but not at the initial 
time points, these sets of genes were described as the Enduring hypoxic response (EHR) of 
Mycobacterium tuberculosis (Rustad et al., 2008).  
The major hypothesis was that these molecules may be expressed in vivo and there by could 
be targets of the immune response. To further understand the biology of latent infection and 
to consider what T cells may preferentially recognize during a latent infection, this systematic 
evaluation of one hundred EHR genes was conducted.  Another hypothesis that was of 
interest to be tested was: when faced with the genomic data from a pathogen, can antigens be 
predicted?  
Therefore, an Immuno informatic approach was designed, whereby the available genomic 
data was coupled with the use of in silico tools to search for promising proteins with epitopes 
that are highly predicted to bind to MHC class II molecules, and in vitro screening of 
shortlisted candidate antigens. This rational approach, was not confined only to the predicted 
binding region of proteins, but developed a protocol for scoring and ranking the prediction 
and prioritization for the gene products (Tables 11 and 12). The prediction algorithm was 
complemented with correction for MHC allelic polymorphism that exists between human 












have been a considerable undertaking, antigens were selected for in vitro screening not only 
based on the predicted MHC-class II–peptide binding, but combined by hierarchies of 
genome based transcriptomic data and absolute abundance of each of the transcripts.  
This study shows that genomic knowledge can aid antigen discovery to an extent when it is 
complemented with population specific MHC-class II-peptide prediction analysis. These 
findings revealed that a number of genes induced by hypoxia were in fact potent T-cell targets 
and therefore offer general support to the hypoxia hypothesis and its relationship to the 
natural infection of MTB.  In addition, also have described interesting, immunologically 
potent T cell targets, which are potential candidates for further evaluation. However, these 
findings did not provide substantial support the hypothesis of preferential recognition of these 
antigens in those with latent disease and rather provides support for a strong overlapping 
immunological spectrum between those with latent and active TB disease as suggested (Barry 
et al., 2009; Young et al., 2009) 
In silico tools offer an attractive alternative to the cumbersome empirical evaluation to 
identify T-cell epitopes that has hitherto been necessary for the discovery of vaccine 
candidates. However, studies have confirmed that in silico methods cannot be wholly relied 
on for selecting crucial peptides for development of vaccines (Gowthaman and Agrewala, 
2008; Gowthaman and Agrewala, 2009; Lin et al., 2008).  
The ProPred prediction algorithm was selected because of its easy user interface, availability 
of all 51 HLA DR alleles (including allelic variants) (Singh and Raghava, 2001), previous 
experimental evaluation (Gowthaman and Agrewala, 2008; Lin et al., 2008) and in antigen 
discovery in both MTB (Al-Attiyah and Mustafa, 2004; Mustafa and Shaban, 2006; 














Therefore a combination of algorithms were used to aid our antigen discovery and also 
reconciled with empirical analysis to test our prediction algorithm. These findings suggest, 
that these in silico tools when complemented with the correction for allelic polymorphism 
found within the different populations can be useful to an extent for the prediction of T cell 
antigens.   
Another hypothesis that was of interest was to test whether, by virtue of up regulation during 
prolonged hypoxia, proteins encoded by such genes would be preferentially recognized by 
latently infected persons. Reconciliation of informatic and empirical evaluation shows that, 
neither the fold induction nor the normalized intensity of the genes/proteins correlates with 
the IFN-γ response. With the exception of modest IFN-γ response to the peptide pool of 
Rv0849-2 and Rv2693-1, and very small levels for Rv2021c (Figure 36 & 38), which were 
significant towards preferential recognition in latent disease, this was not the case. Although, 
there was a trend towards preferential recognition, especially with those with moderate IFN-γ 
response, the latently infected group had a slightly higher magnitude and frequency of 
recognition. Overall, the response between the two clinical groups overlapped. This suggests 
a strong overlap between the immunological spectrum of active and latent disease. Hypoxia 
does characterize granulomas in tuberculosis infection, but it is increasingly re-appreciated 
that even those with active TB disease will have a spectrum of lesions, similar to those of the 
latently infected. Therefore, it is likely that the hypoxic lesions are present in both clinical 
states (Barry et al., 2009).  
This study is the first evaluation of EHR genes for human T cell response. IFN-γ ELISpot 
analysis revealed 5 of 10 immunodominant candidates: Rv1957, Rv2022c, Rv1954, Rv1955 
and Rv1471 with a frequency of response >70%, similar to that of ESAT-10 and CFP-10 
irrespective of clinical group. These are potential candidates for further evaluation as potent T 












share regions of similarity other than M. tuberculosis, M. bovis and M. bovis BCG as 
determined by BLASTn and BLASTp analysis against all nucleotide and protein database 
(Tables 14 and  15). Therefore a response to these proteins is less likely to arise because of 
exposure or infection by environmental or non-tuberculous mycobacteria.  
The immunodominant EHR T cell targets for IFN-γ response are classified as being involved 
in intermediately metabolism and respiration (Rv1471) and unknown function or conserved 
hypotheticals (Rv1954c, Rv1955, Rv1957, Rv2022).  
Rv1955-Rv1956 encode a Toxin-antitoxin (TA) module (Ramage et al., 2009) (Gupta, 2009), 
one of 38 such loci in MTB (Gerdes et al., 2005; Pandey and Gerdes, 2005; Ramage et al., 
2009). Studies have shown that Rv1955, Rv1956 and Rv1957 are co-regulated (Smollett et 
al., 2009). Studies on TA module suggests that these loci provide a control mechanism that 
helps to cope with nutritional stress (Gerdes et al., 2005) such as hypoxia. Recently Schuck 
and colleagues described another protein Rv3407, which forms part of the TA module, to be 
preferentially recognized by T cells of those with latent tuberculosis infection (Schuck et al., 
2009). Taken together, these findings further provide support and indicate a possible role for 
these genes in the maintenance of M. tuberculosis under stressful conditions in vivo.  
Rv1284, a beta-carbonic anhydrase, was the only essential gene that was included in the 
empirical evaluation: It induced both IFN-γ (>50% response) and IL-2 responses. 
Since IFN-γ is a poor correlate of protection (Hanekom et al., 2008), IL-2 ELISpot was 
included  in the analysis as it might better mark immunological memory (Hawkridge et al., 
2008; Millington et al., 2007; Soares et al., 2008). While a range of IFN-γ response to the 
antigens tested by in vitro screening was observed, the IL-2 response was more focused, as 
observed by others (Millington et al., 2007). The magnitude of IL-2 recall response to RD-1 














which induced an IL-2 response similar in magnitude and frequency to ESAT-6 and CFP-10, 
others were of lower magnitude and similar to that of Acr-1.  
These findings support the hypothesis that it is possible, to an extent, to predict antigens using 
genomic data, provided combinations are taken into account. This approach may not only 
hold true for Mycobacterium tuberculosis, but for other pathogens as well. This study 
identified novel immunodominant molecules from the enduring hypoxic response, that could 
be potentially further characterized, to better understand the mechanism and importance of 
hypoxia in vivo. However, this data do not provide strong support, the hypothesis that a 
differential pattern of immune response is associated with latency as antigens that are targets 
of the immune response in latent infection were most often targets in active disease and vice 
versa. This is highly consistent with the evolving view of tuberculosis as a spectrum of 
infection rather than an arbitrary division of active and latent disease forms (Barry et al., 
2009; Young et al., 2009). General support for the importance of hypoxia in vivo does 












Chapter 6: Evaluation of hypoxia inducible Mycobacterium 
tuberculosis specific proteins absent from BCG vaccine strains 
Abstract  
M. tuberculosis (MTB) species-specific antigenic determinants of the human T cell response 
are important  for immunodiagnosis and vaccination. As hypoxia is a stimulus in chronic 
tuberculosis infection, I analyzed transcriptional profiles of MTB subject to 168 hours of 
hypoxia in vitro. I identified two region of difference (RD) 11, and one RD2, encoded 
proteins absent from all M. bovis strains including BCG (Rv2658c and Rv2659c) and from 
commonly used BCG strains (Rv1986) respectively.  
In MTB infected persons the IL-2 ELISpot response to Rv1986 peptides was several times 
greater than the corresponding IFN-  response to the recognized immunodominant ESAT-6 or 
CFP-10 antigens. This IL-2 response was directed narrowly at two epitopic regions containing 
residues 61-80 and 161-180. The predominant T cells responsible for IL-2 production were 
CD4+CD27+CD45RA- single cytokine positive central memory T cells. The IL-2 ELISpot 
response to live MTB bacilli lacking Rv1986 was significantly lower than the response to 
wild type or mutant complemented with Rv1986. The IL-2 ELISpot response to Rv1986 was 
significantly lower in HIV-TB co-infected persons than in HIV uninfected persons and 
significantly increased during antiretroviral therapy. These findings illuminate the partial 
















One third of the world‟s population is considered latently infected: a reservoir from which 
active TB disease will continue to develop for the foreseeable future and thus forming a major 
obstacle to achieve global control. The existence of so many with latent infection highlights 
that the partially effective vaccine: Mycobacterium bovis Bacille Calmette Guérin (BCG) 
does not prevent such infection (Maartens and Wilkinson, 2007).  
Species-specific genes of Mycobacterium tuberculosis are targets of great interest to improve 
vaccination via the selection of protective antigens, and to define immunodiagnostic 
candidates that enhance the specificity and sensitivity of the widely used purified protein 
derivative (PPD) based tuberculin skin test (TST).  
A significant landmark in this respect was the discovery that an M. tuberculosis genomic 
region designated region of difference (RD) 1 is deleted from all strains of BCG and thereby 
partially accounts for the avirulence of the vaccine (Mahairas et al., 1996; Pym et al., 2002). 
RD1 encodes a pair of co-regulated secreted proteins (ESAT-6 and CFP-10) that are highly 
immunogenic (Berthet et al., 1998; Sorensen et al., 1995): restoration of these genes into 
BCG improves its vaccine efficacy (Pym et al., 2003). Assay of the T cell interferon (IFN)-  
secretion in response to the combination of ESAT-6 and CFP-10 (interferon-  release assays, 
IGRA) have been developed that have operational advantages and improve the specificity and 
possibly sensitivity of tuberculosis immunodiagnosis (Pai et al., 2008). 
In addition, M. tuberculosis specific genes such as the insertion sequences, phage inserts may 
be an excellent source of candidate antigens for highly specific tuberculosis diagnostic test, in 
particular those which are also lacking in M. avium and other non-tuberculous mycobacteria. 
One such candidate RD11-encoded Rv2654c has been evaluated previously and is included in 












have been described to be highly induced when MTB was subject to hypoxia, nutritional 
starvation and high temperature. 
The availability of the complete sequence of M. tuberculosis also permitted further genomic 
characterization of various BCG strains (Behr et al., 1999; Brosch et al., 2007; Cole et al., 
1998). It became apparent that, against a background of accumulating single nucleotide 
polymorphisms, BCG underwent sequential genomic deletions that thereby characterize 
various strains. The strains most commonly in use such as BCG Glaxo, Danish and Pasteur 
have most deletions. This led to the proposal that one of the reasons behind the partial vaccine 
efficacy of BCG was that it had become too attenuated to successfully mimic natural MTB 
infection (Behr and Small, 1997). Some empirical evidence in humans favoring this 
hypothesis is provided by the finding that BCG Japan induced greater cytotoxic and T helper 
1 responses in infants than Danish BCG (Davids et al., 2006). The largest difference between 
BCG Japan and BCG Danish is the presence of RD2 in the former but not the latter. 
The discovery of immunodominant antigens in M. tuberculosis has hitherto largely been 
based on dominance in antibody responses that are neither the basis of protection against 
tuberculosis nor of IGRA. A more rational approach might be to relate what is highly 
expressed by bacilli in vivo or in vitro (and thereby potentially available as an antigen) as 
recently investigated in bovines (Sidders et al., 2008).  In humans there has been investigation 
of proteins encoded by genes of the dosR regulon that is induced in axenic culture by hypoxia 
and by nitric oxide (Sherman et al., 2001), stresses that are considered relevant to bacilli in 
nature (MacMicking et al., 1997; Nicholson et al., 1996; Via et al., 2008). Analysis of 
selected dosR regulated proteins confirmed the immunodominance of -crystallin 1 (Acr1) 
encoded by Rv2031 (Leyten et al., 2006; Lin et al., 2007; Wilkinson et al., 1998b), as well as 
potentially infection stage specific antigens (Agrewala and Wilkinson, 1998; Black et al., 














Informatic evaluation of 100 highly induced enduring hypoxic response genes as described in 
Chapter 5, revealed two species specific RD11-encoded (Rv2658c and Rv2659c) and one 
partially species specific RD-2 encoded (Rv1986) genes. Therefore, these genes were 
considered to be excellent candidates for the study of immunogenicity along with other well-
characterized antigens (ESAT-6, CFP-10, Acr1) in humans with active and latent tuberculosis 














Cross-reference of genes with the greatest fold induction in hypoxic culture over 7 days 
(Rustad et al., 2008) described as the enduring hypoxic response of Mycobacterium 
tuberculosis with sequence databases revealed  three RD encoded genes. Two were species-
specific (Rv2658c and Rv2659c, both RD11 encoded), which are absent from all M. bovis and 
M. bovis BCG vaccine strains and one partially species-specific gene (Rv1986, RD-2 
encoded), which is absent from commonly used M. bovis BCG vaccine strains. In addition, 3 
well described antigens were included as internal control: species specific RD1-encoded CFP-
10 and ESAT-6; and dosR encoded Acr-1, which was also present amongst the 100 highly 
induced genes on day 7 of hypoxic culture. 
Analysis of transcripts levels in of bacilli exposed to 7 days of hypoxia 
The fold induction and sigA normalized transcript intensity over a time course of 168 hrs 
hypoxia for these genes (and of Acr1, CFP-10 and ESAT-6) are shown in Figure 47 and 
Appendix B.5. Interestingly whilst the fold induction for the RD1 encoded genes fell, the 
normalized intensity remained at a similar absolute level to that of both EHR and the dosR 
















Figure 47 M. tuberculosis transcript levels from bacilli exposed to 7 days hypoxia in vitro 
Panel A shows the fold induction with reference to the phase of aerobic cultures. There was a 
relative increase in the transcripts of Rv1986, Rv2658c, Rv2659c and Acr1 (Rv2031c) and a fall 
for those of Rv3874 and Rv3875 (CFP-10 and ESAT-6 respectively). 
Panel B shows the median transcript intensity normalized to sigA. There is a very rapid peak in 
Acr1 levels followed by a decline; a sustained increase in Rv1986, Rv2658c and Rv2659c; and a 
fall in Rv3874 and Rv3875. However overall abundance is similar at 168 hours with Rv3874 and 
Rv3875 actually being highest. 













Bioinformatic evaluation of Rv1986, Rv2658c and Rv2659c  
Rv1986 is encoded by the RD2 region, which is deleted during the attenuation of M. bovis 
BCG strains. Rv1986 is a probable conserved integral membrane protein, of unknown 
function, although thought to be involved in transport of lysine across the membrane and 
belongs to the LYSE/YGGA family. It has 5 predicted trans-membrane segments as predicted 
by transMembrane prediction using Hidden Markov Models (TMHMM) as represented in 
Figure 48. TMHMM predicts transmembrane helices and location of the intervening loop 
regions.  
Gene ontology analysis of Rv1986 suggests its involvement in: 
 Biological process: aminoacid transport (Gene Ontology (GO):0006865), which is the 
directed movement of aminoacids, organic acids containing one or more amino 
substituents, into, out of, within or between cells;  
 Cellular component: membrane (GO:0016020) and integral to membrane 
(GO:00162021);  
 Molecular function: lysine permease activity (GO:0005293), which is the catalysis of 
the stereo-specific transfer of lysine, 2,6-diaminohexanonic, across a biological 
membrane.  
 Rv1986 belongs to the functional classes of carrier activity (GO:0005386) and 
















Rv2658c and Rv2659c are encoded by phiRv2 phage insert in M. tuberculosis and therefore 
absent from other members of the MTB complex and other Mycobacteria. Rv2658c is of 
unknown function and in addition to hypoxia, is also highly induced after 4h, 24h and 
96hours of starvation (Betts et al., 2002). There are no predicted trans-membrane segments 
and no gene ontology or functional classification predicted for this gene. 
Rv2659c is a probable integrase, phiRv2 prophage protein, and putative member of the phage 
integrase family of tyrosine recombinases (Bibb and Hatfull, 2002; Hendrix et al., 1999). 
Functionally it is predicted to be involved in sequence integration. Integrases are necessary 
for the integration of a phage in to the host genome by site-specific recombination. In 
conjunction with excision with excisionase, the integrase is also necessary for the excision of 
the prophage from the host genome. Rv2659c in addition to hypoxia, is also highly induced 
under high temperature (Stewart et al., 2002) and up-regulated after 4h, 24h and 96hours of 
starvation (Betts et al., 2002).  
 
 












Gene Ontology analysis of Rv2659c suggests its involvement in: 
 Biological process: DNA recombination (GO:0006310) and DNA integration 
(GO:0015074) 
 Molecular Function: DNA binding (GO:0003677).  
 It belongs to the functional classes of nucleic acid binding (GO:0003676) and cellular 
process (GO:0009987). An ortholog of Rv2659c is present in M. marinum 
(MMAR_4848).  
MHC class II binding peptide prediction  
Analysis of MHC class II binding peptide prediction using ProPred reveled higher number of 
peptides binding to alleles DR1, DR3, DR4, DR7, DR8, DR11 and DR13. (Table 21) 


















0.0839 0.4193 0.1335 0.1429 0.0124 0.3137 0.3292 0.2174 
(b)Number of 
peptides with 




Rv1986 6 29 32 4 28 25 39 8 
Rv2658c 1 11 11 2 3 2 9 2 
Rv2659c 3 14 19 10 21 25 28 12 
Allelic frequency in Xhosa population (du Toit et al., 1988) 
Number of peptides with >30% of the highest binding score any peptide can obtain for the particular allele.  















Empirical Evaluation  
Human subjects 
Patients with active or latent tuberculosis were recruited at the Ubuntu clinic at Khayelitsha 
site B, South Africa. All were of Xhosa ethnicity.  Latent tuberculosis is described as a 
positive TST (≥15mm) or ≥20 SFC/10
6
 PBMC IFN-γ response to ESAT-6 or CFP-10. Active 
tuberculosis is defined by a sputum smear or sputum culture positive for M. tuberculosis. The 
baseline characteristics of subjects enrolled to the study are shown in Table 22. There was a 
significant difference in the median age between the two clinical groups. However, this 
difference did not affect the magnitude or frequency of response. 








Number 20 48  Number 19 
Median age 33 21 <0.0001 Median age 35 
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Interferon-  ELISpot analysis of active and latent tuberculosis 
Interferon-  (IFN- ) ELISpot was performed using PBMC from 40 persons with active (20) or 
latent (20) tuberculosis, and IL-2 ELISpot on 13 and 14 persons in each category. 
Immunodominance was assessed both quantitatively (median SFC/10
6
 PBMC) and by 
frequency of response (> 20 SFC/10
6
 PBMC). The median background response for IFN-  
and IL-2 ELISpot were 6 SFC/10
6
 PBMC and 8 SFC/10
6
 PBMC respectively. Data presented 
after correction for background. 
CFP-10 and ESAT-6 were co-dominant for the IFN-  response when assessed by both 
methods (Figure 49 A and B). The largest SFC response in latent disease was to CFP-10 (102 
SFC/10
6
 PBMC, IQR 38-444). With the exception of ESAT-6 all other responses were 
significantly lower (p ≤ 0.007). The largest response in active disease was to ESAT-6 (172 
SFC/10
6
 PBMC, IQR 47-423). With the exception of CFP-10 all other responses were 
significantly lower (p ≤ 0.002). 
Although peptide pool, Rv2659c-2 was preferentially recognized by latently infected persons 
(6 SFC/10
6
 PBMC, IQR 1-28 versus 0 SFC/10
6
 PBMC, IQR 0-7, p = 0.028) these responses 
were very modest.  
When analyzed by the frequency of response, no pool was preferentially recognized by either 
clinical group (Figure 49 B). The most frequent response in the combined group (latent plus 
active) was to CFP-10 (36/40, 90%): with the exception of ESAT-6 the proportion of persons 















IL-2 ELISpot analysis of active and latent tuberculosis 
Patients with active tuberculosis preferentially recognized pooled peptides from Rv2658c (7 
IL-2 SFC/10
6
 PBMC, IQR 1-23 versus 0 SFC/10
6
 PBMC, IQR 0-6 p = 0.042). However, 
when analyzed by proportion of response, no pool was preferentially recognized by either 
clinical group (Figure 49 C and D). 
There was however a striking IL-2 response in both active and latent disease to Rv1986 pool 
2 (795 SFC/10
6
 PBMC, IQR 51-1428 in active infection; 1194 SFC/10
6
 PBMC, IQR 862-
1650 in latent infection, Figure 49 C and D). All other antigen specific IL-2 responses were 
significantly lower in both latent (p ≤ 0.0007) and active infection (p ≤ 0.02) when compared 
to Rv1986 (Figure 49 C and D). 
In persons with latent tuberculosis, peptide pools covering the amino acid region 1-130 
(peptide pool 1) and covering region 121-250 (peptide pool 2) of Rv2659c induced similar 
levels of IL-2 (median of 76 SFC/10
6
 PBMC, IQR 1-206 and 76 SFC/10
6
 PBMC, IQR 0-
358). These median levels were higher than those of CFP-10 (3 SFC/10
6
 PBMC, IQR 3-194) 
or ESAT-6 (62 SFC/10
6
 PBMC, IQR 7-15). However, in those with active tuberculosis, 
median levels of IL-2 induced by peptide pools 1 (21 SFC/10
6
 PBMC, IQR 1-186) and 2 (14 
SFC/10
6
 PBMC, IQR 0-409) of Rv2659c were lower than those of CFP-10 (40 SFC/10
6
 
PBMC, IQR 14-158) and ESAT-6 (58 SFC/10
6
 PBMC, IQR 22-163) (Figure 49 C and D). 
The most frequent response in the combined group (latent plus active) was also to Rv1986-2 
(24/26, 92%): with the exception of ESAT-6 and CFP-10, the proportion of subjects 

















Interferon-  and IL-2 ELISpot response to peptide pools 
Panel A shows the spot forming cells (SFC) in patients with latent (L) and active (A) tuberculosis. The strongest 
response in latent disease was to CFP-10. With the exception of ESAT-6 all other responses were significantly 
lower (p ≤ 0.007). The strongest response in active disease was to ESAT-6. With the exception of CFP-10 all 
other responses were significantly lower (p ≤ 0.002). Peptide pool Rv2659c-2 was preferentially recognized by 
latently infected persons (p = 0.03).  
Panel B shows the proportion of responders (defined by a response of ≥ 20 SFC/106 PBMC above background). 
No pool was preferentially recognized by either clinical group. The most frequent response in the combined 
group (latent plus active) was to CFP-10: with the exception of ESAT-6 the proportion subjects responding to 
the other antigens was lower in every case (p ≤ 0.002). 
Panel C shows IL-2 spot forming cells (SFC). The strongest response in both active and latent disease was to 
Rv1986-2. All other responses in both latent (p ≤ 0.0007) and active infection (p ≤ 0.02) were significantly 
lower. Peptide pool Rv2658c was preferentially recognized by actively infected persons (p = 0.042).  
Panel D shows the proportion of responders. No pool was preferentially recognized by either clinical group. The 
most frequent response in the combined group (latent plus active) was to Rv1986-2: with the exception of 
ESAT-6 and CFP-10 the proportion subjects responding to the other antigens was lower in every case (p ≤ 
0.009). 















Peptide mapping of the IL-2 response to Rv1986 
Epitope mapping of the individual peptide determinants of the IFN-  response to ESAT-6 and 
























































single peptide giving rise to a response in > 50% subjects (Lalvani et al., 2001a; Pathan et al., 
2001); similar findings are reported for other antigens of M. tuberculosis (Wilkinson et al., 
2005a), I were therefore interested to determine whether a similarly „degenerate‟ pattern of 
multiple IL-2 inducing epitopes occurred in Rv1986.  
PBMC from 20 persons with latent tuberculosis were assayed in the presence of 10 µg/ml of 
each peptide or no stimulus. A highly focused pattern of dominance was observed with 
peptides p61-80 (84 SFC/10
6
 PBMC, IQR 56-134) and p161-180 (68 SFC/10
6
 PBMC, IQR 
49-104) being clearly the best recognized (Figure 50). 90% of subjects had a response > 20 
SFC/10
6
 PBMC to p61-80 and 95% to p161-180 with no other peptide being recognized by > 
45% subjects. There were less frequent and lower magnitude responses to p151-170 perhaps 
suggesting the epitope core for some MHC Class II molecules may include residues common 















Figure 50 Peptide map of IL-2 response to Rv1986 
PBMC from 20 subjects with latent tuberculosis were set up in an IL-2 ELISpot assay with individual 














Phenotype of CD4+ T cells responding to Rv1986 
Analysis of the T cells responsible for type 1 cytokine responses is critical to understand 
protective immunity against TB (Soares et al., 2008). In PBMC from 5 persons with latent 
tuberculosis, the phenotype of CD4+T cells responsible for type 1 cytokine (IFN-γ, IL-2 and 
TNF) production when stimulated with the peptides of Rv1986 (61-80 and 161-180) or the 
combination of peptides from CFP-10 and ESAT-6 as a comparison were determined. T cell 
phenotypes were defined based on the surface markers CD45RA and CD27: Central memory 
cells (TCM)  positive for CD27 and negative for CD45RA; effector memory (TEM) negative 
for both CD27 and CD45RA and Terminally differentiated T cells (Tdiff) negative for CD27 
and positive for CD45RA. Single cytokine positive cells predominated overall (Figure 51). 
Most IL-2 derived from TCM irrespective of stimulus.  The two Rv1986 peptides 
restimulated nearly ten times the percentage of IL-2 producing TCM cells than CFP-10 and 
ESAT-6 (median: 0.226 % CD3+CD4+ TCM vs. 0.024% CD3+CD4+TCM, p=0.055, Figure 
51 panel A and B).  
 
Figure 51 
Phenotype of CD4+ T cells responding to Rv1986 
PBMC  from 5 donors were stimulated either with CFP-10+ESAT-6 (A) or with Rv1986 p61-80+p161-180 (B), 
and phenotype of T cells producing single and multiple cytokines were analyzed using surface and intracellular 
cytokine staining by FACS. T cell phenotype were defined based on the surface markers CD45RA and CD27: 
Central memory cells (TCM) positive for CD27 and negative for CD45RA; effector memory (TEM) negative for 
both CD27 and CD45RA and Terminally differentiated T cells (Tdiff) negative for CD27 and positive for 
CD45RA. The results are expressed as the percentage of CD3+ CD4+ T cells. The stimuli induced different 
populations of T cells. The strongest response to Rv1986 p61-80+p161-180 stimuli was the IL-2 producing 





































Figure 52 Luminex multiplex cytokine analysis 
for Rv1986 and CFP-10 peptide pools 
 
Panels A, B and C shows the production of 
different cytokines and chemokines in 39 
persons with latent or active tuberculosis after 
16 hrs stimulation of PBMC with pooled 
peptides of Rv1986 (1 and 2) or CFP-10 in cell 
culture supernatants respectively. The results are 
represented as pg/ml; bars indicate median 
response with IQR.  The cytokine responses to 
Rv1986 (pool 1 and 2) were significantly higher 
than that of CFP-10 for IL2sR (p<0.0001), TNF 
(p<0.0001), IL-10 (p<0.0001), IL-13 (p≤0.01), 
IL-17(p=0.01), MIP-1alpha (p ≤0.005) and 













Rv1986 induces a distinct pattern of cytokine secretion in addition to IL-2  
The ability of Rv1986 to induce the secretion of cytokines other than IFN-γ and IL-2 when 
compared to CFP-10 was also investigated. 16-hour cell culture supernatants from 39 
persons, with either active (19) or latent (20) tuberculosis were used for this analysis. 
Multiple cytokine secretion was assessed both quantitatively (pg/ml, after background 
correction) and by frequency of response (> 2 fold above background). Similar levels of 
cytokine responses were observed in both analyses in persons with active and latent 
tuberculosis, (data not shown), therefore the clinical groups were combined for further 
analysis. When analyzed quantitatively, Rv1986 pool 1 and 2 stimulated significantly 
higher levels of IL2sR, TNF, IL-10, IL-13, IL-17, MIP-1 alpha and MIP-1 beta than CFP-
10, and similar levels of RANTES. Levels of IL-13 were very modest (Figure 52 A, B and 
C). Thus the Rv1986 peptides were associated with a distinct pattern of cytokine 
production other than IL-2 when compared to CFP-10.  
T cell recognition of M. tuberculosis H37Rv with and without Rv1986 
The recognition of Rv1986 in the context of the whole bacilli was determined using IL-2 
and IFN-γ responses to live strains of MTB in which Rv1986 was intact (MTB H37Rv) or 
deleted (H37Rv∆RD-2) or complemented (H37Rv∆RD-2::Rv1986). 13 persons with latent 
tuberculosis were tested (only 9 patients for IFN-γ due to limitation in cell numbers). 
Although the overall IFN-γ SFC responses to these MTB strains were much stronger than 
the IL-2 response, there was no significant difference in IFN-γ response between these 
strains (Figure 53 B). The IL-2 SFC response to MTB H37Rv was significantly higher than 
to the H37Rv∆RD-2 mutant (median 228 SFC/10
6
 PBMC, IQR 142-325 vs. 130 SFC/10
6
 
PBMC, IQR 53-268; p= 0.002) and complementation by Rv1986 alone substantially 
restored the SFC response (183 SFC/10
6
 PBMC, IQR 86-285; p= 0.002, when compared to 


























Figure 53 Live recognition of M.tuberculosis H37Rv, H37Rv RD2 and H37Rv RD2::Rv1986  
PBMC from persons with latent tuberculosis were co-cultured with M.tuberculosis H37Rv ( ), H37Rv RD2 ( ) and 




Panel A shows IL-2 SFC response. All 3 strains induced substantial IL-2 response (>30 SFC/10
6 
PBMC) in all donors. 
The median IL-2 SFC to MTB H37Rv was highest, followed by H37Rv RD2::Rv1986 and the H37Rv RD2 mutant.  
Panel B shows IFN-  SFC response, which was much stronger than the corresponding IL-2 response. All 3 strains 













Previous studies have described an increase in the IFN-γ response when the MTB strains 
were subject to treatment in vitro with INH (Wilkinson et al., 2006). In order to investigate 
whether the same effect is observed with respect to the IL-2 response, the panel was 
extended to study strains of MTB (in which Rv1986 was intact or deleted) that were 
subject to different conditions namely: INH treatment, heat kill and heat kill with INH. 
Table 23 IL-2 response to different strains of MTB with and without treatment 
MTB H37Rv strain induced higher levels of IL-2 in all conditions (Live+INH, HK and 
HK+INH) than MTB H37Rv∆RD2 (without Rv1986) and MTB H37Rv∆RD2::Rv1986 
(with Rv1986) and followed similar trend as that of the live MTB strains. With the 
exception of Heat Killed strains with INH treatment, both Live+INH and Heat Killed 
H37Rv∆RD2::Rv1986 stains induced significantly higher level of IL-2 when compared to 
H37Rv∆RD2 subject to same treatment (Table 24).   
 Live 
median (IQR) 




Heat Killed + 
INH median 
(IQR) 
H37Rv 222 (142-325) 295 (190-378) 195 (95-246) 218 (102-276) 
H37Rv∆RD2 130 (53-268) 230 (125-313) 158 (46-246) 170 (74-222) 
H37Rv∆RD2::Rv1986 183 (85-285) 240 (162-353) 183 (65-254) 157 (53-257) 
p values (Wilcoxon signed rank paired t test) 
H37Rv vs. 
H37Rv∆RD2 
**0.002 **0.002 **0.001 *0.033 
H37Rv∆RD2 vs. 
H37Rv∆RD2::Rv1986 












The effects of INH treatment and Heat killing of MTB stains on the resultant IL-2 response 
were also compared in MTB H37Rv. INH treatment significantly increased the IL-2 
response (p≤0.002) irrespective of the strain used.  However there was no significant 
difference observed in the response between live and heat killed or heat killed with INH 
treatment (p≥0.17) and also between Heat killed and heat killed with INH treatment. 
Overall, comparable levels of IL-2 were induced by MTB strains subject to heat killing 
with or without INH as that those without any treatment, with the exception of INH 
treatment to live strains (Figure 54). These analysis suggest that INH, which acts by 
disturbing the cell wall biosynthesis of actively dividing bacilli, contributes to the 
increased availability of cell wall related antigenic targets. These antigenic targets thus 
would be more accessible to the circulating antigen specific T cells in the peripheral blood 
and therefore results in the increased T cell response. Similar pattern of response were 








 Figure 54 Effect of treatment on MTB H37Rv 
PBMC from persons with latent tuberculosis were co-cultured with M. tuberculosis H37Rv either as live with ( ) or 
without ( ) INH treatment or heat killed (HK) with ( ) or without  ( ) INH treatment.  
Significant increase in the median response was observed between live strain without treatment and with treatment 
(p=0.002). However, there was no increase in the IL-2 response between Live and Heat killed (p=0.094) or heat 
killed with INH treatment (p=0.376).  












Response of HIV-1 infected persons to Rv1986, ESAT-6 and CFP-10 
The CD4 deficiency caused by HIV-1 infection is the greatest recognized predisposing 
factor to tuberculosis and conversely combined antiretroviral therapy (cART) reduces 
susceptibility by suppressing viral replication and allowing CD4 recovery (Wilkinson et 
al., 2009). I reasoned it would therefore be of interest to compare the IL-2 response to 
Rv1986 and IFN-  and IL-2 response to CFP-10 and ESAT-6 before and during the course 
of antiretroviral therapy. As the IFN-  response to Rv1986 had not been prominent in HIV-
1 uninfected persons this was not assayed. The ELISpot response of 19 HIV-1 infected 
persons without evidence of active tuberculosis was therefore tracked longitudinally over 
the first 36 weeks of therapy. All patients experienced CD4 increases and suppression of 
HIV-1 replication during cART. I could not sample all time points and patients for both 
cytokines due to limitation in the number of cells. Figure 55 shows results of patients 
whose IL-2 and IFN-  response to CFP-10 and ESAT-6 was assayed at least twice and 9 
patients in whom the corresponding IL-2 response to peptides p61-80 and p161-180 could 
be determined.  
Peptide responses were summed for analysis and compared to the values obtained from 20 
HIV-1 uninfected persons of similar background, age and sex (i.e. those shown in Figure 
50). The IL-2 response to the peptides of Rv1986 was significantly lower in HIV-1 
infected persons prior to cART (median 24, IQR 11-43) than in HIV-1 uninfected persons 
(median 160, IQR 114-256, p = 0.009, Figure 55A). A significant increase in response 
occurred during cART therapy such that the median at 36 weeks increased to 106 (IQR 79-
157, p = 0.005). By contrast the IFN-  response to ESAT-6 and CFP-10 was not 
significantly lower in HIV-1 infected persons prior to cART (median 147, IQR 50-965) 
than in HIV-1 uninfected persons (232, IQR 56-563, p = 0.84). Whilst the median response 
did increase during cART therapy, the overall trend was not significant p = 0.22, Figure 50 












HIV-1 infected persons prior to cART (median 2, IQR 0-31) than in HIV-1 uninfected 
persons (median 148, IQR 44-323, p = 0.02, Figure 55 C). No significant increase in 
response occurred during cART therapy. Taken together these findings indicate the 
decreased IL-2 to Rv1986 response prior to therapy correlates with increased susceptibility 
better than the IFN-  response to CFP-10/ESAT-6; and that the partial but significant 
recovery of IL-2 to Rv1986, but unchanged IFN- response to CFP-10/ESAT-6 also 
correlates with the recognized decrease in tuberculosis susceptibility that is conferred by 




Figure 55 Response of HIV-1 infected persons to Rv1986, ESAT-6 and CFP-10  
The IL-2 response to Rv1986 and IFN-  response to CFP-10 and ESAT-6 before and during the 
course of antiretroviral therapy was compared. The respective responses were summed for analysis 
and compared to the values previously obtained for HIV-1 uninfected persons of similar 
background, age and sex.  
A The IL-2 response to the peptides of Rv1986 was significantly lower in HIV-1 infected persons 
prior to cART than in HIV-1 uninfected persons. A significant increase in response occurred during 
cART therapy (p = 0.005 Kruskal-Wallis test).  
B The IFN-  response to ESAT-6 and CFP-10 was not significantly lower in HIV-1 -1 infected 
persons prior to cART than in HIV-1 uninfected persons. The trend in median response during 
cART therapy was not significant (p = 0.22). 
C The IL-2 response to the peptides of ESAT-6 and CFP-10 was significantly lower in HIV-1 
infected persons prior to cART than in HIV-1 uninfected persons (p = 0.02). No significant 



























Whole genome-based transcriptional profiles of M. tuberculosis subject to prolonged 
hypoxia were analyzed to guide the discovery of potential antigens. Because the diagnostic 
potential of species-specific proteins is greatest, two genes upregulated during hypoxia that 
are absent from all M. bovis strains including BCG by virtue of being RD11-encoded 
(Rv2658c and Rv2659c) (Cole, 2002; Gordon et al., 2001) were considered for further 
investigation. The RD2-encoded Rv1986 was also investigated because it is absent from 
most commonly used BCG strains.  
When compared to the well-characterized immunodominant and species-specific 
molecules ESAT-6 and CFP-10, RD11 proteins had inferior ability to restimulate IFN-  
from T cells of persons with either latent or active tuberculosis. However a striking finding 
was the immunodominance of Rv1986 for the IL-2 recall response, directed narrowly at 
two epitopic regions.  
The quantitative IL-2 response to Rv1986 was several times greater than the corresponding 
IFN-  response to either ESAT-6 or CFP-10 (Figure 43 C and D). FACS analysis 
suggested Rv1986 to be a major target of long lived CD4+ central memory T cells. 
Further, Rv1986 peptides are associated with a distinct pattern of cytokine production 
when compared to CFP-10. There was significant recovery of IL-2 response to the peptides 
of Rv1986 than of IFN-γ response to ESAT-6 or CFP-10 during the course of cART in 
HIV-1 infected persons. Moreover, deletion of Rv1986 from the genome of M. 
tuberculosis substantially decreased its ability to restimulate IL-2 secretion. These 
interesting findings are potentially important when considering vaccine-induced and 
natural immunity to tuberculosis and how immunodiagnosis may be improved. In addition 
the persons included in this study would have received BCG Japan, (vaccine strain used 












One hypothesis to be tested was whether, by virtue of upregulation during hypoxia, 
proteins encoded by such genes would be preferentially recognized by latently infected 
persons. Rv2658c and Rv2659c in addition to being hypoxia inducible are also highly 
induced in nutritional starvation (Betts et al., 2002) and Rv2659c under high temperature 
(Stewart et al., 2002). With the exception of the weak IFN-  response to Rv2659c pool 2 
(Figure 43A), preferential recognition proved not to be the case. In contrast, Rv2658c was 
preferentially recognized in those with active tuberculosis by a very weak IL-2 response 
(Figure 43C).  Overall, when compared to CFP-10 and ESAT-6, Rv2658c had inferior 
ability to restimulate either IFN-γ or IL-2 response. Rv2659c although stimulated only 
moderate IFN-γ response, had the ability to induce higher levels of IL-2 than CFP-10 and 
ESAT-6 in those with latent tuberculosis.  
Hypoxia does characterize tuberculous granulomas in vivo (Via et al., 2008) but it is 
increasingly re-appreciated that both active and latent tuberculous lesions exhibit a 
dynamic spectrum of overlapping morphologies (Barry et al., 2009; Capuano et al., 2003; 
Kaplan et al., 2003; Lin et al., 2006; Timm et al., 2003; Ulrichs et al., 2005; Young et al., 
2009) and that hypoxic lesions likely occur in both clinical circumstances. A dominant 
antigenic target that is dosR regulated is Acr1 encoded by Rv2031c, and documented 
preferential T cell recognition of Acr1 by latently infected people (Geluk et al., 2007; 
Wilkinson et al., 1998b). Preferential recognition of Acr1 by latently infected persons was 
not observed in this study (Figure 43) nor in previous IFN-  ELISpot analysis in this 
laboratory (Wilkinson et al., 2005a), which is in fact consistent with expression of Acr1 
throughout experimental infection (Shi et al., 2003; Stewart et al., 2005).  
Although IFN-  is essential to human defense against mycobacteria, it is increasingly 
recognized that assay of PBMC secretion of IFN- is a poor correlate of protection in field 












that might better reflect immunological memory is now being paid and formed the basis 
for this investigation by ELISpot assay of this cytokine (Hawkridge et al., 2008; Millington 
et al., 2007; Soares et al., 2008). Nevertheless, the finding that Rv1986 was so dominant 
for the IL-2 response yet elicited moderate IFN-  secretion was striking.  
The cytokine phenotype of antigen specific T cells is greatly influenced by co-stimulation 
and the cytokine milieu (Hsieh et al., 1993; McKnight et al., 1994). However it has also 
been suggested that the overall affinity of the TcR-peptide-MHC interaction may play a 
role as well (Agrewala and Wilkinson, 1999; Murray et al., 1992). Interestingly an epitope 
in Rv1986 with an anchor at position 167 (corresponding with p161-180) is predicted for 
several DRB1*03, *04, *08, *11 and *13 alleles (Singh and Raghava, 2001): a 
promiscuous binding ability that has been noted for other M. tuberculosis epitopes 
(Agrewala and Wilkinson, 1999) and which might contribute to the almost universal 
response, I observed to this peptide. TMHMM prediction (Figure 42) for Rv1986, 
predicted two regions to be present outside of the membrane, which also corresponds to the 
dominant epitope regions. 
Rv1986 is a putative membrane protein that is recognised by T cells from M. bovis 
infected cows (Cockle et al., 2002). Although the responses to other RD2- encoded 
antigens has been previously evaluated in humans (Chen et al., 2009; Fu et al., 2009; 
Grover et al., 2006; Kalra et al., 2009), the human T cell response to Rv1986 has not been 
reported. Finding that Rv1986 is a dominant target of IL-2 secreting memory T cells 
suggests that this recall response could contribute to protective immunity as suggested by 
the preliminary findings in the HIV-1 infected people on ART (Figure 50). 
These findings also bring a novel twist to an old story: the partial and globally variable 
efficacy of BCG vaccine (Bloom and Fine, 1994; Trunz et al., 2006). A recent study noted 












(e.g. BCG Pasteur) and RD2-positive (e.g. BCG Japan) strains (Horwitz et al., 2009) but 
the discovery that a major target of the human IL-2 response is absent from the most 
commonly used strains is intriguing. Whilst the in vitro diagnostic potential of the two 
dominant peptides presented here is considerable, the most important consequence of this 
work may be to re-evaluate by clinical trials whether BCG strains with and without RD2 












Chapter 7: Conclusions 
The overall aim of the studies presented in this thesis was evaluation of novel 
Mycobacterium tuberculosis antigens by a whole genome based strategy, whereby 
genes highly expressed by the bacilli in vitro or in vivo were related to what is 
recognized by human T cells as an antigen. This was achieved by the analysis of 
whole genome based, transcriptional profiles of Mycobacterium tuberculosis subject 
to 7 days of hypoxia (enduring hypoxic response) using bioinformatic analysis and 
empirical testing to guide antigen discovery. 
The hypotheses tested in this study include: (i) the enduring hypoxic response genes 
are expressed in vivo and thereby available as antigenic targets for the T cell mediated 
immune response, (ii) by virtue of upregulation under hypoxia, these antigens are 
preferentially recognized by the T cells during latent tuberculosis, (iii) genomic 
information from a pathogen might aid in antigen prediction, and (iv) species specific 
genes of Mycobacterium tuberculosis are potential diagnostic targets. 
In addition, within this context, a preliminary comparison of various techniques for 
evaluating the human T cell response (Chapter 3), and T cell epitope mapping using 
synthetic overlapping peptides of the previously described RD11-encoded Rv2654c 
and dosR encoded Rv1733c (Chapter 4) were also performed. 
A systematic Immuno informatic approach was designed to address the over all aim 
(Chapter 5 and 6). The approach included analysis of transcriptional profiles of MTB 
subject to 7 days of hypoxia, coupled with the use of in silico tools to search for 
promising proteins with epitopes that are highly predicted to bind to MHC II 
molecules, and in vitro screening of selected shortlisted candidates. In addition, the 












frequency (af) present in the South African Xhosa population, to account for the HLA 
polymorphism that could influence the T cell response. Selection of candidates was 
also based on including those with high as well as low bioinformatic ranks, in order to 
relate the hierarchies of bioinformatic and empirical testing of these proteins (Chapter 
5).   
Overall, 29 antigen were selected and evaluated in two groups: non- MTB species 
specific (n=26) and MTB species specific (n=3) by IFN-γ and IL-2 ELISpot (Chapter 
5 and 6). Immunodominance was assessed by comparing magnitude and frequency of 
IFN-γ responses of the novel antigens to immunodominant RD1-encoded ESAT-6 and 
CFP-10. Since these candidate antigens were hypoxia-induced, I also included a well 
described dosR-encoded Acr-1 as a reference antigen. It is interesting to note that 
Acr-1 was also present amongst the 100 highly induced EHR genes. 
Many of the EHR encoded MTB proteins were found to be potent T cell targets: 26 
antigens induced an IFN-γ response, of which 17 antigens had a response greater than 
or similar to that of Acr-1 in both magnitude and frequency (Chapter 5 & 6: Figure 
36, 37  & 49 and Table 18).  This finding provides support to the over all strategy for 
antigen discovery and gives general support to the hypoxia hypothesis, and its 
involvement during the course of tuberculosis infection. Previous reports also suggest 
that, dosR encoded antigens induced by the initial transient hypoxic response of MTB 
also induce an immune response (Black et al., 2009; Leyten et al., 2006; Schuck et al., 
2009). 
In addition, these findings give support to the hypothesis that it is possible, to an 












approaches are employed. This approach may not only hold true for Mycobacterium 
tuberculosis, but for other pathogens as well.  
Ten EHR antigens (non species specific) were recognized by more than 50% of 
donors. Of these, 5 novel immunodominant antigens, Rv1957, Rv2022c, Rv1954c, 
Rv1955 and Rv1471 were recognized by more than 70% of donors, and at a similar 
magnitude and frequency to the response of ESAT-6 and CFP-10 (Chapter 5: Figure 
36, 37,  & 44 and Table 18).  Rv1955 encodes a toxin molecule. The finding that it is 
a dominant target of the T cell response suggests a possible role for this gene in the 
maintenance of MTB under stressful conditions. In addition, these novel antigens, 
with the exception of Rv1471, are shared only amongst the MTB complex (Chapter 5: 
Table 14). This provides further support that the observed T cell responses are due to 
MTB infection. These antigens are potential diagnostic targets and warrant further 
investigations. 
RD2-encoded Rv1986 is a major target of the central memory CD4+T cell response 
(Chapter 6). The IL-2 response induced by Rv1986 was several times greater than that 
of ESAT-6 or CFP-10 (Chapter 6 Figure 49 & 51), and was directed narrowly at two 
epitopic regions (Chapter 6 Figure 44). The significance of the Rv1986 IL-2 response 
was also studied in the context of the whole bacilli using MTB H37Rv∆RD2 (RD2 
knock out) and H37Rv∆RD2::Rv1986 (RD2 knock out complemented with Rv1986) 
(Chapter 6 Figure 54). In addition, the IL-2 response to Rv1986 was found to 
correlate with decrease in susceptibility to TB in HIV-1 infected person on 
antiretroviral therapy (Chapter 6 Figure 56). This immunodominant target is absent 
from the commonly used BCG vaccine stains (Behr, 2002; Behr et al., 1999; Gordon 
et al., 2001; Mahairas et al., 1996). The most important consequence of this finding 












without RD2, which might provide further insight into the variations in vaccine 
efficacy. 
By virtue of its upregulation during extended hypoxia, I investigated whether these 
antigens were preferentially recognized by individuals with latent tuberculosis.  
Reconciliation of informatic and empirical evaluation shows that, neither the fold 
induction nor the normalized intensity of the genes/proteins correlates with the IFN-γ 
response (Chapter 5 Figure 36-38). With the exception of a modest IFN-γ response to 
the peptide pool of Rv0849-2, Rv2693-1 (Chapter 5) and Rv2659c-2 (Chapter 6), and 
very small levels for Rv2021c (Figure 36, 38 & 49), which were significant towards 
preferential recognition in latent disease, this was not the case.  
A link between transient increases in transcript abundance during hypoxia and the 
immunogenicity of dosR regulated proteins has earlier been attempted and the term 
„latency antigen‟ has been introduced (Leyten et al., 2006). A dominant antigenic 
target that is dosR regulated is Acr1 encoded by Rv2031c and under some assay 
conditions, studies have documented preferential T cell recognition of Acr1 by 
latently infected people (Geluk et al., 2007; Wilkinson et al., 1998b). Preferential 
recognition of Acr1 by latently infected persons was not observed in this study 
(Chapter 5 and 6: Figure 34, 35 & 43) nor in a previous IFN-  ELISpot analysis 
performed in the same population (Wilkinson et al., 2005a), which is in fact consistent 
with expression of Acr1 throughout experimental infection (Shi et al., 2003; Stewart 
et al., 2005).  
In addition, another immunodominant dosR antigen Rv1733c, was shown to be 
preferentially recognized in latent tuberculosis (Leyten et al., 2006). Preferential 












Conversely a quantitatively higher IFN-  response to the RD1 encoded CFP-10 and 
ESAT-6 antigens has sometimes been associated with active disease (Millington et 
al., 2007; Rangaka et al., 2007a; Vordermeier et al., 2002), attributed to the secretion 
of these proteins by actively replicating bacilli. There was however no higher 
response observed in active tuberculosis compared to latently infected persons 
(Chapter 5 & 6: Figure 34, 35 and 43).  
Differences in infection pressures between low and high incidence areas might 
feasibly contribute to these differences: the clinical environment in which this study 
was conducted suffers an extraordinarily high tuberculosis incidence of ~ 
1500/100,000 with much ongoing transmission (Rangaka et al., 2007b).  
It is also interesting to note that whilst the transcriptomic data showed a fold decrease 
in ESAT-6 and CFP-10 during hypoxia, the absolute abundance of these transcripts 
remained high (Chapters 5 & 6).  Expression of ESAT-6 and CFP-10 under a variety 
of conditions is in agreement with other in vitro expression data (Boshoff et al., 2004; 
Sidders et al., 2008) and adds to data suggesting these molecules may play a role in 
bacillary persistence as well as active infection (Pym et al., 2002).  
Hypoxia does characterize tuberculous granulomas in vivo (Wang et al., 2009b) but it 
is increasingly re-appreciated that both active and latent tuberculous lesions exhibit a 
dynamic spectrum of overlapping morphologies (Capuano et al., 2003; Kaplan et al., 
2003; Lin et al., 2006; Timm et al., 2003; Ulrichs et al., 2005; Young et al., 2009) and 
that hypoxic lesions likely occur in both clinical circumstances. The findings 
presented in this thesis strongly suggest similar and/or overlapping pattern of IFN-γ 














Many of the EHR encoded MTB genes are potent T cell antigens. This finding gives 
general support to the hypoxia hypothesis, and its involvement during the course of 
tuberculosis infection. 
This work does not provide strong support to the hypothesis that a differential pattern 
of immune response is associated with latency. However, these findings provide 
further support to the recent view of latent tuberculosis as a spectrum, as antigens that 
are targets of the immune response in latent infection were most often targets in active 
disease and vice versa.  
A major target of memory T cells is absent from the commonly used BCG vaccine 
strains. Further evaluation of BCG vaccine strains with and without RD2 might give 
insight into the variation in the efficacy. 
These data gives support to the hypothesis that it is possible, to an extent, to predict 
antigens using genomic data, provided combinations (of approaches) are employed. 
The novel findings of this work include: 
 Novel immunodominant EHR encoded antigens of M. tuberculosis (Chapter 5) 
o Rv1957, Rv1955, Rv1954, Rv1471 and Rv2022c, with the magnitude 
and frequency of response similar to that of RD1-encoded ESAT-6 and 
CFP-10 
o Rv1284, Rv0990c, Rv2780, Rv0849, Rv0826:  ≥ 50% recognition in 
the population tested 
 Rv1986 is a major target of central memory CD4+T cells (Chapter 6) 












o IL-2 response directed narrowly to two peptides 
o IL-2 response to Rv1986 better correlate with the decrease in 
susceptibility to TB during antiretroviral therapy 
 T cell epitope mapping of Rv2654c revealed, that the dominant epitope 
recognized in this population (p51-65) is different from what is previously 
described (and included in the commercialized assay QFT-GIT)  (Chapter 4) 
o Preliminary experiments suggest addition of p51-65 to the QFT-GIT, 
increases the percentage positivity 
 Synthetic overlapping peptides might degrade in prolonged incubation whole 
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A.1 Synthetic overlapping peptides obtained from Veterinary Laboratories Agency 























ESAT-6  Sequence 
ESAT-6 (1-16) MTEQQWNFAGIEAAAS 
ESAT-6 (9-24) AGIEAAASAIQGNVTS 
ESAT-6 (17-32) AIQGNVTSIHSLLDEG 
ESAT-6 (25-40) IHSLLDEGKQSLTKLA 
ESAT-6 (33-48) KQSLTKLAAAWGGSGS 
ESAT-6 (41-56) AAWGGSGSEAYQGVQQ 
ESAT-6 (49-64) EAYQGVQQKWDATATE 
ESAT-6 (57-72) KWDATATELNNALQNL 
ESAT-6 (65-80) LNNALQNLARTISEAG 
ESAT-6 (73-88) ARTISEAGQAMASTEG 



























CFP-10 (1-16) MAEMKTDAATLAQEAG 
CFP-10 (9-24) ATLAQEAGNFERISGD 
CFP-10 (17-32) NFERISGDLKTQIDQV 
CFP-10 (25-40) LKTQIDQVESTAGSLQ 
CFP-10 (33-48) ESTAGSLQGQWRGAAG 
CFP-10 (41-56) GQWRGAAGTAAQAAVV 
CFP-10 (49-64) TAAQAAVVRFQEAANK 
CFP-10 (57-72) RFQEAANKQKQELDEI 
CFP-10 (65-80) QKQELDEISTNIRQAG 
CFP-10 (73-88) STNIRQAGVQYSRADE 
CFP-10 (81-96) VQYSRADEEQQQALSS 












A.1.3 :  Acr-1 (20 mers with 12  overlap) 
 
Acr-1 Sequence 
Acr-1 (1-20) MATTLPVQRHPRSLFPEFSE 
Acr-1 (9-28) RHPRSLFPEFSELFAAFPSF 
Acr-1 (17-36) EFSELFAAFPSFAGLRPTFD 
Acr-1 (25-44) FPSFAGLRPTFDTRLMRLED 
Acr-1 (33-52) PTFDTRLMRLEDEMKEGRYE 
Acr-1 (41-60) RLEDEMKEGRYEVRAELPGV 
Acr-1 (49-68) GRYEVRAELPGVDPDKDVDI 
Acr-1 (57-76) LPGVDPDKDVDIMVRDGQLT 
Acr-1 (65-84) DVDIMVRDGQLTIKAERTEQ 
Acr-1 (73-92) GQLTIKAERTEQKDFDGRSE 
Acr-1 (81-100) RTEQKDFDGRSEFAYGSFVR 
Acr-1 (89-108) GRSEFAYGSFVRTVSLPVGA 
Acr-1 (97-116) SFVRTVSLPVGADEDDIKAT 
Acr-1 (105-124) PVGADEDDIKATYDKGILTV 
Acr-1 (113-132) IKATYDKGILTVSVAVSEGK 
Acr-1 (121-140) ILTVSVAVSEGKPTEKHIQI 













A.2 Synthetic overlapping peptides covering 29 EHR antigens purchased from 
Peptide protein research Ltd, UK 
 





Rv0188 Sequence Pool 
Rv0188  (1-20) MSTVHSSIDQHPDLLALRAS 1 
Rv0188  (11-30) HPDLLALRASFDRAAESTIA 1 
Rv0188  (21-40) FDRAAESTIAHFTFGLALLA 1 
Rv0188  (31-50) HFTFGLALLAGLYVAASPWI 1 
Rv0188  (41-60) GLYVAASPWIVGFSATRGLP 1 
Rv0188  (51-70) VGFSATRGLPTCDLIVGIAV 1 
Rv0188  (61-80) TCDLIVGIAVAYLAYGFASA 1 
Rv0188  (71-90) AYLAYGFASALDRTHGMTWT 1 
Rv0188  (81-100) LDRTHGMTWTLPVLGVWVIF 1 
Rv0188  (91-110) LPVLGVWVIFSPWVLPGVAV 1 
Rv0188  (100-120) SPWVLPGVAVTAGMMWSHII 1 
Rv0188  (110-130) TAGMMWSHIIAGAVVAVLGF 1 














Rv0767c Sequence Pool 
Rv0767c (1-20) VSSDVLVTTPAQRQTEPHAE 1 
Rv0767c (11-30) AQRQTEPHAEAVSRNRRQQA 1 
Rv0767c (21-40) AVSRNRRQQATFRKVLAAAM 1 
Rv0767c (31-50) TFRKVLAAAMATLREKSYAD 1 
Rv0767c (41-60) ATLREKSYADLTVRLVAARA 1 
Rv0767c (51-70) LTVRLVAARAKVAPATAYTY 1 
Rv0767c (61-80) KVAPATAYTYFSSKNHLIAE 1 
Rv0767c (71-90) FSSKNHLIAEVYLDLVRQVP 1 
Rv0767c (81-100) VYLDLVRQVPCVTDVNVPMP 1 
Rv0767c (91-110) CVTDVNVPMPIRVTSSLRHL 1 
Rv0767c (101-120) IRVTSSLRHLALVVADEPEI 2 
Rv0767c (111-130) ALVVADEPEIGAACTAALLD 2 
Rv0767c (121-140) GAACTAALLDGGADPAVRAV 2 
Rv0767c (131-150) GGADPAVRAVRDRIGAEIHR 2 
Rv0767c (141-160) RDRIGAEIHRRITSAIGPGA 2 
Rv0767c (151-170) RITSAIGPGADPGTVFALEM 2 
Rv0767c (161-180) DPGTVFALEMAFFGALVQAG 2 
Rv0767c (171-190) AFFGALVQAGSGTFTYHEIA 2 
Rv0767c (181-200) SGTFTYHEIADRLGYVVGLI 2 















A.2. 3: Rv0826 
 
Rv0826 Sequence Pool 
Rv0826 (1-20) VTQDTSATCPLTSTVQDSSP 1 
Rv0826 (11-30) LTSTVQDSSPVAGQLGRPIG 1 
Rv0826 (21-40) VAGQLGRPIGFRGLAGGCPV 1 
Rv0826 (31-50) FRGLAGGCPVSPLGYESPPL 1 
Rv0826 (41-60) SPLGYESPPLPLGPDSLTWR 1 
Rv0826 (51-70) PLGPDSLTWRYFGDWRGMLQ 1 
Rv0826 (61-80) YFGDWRGMLQGPWAGSMQNM 1 
Rv0826 (71-90) GPWAGSMQNMHPQLGAAVED 1 
Rv0826 (81-100) HPQLGAAVEDHSTFFRERWP 1 
Rv0826 (91-110) HSTFFRERWPRLLRSLYPIG 1 
Rv0826 (101-120) RLLRSLYPIGGVVFDGDRAP 1 
Rv0826 (111-130) GVVFDGDRAPVTGVQVRDYH 2 
Rv0826 (121-140) VTGVQVRDYHITIKGVDGAG 2 
Rv0826 (131-150) ITIKGVDGAGRRYHALNPDV 2 
Rv0826 (141-160) RRYHALNPDVFYWAHATFFV 2 
Rv0826 (151-170) FYWAHATFFVGTLHVAERFC 2 
Rv0826 (161-180) GTLHVAERFCGGLTEAQRRQ 2 
Rv0826 (171-190) GGLTEAQRRQLFDEHVQWYR 2 
Rv0826 (181-200) LFDEHVQWYRMYGMSMRPVP 2 
Rv0826 (191-210) MYGMSMRPVPATWEEFQDYW 2 
Rv0826 (201-220) ATWEEFQDYWDHMCRNVLEN 2 
Rv0826 (211-230) DHMCRNVLENNFAARAVLDL 2 
Rv0826 (221-240) NFAARAVLDLTELPKPPFAQ 2 
Rv0826 (231-250) TELPKPPFAQRVPDWLWAAP 3 
Rv0826 (241-260) RVPDWLWAAPRKLLARFFVW 3 
Rv0826 (251-270) RKLLARFFVWLTVGLYDPPV 3 
Rv0826 (261-280) LTVGLYDPPVRELMGYRWLR 3 
Rv0826 (271-290) RELMGYRWLRRDEWLHRRFG 3 
Rv0826 (281-300) RDEWLHRRFGDIVRLVFALV 3 
Rv0826 (291-310) DIVRLVFALVPFRFRKHPRA 3 
Rv0826 (301-320) PFRFRKHPRARAGWDRATGR 3 
Rv0826 (311-330) RAGWDRATGRIPADAPLVQT 3 
Rv0826 (321-340) IPADAPLVQTPARNLPPPDE 3 
Rv0826 (331-350) PARNLPPPDERDNPTHYCPK 3 
















Rv0847 Sequence Pool 
Rv0847 (1-20) VVWMRSAIVAVALGVTVAAV 1 
Rv0847 (11-30) VALGVTVAAVAAACWLPQLH 1 
Rv0847 (21-40) AAACWLPQLHRHVAHPNHPL 1 
Rv0847 (31-50) RHVAHPNHPLTTSVGSEFVI 1 
Rv0847 (41-60) TTSVGSEFVINTDHGHLVDN 1 
Rv0847 (51-70) NTDHGHLVDNSMPPCPERLA 1 
Rv0847 (61-80) SMPPCPERLATAVLPRSATP 1 
Rv0847 (71-90) TAVLPRSATPVLLPDVVAAA 1 
Rv0847 (81-100) VLLPDVVAAAPGMTAALTDP 1 
Rv0847 (91-110) PGMTAALTDPVAPAARGPPA 1 
Rv0847 (101-120) VAPAARGPPAAQGSVRTGQD 1 














Rv0849 Sequence Pool 
Rv0849 (1-20) MGARAIFRGFNRPSRVLMIN 1 
Rv0849 (11-30) NRPSRVLMINQFGINIGFYM 1 
Rv0849 (21-40) QFGINIGFYMLMPYLADYLA 1 
Rv0849 (31-50) LMPYLADYLAGPLGLAAWAV 1 
Rv0849 (41-60) GPLGLAAWAVGLVMGVRNFS 1 
Rv0849 (51-70) GLVMGVRNFSQQGMFFVGGT 1 
Rv0849 (61-80) QQGMFFVGGTLADRFGYKPL 1 
Rv0849 (71-90) LADRFGYKPLIIAGCLIRTG 1 
Rv0849 (81-100) IIAGCLIRTGGFALLVVAQS 1 
Rv0849 (91-110) GFALLVVAQSLPSVLIAAAA 1 
Rv0849 (101-120) LPSVLIAAAATGFAGALFNP 2 
Rv0849 (111-130) TGFAGALFNPAVRGYLAAEA 2 
Rv0849 (121-140) AVRGYLAAEAGERKIEAFAM 2 
Rv0849 (131-150) GERKIEAFAMFNVFYQSGIL 2 
Rv0849 (141-160) FNVFYQSGILLGPLVGLVLL 2 
Rv0849 (151-170) LGPLVGLVLLALDFRITVLA 2 
Rv0849 (161-180) ALDFRITVLAAAGVFGLLTV 2 
Rv0849 (171-190) AAGVFGLLTVAQLVALPQHR 2 
Rv0849 (181-200) AQLVALPQHRADSEREKTSI 2 
Rv0849 (191-210) ADSEREKTSILQDWRVVVRN 2 
Rv0849 (201-220) LQDWRVVVRNRPFLTLAAAM 3 
Rv0849 (211-230) RPFLTLAAAMTGCYALSFQI 3 
Rv0849 (221-240) TGCYALSFQIYLALPMQASI 3 
Rv0849 (231-250) YLALPMQASILMPRNQYLLI 3 
Rv0849 (241-260) LMPRNQYLLIAAMFAVSGLV 3 
Rv0849 (251-270) AAMFAVSGLVAVGGQLRITR 3 
Rv0849 (261-280) AVGGQLRITRWFAVRWGAER 3 
Rv0849 (271-290) WFAVRWGAERSLVVGATILA 3 
Rv0849 (281-300) SLVVGATILAASFIPVAVIP 3 
Rv0849 (291-310) ASFIPVAVIPNGQRFGVAVA 3 
Rv0849 (301-320) NGQRFGVAVAVMALVLSASL 4 
Rv0849 (311-330) VMALVLSASLLAVASAALFP 4 
Rv0849 (321-340) LAVASAALFPFEMRAVVALS 4 
Rv0849 (331-350) FEMRAVVALSGDRLVATHYG 4 
Rv0849 (341-350) GDRLVATHYGFYSTIVGVGV 4 
Rv0849 (351-360) FYSTIVGVGVLVGNLAIGSL 4 
Rv0849 (361-370) LVGNLAIGSLMSAARRLNTD 4 
Rv0849 (371-380) MSAARRLNTDEIVWGGLILV 4 
Rv0849 (381-390) EIVWGGLILVGIVAVAGLRR 4 
Rv0849 (391-400) GIVAVAGLRRLDTFTSGSQN 4 













A.2.6 : Rv0967 
Rv0967 Sequence Pool 
Rv0967 (1-20) MSKELTAKKRAALNRLKTVR 1 
Rv0967 (11-30) AALNRLKTVRGHLDGIVRML 1 
Rv0967 (21-40) GHLDGIVRMLESDAYCVDVM 1 
Rv0967 (31-50) ESDAYCVDVMKQISAVQSSL 1 
Rv0967 (41-60) KQISAVQSSLERANRVMLHN 1 
Rv0967 (51-70) ERANRVMLHNHLETCFSTAV 1 
Rv0967 (61-80) HLETCFSTAVLDGHGQAAIE 1 
Rv0967 (71-90) LDGHGQAAIEELIDAVKFTP 1 
Rv0967 (81-100) ELIDAVKFTPALTGPHARLG 1 
Rv0967 (91-110) ALTGPHARLGGAAVGESATE 1 

















Rv0990c Sequence Pool 
Rv0990c (1-20) VAESSLNPSLVSRISAFLRP 1 
Rv0990c (11-30) VSRISAFLRPDWTRTVRARR 1 
Rv0990c (21-40) DWTRTVRARRFAAAGLVMLA 1 
Rv0990c (31-50) FAAAGLVMLAGVAALRSNPE 1 
Rv0990c (41-60) GVAALRSNPEDDRAEVVVAA 1 
Rv0990c (51-70) DDRAEVVVAAHDLRPGTALT 1 
Rv0990c (61-80) HDLRPGTALTPGDVRLEKRS 1 
Rv0990c (71-90) PGDVRLEKRSATTLPDGSQA 1 
Rv0990c (81-100) ATTLPDGSQADLDAVVGSTL 1 
Rv0990c (91-110) DLDAVVGSTLASPTRRGEVL 1 
Rv0990c (101-120) ASPTRRGEVLTDVRLLGSRL 2 
Rv0990c (111-130) TDVRLLGSRLAESTAGPDAR 2 
Rv0990c (121-140) AESTAGPDARIVPLHLADSA 2 
Rv0990c (131-150) IVPLHLADSALVDLVRVGDV 2 
Rv0990c (141-160) LVDLVRVGDVVDVLAAPVTD 2 
Rv0990c (151-170) VDVLAAPVTDSPAALRLLAT 2 
Rv0990c (161-180) SPAALRLLATDAIVVLVSAQ 2 
Rv0990c (171-190) DAIVVLVSAQQKAQAADSDR 2 
Rv0990c (181-200) QKAQAADSDRVVLVALPARL 2 
Rv0990c (191-210) VVLVALPARLANTVAGAALG 2 














Rv0991c Sequence Pool 
Rv0991c (1-20) VPTYSYECTQCANRFDVVQA 1 
Rv0991c (11-30) CANRFDVVQAFTDDALTTCE 1 
Rv0991c (21-40) FTDDALTTCERCSGRLRKLF 1 
Rv0991c (31-50) RCSGRLRKLFNAVGVVFKGT 1 
Rv0991c (41-60) NAVGVVFKGTGFYRTDSRES 1 
Rv0991c (51-70) GFYRTDSRESGKKSKSQTNG 1 
Rv0991c (61-80) GKKSKSQTNGSSTSESTKSS 1 
Rv0991c (71-90) SSTSESTKSSGSSGSSGSSE 1 
Rv0991c (81-100) GSSGSSGSSESKASGSTEKS 1 
















Rv1284 Sequence Pool 
Rv1284 (1-20) VTVTDDYLANNVDYASGFKG 1 
Rv1284 (11-30) NVDYASGFKGPLPMPPSKHI 1 
Rv1284 (21-40) PLPMPPSKHIAIVACMDARL 1 
Rv1284 (31-50) AIVACMDARLDVYRMLGIKE 1 
Rv1284 (41-60) DVYRMLGIKEGEAHVIRNAG 1 
Rv1284 (51-70) GEAHVIRNAGCVVTDDVIRS 1 
Rv1284 (61-80) CVVTDDVIRSLAISQRLLGT 1 
Rv1284 (71-90) LAISQRLLGTREIILLHHTD 2 
Rv1284 (81-100) REIILLHHTDCGMLTFTDDD 2 
Rv1284 (91-110) CGMLTFTDDDFKRAIQDETG 2 
Rv1284 (101-120) FKRAIQDETGIRPTWSPESY 2 
Rv1284 (111-130) IRPTWSPESYPDAVEDVRQS 2 
Rv1284 (121-140) PDAVEDVRQSLRRIEVNPFV 2 
Rv1284 (131-150) LRRIEVNPFVTKHTSLRGFV 2 




















Rv1471 Sequence Pool 
Rv1471 (1-20) VTTRDLTAAQFNETIQSSDM 1 
Rv1471 (11-30) FNETIQSSDMVLVDYWASWC 1 
Rv1471 (21-40) VLVDYWASWCGPCRAFAPTF 1 
Rv1471 (31-50) GPCRAFAPTFAESSEKHPDV 1 
Rv1471 (41-60) AESSEKHPDVVHAKVDTEAE 1 
Rv1471 (51-70) VHAKVDTEAERELAAAAQIR 1 
Rv1471 (61-80) RELAAAAQIRSIPTIMAFKN 1 
Rv1471 (71-90) SIPTIMAFKNGKLLFNQAGA 1 
Rv1471 (81-100) GKLLFNQAGALPPAALESLV 1 
Rv1471 (91-110) LPPAALESLVQQLKAYEVEA 1 

















Rv1954c Sequence Pool 
Rv1954c (1-20) MAAGSGGGTVGLVLPRVASL 1 
Rv1954c (11-30) GLVLPRVASLSGLDGAPTVP 1 
Rv1954c (21-40) SGLDGAPTVPEGSDKALMHL 1 
Rv1954c (31-50) EGSDKALMHLGDPPRRCDTH 1 
Rv1954c (41-60) GDPPRRCDTHPDGTSSAAAA 1 
Rv1954c (51-70) PDGTSSAAAALVLRRIDVHP 1 
Rv1954c (61-80) LVLRRIDVHPLLTGLGRGRQ 1 
Rv1954c (71-90) LLTGLGRGRQTVSLRNGHLV 1 
Rv1954c (81-100) TVSLRNGHLVATANRAILSR 2 
Rv1954c (91-110) ATANRAILSRRRSRLTRGRS 2 
Rv1954c (101-120) RRSRLTRGRSFTSHLITSCP 2 
Rv1954c (111-130) FTSHLITSCPRLDDHQHRHP 2 
Rv1954c (121-140) RLDDHQHRHPTRCRAEHAGC 2 
Rv1954c (131-150) TRCRAEHAGCTVATCIPNAR 2 
Rv1954c (141-160) TVATCIPNARDPAPGHQTPR 2 
















Rv1955 Sequence Pool 
Rv1955 (1-20) VPSGWVSHRLGGSPKCISAL 1 
Rv1955 (11-30) GGSPKCISALSLPSGTVGAP 1 
Rv1955 (21-40) SLPSGTVGAPSKPDNDATRG 1 
Rv1955 (31-50) SKPDNDATRGRTRPTVPPPD 1 
Rv1955 (41-60) RTRPTVPPPDPAAMGTWKFF 1 
Rv1955 (51-70) PAAMGTWKFFRASVDGRPVF 1 
Rv1955 (61-80) RASVDGRPVFKKEFDKLPDQ 1 
Rv1955 (71-90) KKEFDKLPDQARAALIVLMQ 1 
Rv1955 (81-100) ARAALIVLMQRYLVGDLAAG 2 
Rv1955 (91-110) RYLVGDLAAGSIKPIRGDIL 2 
Rv1955 (101-120) SIKPIRGDILELRWHEANNH 2 
Rv1955 (111-130) ELRWHEANNHFRVLFFRWGQ 2 
Rv1955 (121-140) FRVLFFRWGQHPVALTAFYK 2 
Rv1955 (131-150) HPVALTAFYKNQQKTPKTKI 2 
Rv1955 (141-160) NQQKTPKTKIETALDRQKIW 2 

















Rv1956 Sequence Pool 
Rv1956 (1-20) MSIDFPLGDDLAGYIAEAIA 1 
Rv1956 (11-30) LAGYIAEAIAADPSFKGTLE 1 
Rv1956 (21-40) ADPSFKGTLEDAEEARRLVD 1 
Rv1956 (31-50) DAEEARRLVDALIALRKHCQ 1 
Rv1956 (41-60) ALIALRKHCQLSQVEVAKRM 1 
Rv1956 (51-70) LSQVEVAKRMGVRQPTVSGF 1 
Rv1956 (61-80) GVRQPTVSGFEKEPSDPKLS 1 
Rv1956 (71-90) EKEPSDPKLSTLQRYARALD 1 
Rv1956 (81-100) TLQRYARALDARLRLVLEVP 1 
Rv1956 (91-110) ARLRLVLEVPTLREVPTWHR 1 
Rv1956 (101-120) TLREVPTWHRLSSYRGSARD 1 
Rv1956 (111-130) LSSYRGSARDHQVRVGADKE 1 
Rv1956 (121-140) HQVRVGADKEILMQTNWARH 1 














Rv1957 Sequence Pool 
Rv1957 (1-20) MTDRTDADDLDLQRVGARLA 1 
Rv1957 (11-30) DLQRVGARLAARAQIRDIRL 1 
Rv1957 (21-40) ARAQIRDIRLLRTQAAVHRA 1 
Rv1957 (31-50) LRTQAAVHRAPKPAQGLTYD 1 
Rv1957 (41-60) PKPAQGLTYDLEFEPAVDAD 1 
Rv1957 (51-70) LEFEPAVDADPATISAFVVR 1 
Rv1957 (61-80) PATISAFVVRISCHLRIQNQ 1 
Rv1957 (71-90) ISCHLRIQNQAADDDVKEGD 1 
Rv1957 (81-100) AADDDVKEGDTKDETQDVAT 2 
Rv1957 (91-110) TKDETQDVATADFEFAALFD 2 
Rv1957 (101-120) ADFEFAALFDYHLQEGEDDP 2 
Rv1957 (111-130) YHLQEGEDDPTEEELTAYAA 2 
Rv1957 (121-140) TEEELTAYAATTGRFALYPY 2 
Rv1957 (131-150) TTGRFALYPYIREYVYDLTG 2 
Rv1957 (141-160) IREYVYDLTGRLALPPLTLE 2 
Rv1957 (151-170) RLALPPLTLEILSRPMPVSP 2 















Rv2021c Sequence Pool 
Rv2021c (1-20) MAMTLRDMDAVRPVNREAVD 1 
Rv2021c (11-30) VRPVNREAVDRHKARMRDEV 1 
Rv2021c (21-40) RHKARMRDEVRAFRLRELRA 1 
Rv2021c (31-50) RAFRLRELRAAQSLTQVQVA 1 
Rv2021c (41-60) AQSLTQVQVAALAHIRQSRV 1 
Rv2021c (51-70) ALAHIRQSRVSSIENGDIGS 1 
Rv2021c (61-80) SSIENGDIGSAQVNTLRKYV 1 
Rv2021c (71-90) AQVNTLRKYVSALGGELDIT 1 





























Rv2022c Sequence Pool 
Rv2022c (1-20) VNVPWENAHGGALYCLIRGD 1 
Rv2022c (11-30) GALYCLIRGDEFSAWHRLLF 1 
Rv2022c (21-40) EFSAWHRLLFQRPGCAESVL 1 
Rv2022c (31-50) QRPGCAESVLACRHFLDGSP 1 
Rv2022c (41-60) ACRHFLDGSPVARCSYPEEY 1 
Rv2022c (51-70) VARCSYPEEYHPCVISRIAL 1 
Rv2022c (61-80) HPCVISRIALLCDSVGWTAD 1 
Rv2022c (71-90) LCDSVGWTADVERISAWLNG 1 
Rv2022c (81-100) VERISAWLNGLDRETYELVF 1 
Rv2022c (91-110) LDRETYELVFAAIEVLEEEG 1 
Rv2022c (101-120) AAIEVLEEEGPALGCPLVDT 2 
Rv2022c (111-130) PALGCPLVDTVRGSRHKNMK 2 
Rv2022c (121-140) VRGSRHKNMKELRPGSQGRS 2 
Rv2022c (131-150) ELRPGSQGRSEVRILFAFDP 2 
Rv2022c (141-160) EVRILFAFDPARQAIMLAAG 2 
Rv2022c (151-170) ARQAIMLAAGNKAGRWTQWY 2 
Rv2022c (161-180) NKAGRWTQWYDEKIKAADEM 2 
Rv2022c (171-190) DEKIKAADEMFAEHLAQFED 2 














Rv2466c Sequence Pool 
Rv2466c (1-20) MLEKAPQKSVADFWFDPLCP 1 
Rv2466c (11-30) ADFWFDPLCPWCWITSRWIL 1 
Rv2466c (21-40) WCWITSRWILEVAKVRDIEV 1 
Rv2466c (31-50) EVAKVRDIEVNFHVMSLAIL 1 
Rv2466c (41-60) NFHVMSLAILNENRDDLPEQ 1 
Rv2466c (51-70) NENRDDLPEQYREGMARAWG 1 
Rv2466c (61-80) YREGMARAWGPVRVAIAAEQ 1 
Rv2466c (71-90) PVRVAIAAEQAHGAKVLDPL 1 
Rv2466c (81-100) AHGAKVLDPLYTAMGNRIHN 1 
Rv2466c (91-110) YTAMGNRIHNQGNHELDEVI 1 
Rv2466c (101-120) QGNHELDEVITQSLADAGLP 2 
Rv2466c (111-130) TQSLADAGLPAELAKAATSD 2 
Rv2466c (121-140) AELAKAATSDAYDNALRKSH 2 
Rv2466c (131-150) AYDNALRKSHHAGMDAVGED 2 
Rv2466c (141-160) HAGMDAVGEDVGTPTIHVNG 2 
Rv2466c (151-170) VGTPTIHVNGVAFFGPVLSK 2 
Rv2466c (161-180) VAFFGPVLSKIPRGEEAGKL 2 
Rv2466c (171-190) IPRGEEAGKLWDASVTFASY 2 
Rv2466c (181-210) WDASVTFASYPHFFELKRTR 2 














Rv2517c Sequence Pool 
Rv2517c (1-20) VNSAIIKIAKWAQSQQWTVE 1 
Rv2517c (11-30) WAQSQQWTVEDDASGYTRFY 1 
Rv2517c (21-40) DDASGYTRFYNPQGVYIARF 1 
Rv2517c (31-50) NPQGVYIARFPATPSNEYRR 1 
Rv2517c (41-60) PATPSNEYRRMRDLLGALKK 1 
Rv2517c (51-70) MRDLLGALKKAGLTWPPPSK 1 
Rv2517c (61-80) AGLTWPPPSKKERRAQHRKE 1 






Rv2660c Sequence Pool 
Rv2660c (1-20) VIAGVDQALAATGQASQRAA 1 
Rv2660c (11-30) ATGQASQRAAGASGGVTVGV 1 
Rv2660c (21-40) GASGGVTVGVGVGTEQRNLS 1 
Rv2660c (31-50) GVGTEQRNLSVVAPSQFTFS 1 
Rv2660c (41-60) VVAPSQFTFSSRSPDFVDET 1 
Rv2660c (51-70) SRSPDFVDETAGQSWCAILG 1 















Rv2662 Sequence Pool 
Rv2662 (1-20) MDDLTRLRRELLDRFDVRDF 1 
Rv2662 (11-30) LLDRFDVRDFTDWPPASLRA 1 
Rv2662 (21-40) TDWPPASLRALIATYDPWID 1 
Rv2662 (31-50) LIATYDPWIDMTASPPQPVS 1 
Rv2662 (41-60) MTASPPQPVSPGGPRLRLVR 1 
Rv2662 (51-70) PGGPRLRLVRLTTNPSARAA 1 
Rv2662 (61-80) LTTNPSARAAPIGNGGDSSV 1 






Rv2663 Sequence Pool 
Rv2663 (1-20) VEVRASARKHGINDDAMLHA 1 
Rv2663 (11-30) GINDDAMLHAYRNALRYVEL 1 
Rv2663 (21-40) YRNALRYVELEYHGEVQLLV 1 
Rv2663 (31-50) EYHGEVQLLVIGPDQTGRLL 1 
Rv2663 (41-60) IGPDQTGRLLELVIPADEPP 1 
Rv2663 (51-70) ELVIPADEPPRIIHANVLRP 1 















Rv2664 Sequence Pool 
Rv2664 (1-20) VKHKTDIDEWLDTIEPNPAD 1 
Rv2664 (11-30) LDTIEPNPADAHDASHLRRI 1 
Rv2664 (21-40) AHDASHLRRIIAAKEAVQTA 1 
Rv2664 (31-50) IAAKEAVQTAESELRAAVNA 1 
Rv2664 (41-60) ESELRAAVNAARAAGDTWAA 1 
Rv2664 (51-70) ARAAGDTWAAIGVALGITRQ 1 















Rv2780 Sequence Pool 
Rv2780 (1-20) MRVGIPTETKNNEFRVAITP 1 
Rv2780 (11-30) NNEFRVAITPAGVAELTRRG 1 
Rv2780 (21-40) AGVAELTRRGHEVLIQAGAG 1 
Rv2780 (31-50) HEVLIQAGAGEGSAITDADF 1 
Rv2780 (41-60) EGSAITDADFKAAGAQLVGT 1 
Rv2780 (51-70) KAAGAQLVGTADQVWADADL 1 
Rv2780 (61-80) ADQVWADADLLLKVKEPIAA 1 
Rv2780 (71-90) LLKVKEPIAAEYGRLRHGQI 1 
Rv2780 (81-100) EYGRLRHGQILFTFLHLAAS 1 
Rv2780 (91-110) LFTFLHLAASRACTDALLDS 1 
Rv2780 (101-120) RACTDALLDSGTTSIAYETV 1 
Rv2780 (111-130) GTTSIAYETVQTADGALPLL 1 
Rv2780 (121-140) QTADGALPLLAPMSEVAGRL 2 
Rv2780 (131-150) APMSEVAGRLAAQVGAYHLM 2 
Rv2780 (141-160) AAQVGAYHLMRTQGGRGVLM 2 
Rv2780 (151-170) RTQGGRGVLMGGVPGVEPAD 2 
Rv2780 (161-180) GGVPGVEPADVVVIGAGTAG 2 
Rv2780 (171-190) VVVIGAGTAGYNAARIANGM 2 
Rv2780 (181-200) YNAARIANGMGATVTVLDIN 2 
Rv2780 (191-210) GATVTVLDINIDKLRQLDAE 2 
Rv2780 (201-220) IDKLRQLDAEFCGRIHTRYS 2 
Rv2780 (211-230) FCGRIHTRYSSAYELEGAVK 2 
Rv2780 (221-240) SAYELEGAVKRADLVIGAVL 2 
Rv2780 (231-250) RADLVIGAVLVPGAKAPKLV 2 
Rv2780 (241-260) VPGAKAPKLVSNSLVAHMKP 3 
Rv2780 (251-270) SNSLVAHMKPGAVLVDIAID 3 
Rv2780 (261-280) GAVLVDIAIDQGGCFEGSRP 3 
Rv2780 (271-290) QGGCFEGSRPTTYDHPTFAV 3 
Rv2780 (281-300) TTYDHPTFAVHDTLFYCVAN 3 
Rv2780 (291-310) HDTLFYCVANMPASVPKTST 3 
Rv2780 (301-320) MPASVPKTSTYALTNATMPY 3 
Rv2780 (311-330) YALTNATMPYVLELADHGWR 3 
Rv2780 (321-340) VLELADHGWRAACRSNPALA 3 
Rv2780 (331-350) AACRSNPALAKGLSTHEGAL 3 
Rv2780 (341-350) KGLSTHEGALLSERVATDLG 3 














Rv2693c Sequence Pool 
Rv2693c (1-20) VNANRTSAQRLLAQAGGVSG 1 
Rv2693c (11-30) LLAQAGGVSGLVYSSLPVVT 1 
Rv2693c (21-40) LVYSSLPVVTFVVASSAAGL 1 
Rv2693c (31-50) FVVASSAAGLLPAIGFALSM 1 
Rv2693c (41-60) LPAIGFALSMAGLILLWRLL 1 
Rv2693c (51-70) AGLILLWRLLRRESARPVVA 1 
Rv2693c (61-80) RRESARPVVAGFCGVAVCAL 1 
Rv2693c (71-90) GFCGVAVCALIAYLVGQSKG 1 
Rv2693c (81-100) IAYLVGQSKGYFLLGIWMSL 1 
Rv2693c (91-110) YFLLGIWMSLLWAVVFTLSI 1 
Rv2693c (101-120) LWAVVFTLSILIRRPIVGYL 1 
Rv2693c (111-130) LIRRPIVGYLWSWLSGRDRA 2 
Rv2693c (121-140) WSWLSGRDRAWRDVSRAVFA 2 
Rv2693c (131-150) WRDVSRAVFAFDVATLGWTL 2 
Rv2693c (141-160) FDVATLGWTLVFAARFIVQR 2 
Rv2693c (151-170) VFAARFIVQRHLYDADKTGW 2 
Rv2693c (161-180) HLYDADKTGWLGVARIGMGW 2 
Rv2693c (171-190) LGVARIGMGWPLTALAALAT 2 
Rv2693c (181-200) PLTALAALATYAAIKAAQRA 2 
Rv2693c (191-210) YAAIKAAQRAILASHDAAAV 2 
Rv2693c (201-220) ILASHDAAAVGGAAEFDADA 2 














Rv3334 Sequence Pool 
Rv3334 (1-20) MKISEVAALTNTSTKTLRFY 1 
Rv3334 (11-30) NTSTKTLRFYENSGLLPPPA 1 
Rv3334 (21-40) ENSGLLPPPARTASGYRNYG 1 
Rv3334 (31-50) RTASGYRNYGPEIVDRLRFI 1 
Rv3334 (41-60) PEIVDRLRFIHRGQAAGLAL 1 
Rv3334 (51-70) HRGQAAGLALQEVRQILAIH 1 
Rv3334 (61-80) QEVRQILAIHDRGEAPCAHV 1 
Rv3334 (71-90) DRGEAPCAHVRQLLSTRIDE 2 
Rv3334 (81-100) RQLLSTRIDEVRAQIAELIA 2 
Rv3334 (91-110) VRAQIAELIALEGHLQTLLD 2 
Rv3334 (101-120) LEGHLQTLLDHASYGPPTEH 2 
Rv3334 (111-130) HASYGPPTEHDHSTVCWILE 2 
Rv3334 (121-140) DHSTVCWILESDLDEPTAIE 2 















Rv3406 Sequence Pool 
Rv3406 (1-20) MTDLITVKKLGSRIGAQIDG 1 
Rv3406 (11-30) GSRIGAQIDGVRLGGDLDPA 1 
Rv3406 (21-40) VRLGGDLDPAAVNEIRAALL 1 
Rv3406 (31-50) AVNEIRAALLAHKVVFFRGQ 1 
Rv3406 (41-60) AHKVVFFRGQHQLDDAEQLA 1 
Rv3406 (51-70) HQLDDAEQLAFAGLLGTPIG 1 
Rv3406 (61-80) FAGLLGTPIGHPAAIALADD 1 
Rv3406 (71-90) HPAAIALADDAPIITPINSE 1 
Rv3406 (81-100) APIITPINSEFGKANRWHTD 1 
Rv3406 (91-110) FGKANRWHTDVTFAANYPAA 1 
Rv3406 (101-120) VTFAANYPAASVLRAVSLPS 2 
Rv3406 (111-130) SVLRAVSLPSYGGSTLWANT 2 
Rv3406 (121-140) YGGSTLWANTAAAYAELPEP 2 
Rv3406 (131-150) AAAYAELPEPLKCLTENLWA 2 
Rv3406 (141-160) LKCLTENLWALHTNRYDYVT 2 
Rv3406 (151-170) LHTNRYDYVTTKPLTAAQRA 2 
Rv3406 (161-180) TKPLTAAQRAFRQVFEKPDF 2 
Rv3406 (171-190) FRQVFEKPDFRTEHPVVRVH 2 
Rv3406 (181-200) RTEHPVVRVHPETGERTLLA 2 
Rv3406 (191-210) PETGERTLLAGDFVRSFVGL 2 
Rv3406 (201-220) GDFVRSFVGLDSHESRVLFE 3 
Rv3406 (211-230) DSHESRVLFEVLQRRITMPE 3 
Rv3406 (221-240) VLQRRITMPENTIRWNWAPG 3 
Rv3406 (231-250) NTIRWNWAPGDVAIWDNRAT 3 
Rv3406 (241-260) DVAIWDNRATQHRAIDDYDD 3 
Rv3406 (251-270) QHRAIDDYDDQHRLMHRVTL 3 
Rv3406 (261-280) QHRLMHRVTLMGDVPVDVYG 3 
Rv3406 (271-290) MGDVPVDVYGQASRVISGAP 3 





























Rv1986 Sequence Pool 
Rv1986 (1-20) VNSPLVVGFLACFTLIAAIG 1 
Rv1986 (11-30) ACFTLIAAIGAQNAFVLRQG 1 
Rv1986 (21-40) AQNAFVLRQGIQREHVLPVV 1 
Rv1986 (31-50) IQREHVLPVVALCTVSDIVL 1 
Rv1986 (41-60) ALCTVSDIVLIAAGIAGFGA 1 
Rv1986 (51-70) IAAGIAGFGALIGAHPRALN 1 
Rv1986 (61-80) LIGAHPRALNVVKFGGAAFL 1 
Rv1986 (71-90) VVKFGGAAFLIGYGLLAARR 1 
Rv1986 (81-100) IGYGLLAARRAWRPVALIPS 1 
Rv1986 (91-110) AWRPVALIPSGATPVRLAEV 1 
Rv1986 (101-120) GATPVRLAEVLVTCAAFTFL 2 
Rv1986 (111-130) LVTCAAFTFLNPHVYLDTVV 2 
Rv1986 (121-140) NPHVYLDTVVLLGALANEHS 2 
Rv1986 (131-150) LLGALANEHSDQRWLFGLGA 2 
Rv1986 (141-160) DQRWLFGLGAVTASAVWFAT 2 
Rv1986 (151-170) VTASAVWFATLGFGAGRLRG 2 
Rv1986 (161-180) LGFGAGRLRGLFTNPGSWRI 2 
Rv1986 (171-190) LFTNPGSWRILDGLIAVMMV 2 













Rv2658c Sequence Pool 
Rv2658c (1-20) MADAVKYVVMCNCDDEPGAL 1 
Rv2658c (11-30) CNCDDEPGALIIAWIDDERP 1 
Rv2658c (21-40) IIAWIDDERPAGGHIQMRSN 1 
Rv2658c (31-50) AGGHIQMRSNTRFTETQWGR 1 
Rv2658c (41-60) TRFTETQWGRHIEWKLECRA 1 
Rv2658c (51-70) HIEWKLECRACRKYAPISEM 1 
Rv2658c (61-80) CRKYAPISEMTAAAILDGFG 1 
Rv2658c (71-90) TAAAILDGFGAKLHELRTST 1 
Rv2658c (81-100) AKLHELRTSTIPDADDPSIA 1 
Rv2658c (91-110) IPDADDPSIAEARHVIPFSA 1 














Rv2659c Sequence Pool 
Rv2659c (1-20) VTQTGKRQRRKFGRIRQFNS 1 
Rv2659c (11-30) KFGRIRQFNSGRWQASYTGP 1 
Rv2659c (21-40) GRWQASYTGPDGRVYIAPKT 1 
Rv2659c (31-50) DGRVYIAPKTFNAKIDAEAW 1 
Rv2659c (41-60) FNAKIDAEAWLTDRRREIDR 1 
Rv2659c (51-70) LTDRRREIDRQLWSPASGQE 1 
Rv2659c (61-80) QLWSPASGQEDRPGAPFGEY 1 
Rv2659c (71-90) DRPGAPFGEYAEGWLKQRGI 1 
Rv2659c (81-100) AEGWLKQRGIKDRTRAHYRK 1 
Rv2659c (91-110) KDRTRAHYRKLLDNHILATF 1 
Rv2659c (101-120) LLDNHILATFADTDLRDITP 1 
Rv2659c (111-130) ADTDLRDITPAAVRRWYATT 1 
Rv2659c (121-140) AAVRRWYATTAVGTPTMRAH 2 
Rv2659c (131-150) AVGTPTMRAHSYSLLRAIMQ 2 
Rv2659c (141-160) SYSLLRAIMQTALADDLIDS 2 
Rv2659c (151-170) TALADDLIDSNPCRISGAST 2 
Rv2659c (161-180) NPCRISGASTARRVHKIRPA 2 
Rv2659c (171-190) ARRVHKIRPATLDELETITK 2 
Rv2659c (181-200) TLDELETITKAMPDPYQAFV 2 
Rv2659c (191-210) AMPDPYQAFVLMAAWLAMRY 2 
Rv2659c (201-220) LMAAWLAMRYGELTELRRKD 2 
Rv2659c (211-230) GELTELRRKDIDLHGEVARV 2 
Rv2659c (221-240) IDLHGEVARVRRAVVRVGEG 2 
Rv2659c (231-250) RRAVVRVGEGFKVTTPKSDA 2 
Rv2659c (241-260) FKVTTPKSDAGVRDISIPPH 3 
Rv2659c (251-270) GVRDISIPPHLIPAIEDHLH 3 
Rv2659c (261-280) LIPAIEDHLHKHVNPGRESL 3 
Rv2659c (271-290) KHVNPGRESLLFPSVNDPNR 3 
Rv2659c (281-300) LFPSVNDPNRHLAPSALYRM 3 
Rv2659c (291-310) HLAPSALYRMFYKARKAAGR 3 
Rv2659c (301-320) FYKARKAAGRPDLRVHDLRH 3 
Rv2659c (311-330) PDLRVHDLRHSGAVLAASTG 3 
Rv2659c (321-340) SGAVLAASTGATLAELMQRL 3 
Rv2659c (331-350) ATLAELMQRLGHSTAGAALR 3 
Rv2659c (341-360) GHSTAGAALRYQHAAKGRDR 3 
Rv2659c (351-370) YQHAAKGRDREIAALLSKLA 3 













B.1 Hypoxic time course data (Fold induction) including rank at 7 day* 
S.No Name Gene name 4 hours 1 day 4 day 7 day Rank At 7 
day 
R (FI) 
1 Rv0140 Rv0140 0.116 0.962 1.870 3.180 47 
2 Rv0188 Rv0188 0.871 0.883 1.866 2.638 76 
3 Rv0233 nrdB 1.562 2.360 2.988 2.492 86 
4 Rv0251c hsp 0.247 3.304 3.722 4.117 16 
5 Rv0268c Rv0268c 0.613 0.795 1.535 2.800 69 
6 Rv0327c cyp135A1 -0.230 2.048 1.905 2.924 65 
7 Rv0350 dnaK 0.421 1.875 1.693 2.335 96 
8 Rv0384c clpB 0.268 2.527 2.626 2.941 63 
9 Rv0474 Rv0474 0.712 2.254 3.966 3.390 33 
10 Rv0520 Rv0520 0.133 1.125 1.837 3.296 38 
11 Rv0521 Rv0521 0.232 1.292 1.521 2.317 99 
12 Rv0754 PE_PGRS11 0.755 2.730 3.046 3.056 54 
13 Rv0766c cyp123 0.090 2.339 3.645 3.040 55 
14 Rv0767c Rv0767c 0.172 2.666 4.720 4.019 19 
15 Rv0791c Rv0791c 0.018 2.647 3.409 3.040 56 
16 Rv0793 Rv0793 0.140 2.130 2.706 2.730 72 
17 Rv0826 Rv0826 0.345 1.889 3.697 3.477 31 
18 Rv0846c Rv0846c 0.645 3.214 2.777 3.538 30 
19 Rv0847 lpqS 2.175 5.352 5.035 5.564 1 
20 Rv0848 cysK2 1.771 4.725 3.596 4.040 17 
21 Rv0849 Rv0849 1.280 3.809 3.439 2.592 83 
22 Rv0940c Rv0940c 0.699 1.901 3.028 2.684 73 
23 Rv0967 Rv0967 0.324 3.843 3.992 4.806 5 
24 Rv0976c Rv0976c 1.526 2.052 3.660 3.105 51 
25 Rv0986 Rv0986 -0.715 1.305 1.045 2.526 85 
26 Rv0990c Rv0990c 1.707 2.604 3.178 3.902 21 
27 Rv0991c Rv0991c 0.233 3.418 3.406 5.230 2 
28 Rv1169c PE11 -0.113 2.702 1.799 3.224 44 
29 Rv1221 sigE -0.657 1.283 2.085 2.771 70 
30 Rv1284 Rv1284 0.488 1.854 3.020 3.107 50 
31 Rv1285 cysD 0.947 3.186 3.082 2.403 92 
32 Rv1403c Rv1403c 0.397 2.559 3.426 3.984 20 
33 Rv1405c Rv1405c 1.030 2.537 3.029 3.370 34 
34 Rv1471 trxB1 -0.172 2.847 3.101 4.556 8 
35 Rv1587c Rv1587c 0.384 3.030 3.012 2.313 100 












37 Rv1806 PE20 0.350 0.849 1.397 4.393 9 
38 Rv1813c Rv1813c 3.608 4.479 4.113 4.029 18 
39 Rv1875 Rv1875 0.156 0.878 1.950 3.745 24 
40 Rv1909c furA 0.092 1.210 1.588 2.989 59 
41 Rv1954c Rv1954c 0.514 1.389 2.868 2.678 74 
42 Rv1955 Rv1955 0.192 2.506 4.304 4.383 10 
43 Rv1956 Rv1956 0.355 2.228 2.726 3.115 49 
44 Rv1957 Rv1957 -0.152 1.872 3.831 3.542 28 
45 Rv1986 Rv1986 1.099 3.765 3.603 3.058 53 
46 Rv1990c Rv1990c 0.664 1.686 2.434 3.151 48 
47 Rv1994c Rv1994c 1.210 2.839 2.219 3.220 45 
48 Rv1995 Rv1995 2.410 4.472 2.265 2.317 98 
49 Rv1996 Rv1996 4.857 3.237 3.956 2.945 62 
50 Rv2007c fdxA 3.909 3.618 2.718 2.623 81 
51 Rv2011c Rv2011c 0.125 1.739 1.626 2.906 66 
52 Rv2012 Rv2012 0.491 1.887 3.218 3.317 36 
53 Rv2021c Rv2021c -0.310 1.152 2.032 2.483 87 
54 Rv2022c Rv2022c -0.055 0.970 2.102 2.948 61 
55 Rv2025c Rv2025c 0.836 2.099 3.042 2.878 68 
56 Rv2030c Rv2030c 5.855 3.327 2.593 2.984 60 
57 Rv2031c hspX 5.335 4.015 4.948 4.217 14 
58 Rv2032 acg 4.032 3.461 1.974 3.210 46 
59 Rv2034 Rv2034 0.681 3.744 5.049 4.997 3 
60 Rv2035 Rv2035 0.267 3.089 3.793 3.828 23 
61 Rv2036 Rv2036 0.730 2.593 2.043 3.310 37 
62 Rv2050 Rv2050 0.786 2.333 2.791 3.238 41 
63 Rv2465c rpiB -0.347 0.895 1.524 2.994 57 
64 Rv2466c Rv2466c 0.054 2.933 3.045 4.153 15 
65 Rv2504c scoA 0.813 1.125 1.427 2.669 75 
66 Rv2517c Rv2517c 0.387 1.655 2.591 2.633 78 
67 Rv2558 Rv2558 1.504 1.167 3.097 3.636 27 
68 Rv2617c Rv2617c 0.065 0.398 1.358 2.482 88 
69 Rv2623 TB31.7 3.999 3.296 3.348 3.234 42 
70 Rv2626c Rv2626c 3.895 4.346 4.127 4.755 6 
71 Rv2627c Rv2627c 2.318 2.634 2.522 3.280 40 
72 Rv2628 Rv2628 2.312 1.853 1.693 2.427 91 
73 Rv2642 Rv2642 0.034 2.632 4.110 4.741 7 
74 Rv2643 arsC 0.371 2.258 2.828 3.729 25 
75 Rv2658c Rv2658c 2.145 4.680 4.933 4.286 13 
76 Rv2659c Rv2659c 1.489 3.565 3.435 3.286 39 
77 Rv2660c Rv2660c 1.099 2.501 2.958 2.471 89 
78 Rv2662 Rv2662 0.658 1.684 1.367 3.348 35 
79 Rv2663 Rv2663 0.439 1.297 1.241 2.901 67 












81 Rv2693c Rv2693c 0.180 0.773 2.242 2.348 94 
82 Rv2694c Rv2694c 0.149 1.591 2.496 2.624 79 
83 Rv2699c Rv2699c -0.485 0.574 1.209 2.633 77 
84 Rv2780 ald 2.438 3.826 3.199 2.448 90 
85 Rv2913c Rv2913c 0.117 0.965 3.290 3.540 29 
86 Rv2962c Rv2962c 0.742 2.577 2.407 2.334 97 
87 Rv2963 Rv2963 1.404 4.271 3.982 3.069 52 
88 Rv3130c Rv3130c 4.534 3.615 3.266 3.712 26 
89 Rv3131 Rv3131 2.908 2.750 1.953 2.368 93 
90 Rv3269 Rv3269 2.794 2.144 3.167 2.930 64 
91 Rv3288c usfY 0.812 2.897 2.242 2.609 82 
92 Rv3290c lat 0.791 2.642 2.099 3.224 43 
93 Rv3334 Rv3334 0.189 2.628 2.447 3.399 32 
94 Rv3406 Rv3406 0.248 0.715 2.846 4.310 11 
95 Rv3503c fdxD 1.221 1.719 2.962 2.552 84 
96 Rv3515c fadD19 0.305 2.867 3.017 2.990 58 
97 Rv3536c Rv3536c 0.456 1.550 3.337 3.887 22 
98 Rv3597c lsr2 -0.025 0.347 2.143 2.345 95 
99 Rv3681c whiB4 0.994 1.392 1.807 2.623 80 
100 Rv3862c whiB6 0.615 2.317 3.983 4.301 12 
 
*M. tuberculosis transcript levels from bacilli exposed to 7 days of hypoxia in vitro. 
Fold Induction (FI) at 4 hours, 24 hours, 4 days and 7 days, with respective ranks: 
(RFI)  












B.2 Raw intensity data normalized to SigA  (abundance) * 








































































1 Rv0140 Rv0140 0.61 1.21 1.26 5.10 46 13 29.5 26 
2 Rv0188 Rv0188 0.54 1.15 2.10 2.78 26 26 26 22 
3 Rv0233 nrdB 0.32 0.89 1.21 1.76 51 51 51 50 
4 Rv0251c hsp 0.84 1.34 11.87 13.22 3 3 3 2 
5 Rv0268c Rv0268c 0.51 0.34 0.83 1.39 66 59 62.5 67 
6 Rv0327c cyp135A1 0.01 0.00 0.14 0.18 98 100 99 100 
7 Rv0350 dnaK 1.19 1.17 5.58 4.17 4 17 10.5 7 
8 Rv0384c clpB 0.32 0.58 1.25 1.58 47 54 50.5 49 
9 Rv0474 Rv0474 0.37 0.50 4.37 4.84 7 15 11 9 
10 Rv0520 Rv0520 0.11 0.10 0.48 0.63 83 84 83.5 85 
11 Rv0521 Rv0521 0.18 0.21 0.46 0.53 86 89 87.5 88 
12 Rv0754 PE_PGRS11 0.03 0.02 0.54 0.65 80 82 81 80 
13 Rv0766c cyp123 0.08 0.16 1.32 1.07 41 66 53.5 57 
14 Rv0767c Rv0767c 0.07 0.03 3.49 2.63 10 28 19 18 
15 Rv0791c Rv0791c 0.10 0.04 0.89 0.96 61 70 65.5 71 
16 Rv0793 Rv0793 0.06 0.09 0.47 0.44 84 92 88 89 
17 Rv0826 Rv0826 0.34 0.91 3.43 3.07 11 25 18 16 
18 Rv0846c Rv0846c 0.05 0.06 0.51 0.65 82 83 82.5 83 
19 Rv0847 lpqS 0.21 0.74 21.75 9.97 1 5 3 3 
20 Rv0848 cysK2 0.13 0.18 2.68 1.82 18 48 33 29 
21 Rv0849 Rv0849 0.07 0.11 0.46 0.46 87 91 89 90 
22 Rv0940c Rv0940c 0.12 0.13 0.85 2.01 65 41 53 55 
23 Rv0967 Rv0967 0.37 0.35 14.37 22.70 2 2 2 1 
24 Rv0976c Rv0976c 0.08 0.20 0.65 0.52 73 90 81.5 81 
25 Rv0986 Rv0986 0.08 0.03 0.26 0.63 96 85 90.5 92 
26 Rv0990c Rv0990c 0.20 0.60 1.16 2.16 52 39 45.5 41 
27 Rv0991c Rv0991c 0.29 0.39 5.16 6.96 6 11 8.5 5 
28 Rv1169c PE11 0.17 0.19 0.70 2.52 70 33 51.5 51 
29 Rv1221 sigE 1.26 0.52 3.98 26.16 8 1 4.5 4 
30 Rv1284 Rv1284 0.13 0.13 0.58 0.62 77 86 81.5 82 
31 Rv1285 cysD 0.25 0.42 1.27 1.03 44 68 56 61 
32 Rv1403c Rv1403c 0.05 0.09 0.92 1.34 60 62 61 64 
33 Rv1405c Rv1405c 0.18 0.41 1.55 1.90 34 44 39 36 
34 Rv1471 trxB1 0.15 0.08 1.85 2.18 31 38 34.5 31 
35 Rv1587c Rv1587c 0.20 0.17 2.49 2.05 20 40 30 27 
36 Rv1738 Rv1738 0.11 4.74 0.54 1.40 79 58 68.5 75 
37 Rv1806 PE20 0.06 0.08 0.39 2.22 89 37 63 68 
38 Rv1813c Rv1813c 0.20 2.03 2.02 1.38 30 60 45 40 
39 Rv1875 Rv1875 0.31 0.33 0.86 9.15 64 6 35 32 












41 Rv1954c Rv1954c 0.02 0.01 0.42 0.22 88 99 93.5 94 
42 Rv1955 Rv1955 0.14 0.13 5.36 3.84 5 19 12 12 
43 Rv1956 Rv1956 0.16 0.12 2.34 2.53 22 32 27 23 
44 Rv1957 Rv1957 0.26 0.16 1.04 1.80 56 49 52.5 53 
45 Rv1986 Rv1986 0.16 0.21 2.10 1.35 25 61 43 39 
46 Rv1990c Rv1990c 0.19 0.48 1.25 1.75 48 52 50 48 
47 Rv1994c Rv1994c 0.41 0.96 1.46 8.08 38 8 23 20 
48 Rv1995 Rv1995 0.01 0.11 0.27 0.29 95 97 96 96 
49 Rv1996 Rv1996 0.09 1.11 0.38 0.60 92 88 90 91 
50 Rv2007c fdxA 0.25 5.17 0.65 1.15 72 64 68 74 
51 Rv2011c Rv2011c 0.19 0.14 1.11 1.67 53 53 53 56 
52 Rv2012 Rv2012 0.10 0.13 1.10 1.77 54 50 52 52 
53 Rv2021c Rv2021c 0.32 0.16 1.29 1.17 42 63 52.5 54 
54 Rv2022c Rv2022c 0.22 0.16 0.74 0.85 69 73 71 76 
55 Rv2025c Rv2025c 0.23 0.39 1.54 1.41 35 56 45.5 42 
56 Rv2030c Rv2030c 0.03 1.28 0.13 0.36 99 96 97.5 99 
57 Rv2031c hspX 0.14 4.09 0.63 1.40 75 57 66 72 
58 Rv2032 acg 0.03 0.55 0.17 0.38 97 95 96 97 
59 Rv2034 Rv2034 0.16 0.24 3.37 7.18 14 9 11.5 11 
60 Rv2035 Rv2035 0.21 0.27 2.24 3.68 23 20 21.5 19 
61 Rv2036 Rv2036 0.17 0.33 0.87 1.89 63 45 54 58 
62 Rv2050 Rv2050 0.94 1.30 3.17 4.57 17 16 16.5 15 
63 Rv2465c rpiB 0.58 0.47 1.00 2.24 58 36 47 45 
64 Rv2466c Rv2466c 0.35 0.54 3.29 10.81 16 4 10 6 
65 Rv2504c scoA 0.22 0.28 0.75 3.29 68 24 46 44 
66 Rv2517c Rv2517c 0.40 0.56 1.50 4.94 36 14 25 21 
67 Rv2558 Rv2558 0.29 0.72 2.03 1.82 29 47 38 35 
68 Rv2617c Rv2617c 0.38 0.58 1.23 3.63 50 21 35.5 33 
69 Rv2623 TB31.7 0.27 1.42 0.58 0.99 78 69 73.5 77 
70 Rv2626c Rv2626c 0.16 1.55 0.88 2.30 62 35 48.5 46 
71 Rv2627c Rv2627c 0.06 0.22 0.12 0.40 100 94 97 98 
72 Rv2628 Rv2628 0.24 0.92 0.52 0.81 81 74 77.5 79 
73 Rv2642 Rv2642 0.24 0.24 3.42 7.14 12 10 11 10 
74 Rv2643 arsC 0.08 0.09 0.60 2.38 76 34 55 59 
75 Rv2658c Rv2658c 0.04 0.18 1.25 0.66 49 80 64.5 70 
76 Rv2659c Rv2659c 0.10 0.14 1.47 0.72 37 79 58 62 
77 Rv2660c Rv2660c 0.01 0.01 0.33 0.28 93 98 95.5 95 
78 Rv2662 Rv2662 0.10 0.06 0.30 0.95 94 71 82.5 84 
79 Rv2663 nrdB 0.21 0.20 0.76 2.57 67 31 49 47 
80 Rv2664 Rv2664 0.11 0.11 0.69 1.56 71 55 63 69 
81 Rv2693c Rv2693c 0.31 0.24 1.70 1.96 32 43 37.5 34 
82 Rv2694c Rv2694c 0.88 1.04 3.60 5.60 9 12 10.5 8 
83 Rv2699c Rv2699c 0.24 0.16 0.39 0.66 90 81 85.5 86 
84 Rv2780 ald 0.86 3.41 3.35 3.58 15 22 18.5 17 












86 Rv2962c Rv2962c 0.09 0.13 0.38 0.42 91 93 92 93 
87 Rv2963 Rv2963 0.11 0.23 1.40 0.74 40 78 59 63 
88 Rv3031 Rv3130c 1.27 2.06 2.07 2.65 27 27 27 24 
89 Rv3130c Rv3131 0.07 3.66 0.47 0.62 85 87 86 87 
90 Rv3269 Rv3269 0.64 3.96 1.44 0.90 39 72 55.5 60 
91 Rv3288c usfY 0.19 0.36 2.12 1.06 24 67 45.5 43 
92 Rv3290c lat 0.60 1.18 2.37 8.68 21 7 14 13 
93 Rv3334 Rv3334 0.21 0.12 2.51 2.01 19 42 30.5 28 
94 Rv3406 Rv3406 0.11 0.10 1.56 1.85 33 46 39.5 37 
95 Rv3503c fdxD 0.18 0.45 1.26 0.75 45 77 61 65 
96 Rv3515c fadD19 0.14 0.17 0.97 1.09 59 65 62 66 
97 Rv3536c Rv3536c 0.15 0.09 1.28 3.40 43 23 33 30 
98 Rv3597c lsr2 1.21 0.81 2.04 2.58 28 30 29 25 
99 Rv3681c whiB4 0.32 0.61 1.06 2.58 55 29 42 38 
100 Rv3862c whiB6 0.09 0.06 3.38 4.14 13 18 15.5 14 
 
 
*M. tuberculosis transcript levels from bacilli exposed to 7 days of hypoxia in vitro. Median intensity 
normalized to SigA levels (NI) at 4 hours, 24hours, 4 days and 7 days. Also included rank based on the 
transcript levels at day 4 and day 7; average score of ranks at day 4 and day 7; with respective ranks: 
(RNI). 
















B.3 Allelic frequency in South African Xhosa Population (du Toit et al., 1988) 
 
HLA Antigens DR1 DR3 DR4 DR7 DR8 DR9  DR11 (DR5)  DR13 (DR6) DR15 (DR2) 













B.4 Properties of EHR proteins (n=26)** 





Hypothetical protein Hypothetical protein Lipoprotein lpqS 
Essentiality Non-essential Non-essential Non-essential Non-essential 
Up-regulation in     
Starvation +    
High temperature + + +  
Domain  
Bacterial regulatory 
protein, tetR family 
  
Gene ontology     
Gene Family     
Expression 
Altered enhanced 
expression in Rv3676 
deleted mutants 
  
Lower level of 
expression in phoP 
(Rv0757) mutant 
























Contains possible signal 















 Rv0849 Rv0967 Rv0990c Rv0991c 
Function 
Integral membrane 
protein, involved in 
the transport (drugs) 
across membrane 
Hypothetical protein Hypothetical protein Serine rich protein 
Essentiality Non-essential Non-essential Non-essential Non-essential 
Up-regulation in     
Starvation     
High temperature     
Domain  MSF 
Uncharacterised BCT, 
COG1937 (start 29 end 
70) 
SAF domain  – protein 
domain ; 54-116  
 
Gene ontology  




2) Molecular function: 








turnover , chaperones 
3)Cellular process : 
adaptation to atypical 
conditions 
 
Gene Family     




 control  


































   
Additional Note 
Similar to the 
multidrug resistance 
protein mdtH 
Also similar to MTB 




MSF Major facilitator superfamily 
BCR Breakpoint cluster region 












 Rv1284 Rv1471 Rv1954c Rv1955 
Function 
Beta-carbonic 
anhydrase  (canA) 
Thioredoxin trxB1 Hypothetical protein 
Hypothetical protein. 
Part of the TA 
module, Possible 
Toxin 
Essentiality Essential Non-essential Non-essential Non-essential 
Up-regulation in     
Starvation +  + + 



















1) Biological process 





and Zinc ion binding 
1) Biological process 


















































Additional Note  
Contains PS00194 
Thiroredoxin family 
active site. Belongs 
to the thiredoxin 
family 
End Overlaps next 
ORF upstream, 
Rv1955 
N terminal overlaps 
with another ORF , 
Rv1954c 
 













 Rv1956 Rv1957 Rv2021c Rv2022c 
Function 
Transcriptional 
regulatory protein (part 





Essential Non-Essential Non-essential Non-essential Non-essential 
Up-regulation in     
Starvation +    
High temperature     
Domain 
Protein domain- Helix 
turn helix. 
   
Gene ontology     
Gene Family     




























at  53-73 (+4.78 SD) 
 
helix-turn-helix at 45-
66  (score 
1472,+4.20 SD) 
 
Operon Rv1956 and Rv1957 Rv1956 and Rv1957 Rv2021c/2022c/2023c Rv2021c/2022c/2023c 
Additional Note 
Molecular function: 




















 Rv2466 Rv2517 Rv2660c Rv2662 
Function Hypothetical protein Hypothetical protein Hypothetical protein Hypothetical protein 
Essentiality Non-essential Non-essential Non-essential Non-essential 
Up-regulation 
in 
    
Starvation  + +  
High 
temperature 











   
Gene Family DSBA oxidoreductase    









Rv2516c, Rv2034, Rv3182, 
Rv3334, Rv3188, Rv2663, 
Rv2827c, Rv2035, Rv1990c, 
Rv3917c (parB) 
Rv0841, Rv2034, Rv0767c, 
Rv2662, Rv0122, Rv0840c 









    



























Conserved integral membrane 
alanine and leucine rich protein 
Secreted l-alanine 
dehydrogenase ald (40kDa 
antigen) TB43 
Essentiality Non-essential Non-essential Non-essential Non-essential 
Up-regulation 
in 
    
Starvation +   + 
High 
temperature 
    
Domain    
1) Alanine dehydrogenease/PNT, 
c terminal domain.  
2) Alanine dehydrogenase/PNT, 
N-terminal domain 
Gene ontology    
1) Biological process-oxidation 
reduction 
2) Molecular function- alanine 
dehydrogenase activity; binding; 
electron carrier activity 
3) Cellular component – 
extracellular region 
4) Functional annotation - 

















Rv3965 (mmr), Rv1853 (ureD), 
Rv0401, Rv2471 (aglA), 
Rv1635c, Rv2209, Rv0615, 
Rv2291 (sseB), Rv3903c, 
Rv2117 
Rv3287c (rsbW), Rv3290c (lat), 
Rv3288c (usfY), Rv0188, 
Rv2557, Rv0810c, Rv2659c, 
Rv0274, Rv0088, Rv0064 
Protein 
Structure 
    
Operon Rv2663-Rv2664 Rv2663-Rv2664 Rv2693c-2694c  
Additional Note   
1) Predicted transmembrane 
protein- identified in culture 
filtrates of MTB H37Rv (Malen 
et al., 2008)  
2) Signal peptide prediction and 
cleavable signal sequence 
confirmed experimentally. 
(Malen et al., 2008) 
1) Secreted l-alanine 
dehydrogenase ald (40HDA 
antigen)/ TB43.  
2) Contains PS00836 and 
PS00837 alanine dehydrogenase 
and pyridine nucleotide 
transhydrogenase signature 1 and 
2 
3) Epitope prediction :- 
FCGRIHTRYSSAYEL – B cell 
epitopes are predicted 












 Rv3334 Rv3406 
Function transcriptional regulatory protein probable dioxygeneae 
Essentiality Non-essential Non-essential 
Up-regulation in   
Starvation +  
High temperature +  
Domain 
1) MerR family regulatory protein.  
2) MerR, DNA binding 
 
Gene ontology 
1) Biological process – regulation of 
transcription, DNA dependent. 
2) Molecular function – nucleotide 
binding; transcription factor activity 
1) Biological process: oxidation reduction.   
2) Molecular function: electron carrier activity; oxidoreductase 
activity, acting on a single donors with incorporation of 
molecular oxygen, incorporation of two atoms of oxygen 
 
Gene Family   
Expression   
Co-expression 
Rv2034, Rv2517c, Rv3188, Rv3182, 
Rv1990c, Rv2035, Rv2827c, Rv2516c, 
Rv2663, Rv1991c 
Rv0474, Rv0475 (hbhA), Rv3061c (fadE22), Rv1533, 
Rv0068, Rv3405c, Rv0244c (fadE5), Rv0476, 
Rv1168c(PPE17), Rv0477 
 
Protein Structure   Contains probable helix-turn  
Operon  Rv3406-3407-3408 
Additional Note 
1) DNA micro array shows lower level 
of expression in H37Rv during Mg2+ 
starvation  
2) Similar to many regulatory proteins 





+          Upregulation 
** Table compiled with data obtained from : TubercuList (http://genolist.pasteur.fr/TubercuList/ 
and http://tuberculist.epfl.ch/ ), TBDB (http://www.tbdb.org/ ), TDR Targets database 
(http://tdrtargets.org/ ), MTBreg (http://www.doe-mbi.ucla.edu/Services/MTBreg/ ), BiohealthBase 
(www.biohealthbase.org ), webTB (http://www.webtb.org/ ), BioCye database collection 











B.5 M. tuberculosis transcript levels in bacilli exposed to 7 days hypoxia in vitro 
(Rustad et.al, 2008) 
  Log base2 Hypoxia/Log 
(a)
 
Median transcript intensity 
 normalised to SigA 
(b)
 
Rv# Gene name 4hrs 1day 4days 7days 4hrs 1day 4days 7days 
Rv3875 ESAT-6 -0.34 -2.17 -1.88 -1.40 5.97 4.22 3.49 4.33 
Rv3874 CFP-10 0.14 -1.20 -0.56 -1.03 7.42 2.3 1.97 4.04 
Rv2659c Rv2659c 1.49 3.56 3.43 3.29 0.14 1.66 1.47 0.72 
Rv2658c Rv2658c 2.15 4.68 4.93 4.29 0.18 1.69 1.25 0.66 
Rv2031c Acr1 5.34 4.02 4.95 4.22 4.09 1.84 0.63 1.40 
Rv1986 Rv1986 1.10 3.77 3.60 3.06 0.21 2.38 2.10 1.35 
 
(a) Shows the fold induction over hypoxic time course with reference to phase of aerobic cultures.  





















Appendix Figure C.1 Comparison of absolute IFN-g response in 7day whole blood 
incubation assay and QFT-GIT assay 
 
 
Figure shows direct comparison of the absolute values of IFN-  in 7 day WBA using 
recombinant protein (Rec ESAT-6)  represented in pg/ml and QFT-GIT (AG-Nil) in 
IU/ml. Dotted line indicate positive cut off for QFT as per manufacture‟s instruction. 
 
 
